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Abstract 
Soluble guanylate cyclase is a multidimeric enzyme that regulates cardiovascular 
homeostasis and is the receptor for nitric oxide in the brain. The enzyme is the known 
target for a new agonist drug used for the treatment of pulmonary hypertension. Whilst 
drug discovery has been successful for the finding of small molecules that activate the 
enzyme, the currently available inhibitors lack selectivity as they act through oxidation of a 
heme prosthetic group in the enzyme, which is conserved amongst other hemeproteins. 
Nonetheless, it has been suggested that inhibition of soluble guanylate cyclase by small 
molecules could be useful in the treatment of neurological conditions such as Parkinson’s 
Disease. In this thesis, new activators of soluble guanylate cyclase have been identified by 
virtual screening, and a new class of inhibitors has been designed and synthesised. The 
synthetic routes developed are efficient and take advantage of microwave-assisted organic 
synthesis. The drug-target interaction was characterised using a biophysical technique 
based on surface plasmon resonance, which allows the detection of label-free binding 
between small molecules and biological macromolecules. The biophysical assay has been 
developed using different constructs of soluble guanylate cyclase and validated through 
binding of the natural ligands ATP and GTP. The instrument and assay design were 
validated using the well-defined interaction between natriuretic peptides and the 
extracellular domain of natriuretic peptide type-C. Additional biochemical characterisation 
of the ligands allowed discrimination between activators and inhibitors. This combination 
of biophysical and biochemical techniques allowed the identification of the catalytic 
domain of soluble guanylate cyclase as the target for binding of the new class of 
synthesised inhibitors and has given insight into the functional groups necessary for activity 
and binding to the enzyme.  
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1. General introduction 
1.1. Target-based drug discovery 
As scientific and technological advances are made every day there is an implicit expectation 
that these will in some way improve our lives, whether it is to make us live longer, happier, 
or more comfortable. On one hand, population is growing and life expectancy is increasing, 
so we are becoming more efficient at postponing death; on the other hand, diseases such 
as cancer, heart diseases, Alzheimer’s and other cardiovascular and neurological diseases 
still present our biggest fears. Whether medical conditions are genetic, environmental or 
lifestyle induced, biomedical research has allowed the discovery of the molecular 
mechanisms that underlie a great number of diseases, providing for a better 
comprehension of how the human body works and fails, which in turn provides the 
possibility to devise new treatments. 
In the past, drug development would start with the identification of a lead compound with 
useful activity, which would then be modified to develop a clinically useful drug. Research 
into the drug target and mechanism of action often took place many years after discovery 
of the drug. Current state of the art technology allows for a rational drug design, which 
starts with the identification of a biomolecular target. Target-based drug discovery focusses 
on finding modulators of the activity of a specific biological macromolecule which can be 
associated with a disease model. The basic requirements for this approach to drug 
discovery are a druggable target and a bioassay, which usually allow a library of compounds 
to be screened for binding and/or activity. Once a hit compound has been identified, drug 
design aims at optimizing drug-target interactions in order to obtain an improved 
compound with greater activity, which can then undergo development in order to improve 
its absorption and bioavailability, reduce its toxicity and side effects (Figure 1).  
 
Figure 1. The pipeline of drug discovery. 
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1.1.1. The druggable genome 
The “druggable genome” is represented by the ~ 30,000 genes in the human genome that 
express proteins able to bind drug-like molecules. Approximately half of these proteins 
remain functionally unclassified. Hopkins et al. analysis of known molecular targets 
concluded that only 130 protein families represent the known drug targets and nearly half 
of these targets fall into just six gene families: G-protein-coupled receptors (GPCRs), 
serine/threonine and tyrosine protein kinases, zinc metallopeptidases, serine proteases, 
nuclear hormone receptors and phosphodiesterases (PDEs).1  
The effective number of drug targets has been estimated by analytical methods, leading to 
a controversy in numbers, as it primarily depends on the definition one gives to “the 
druggable genome”.2-4 Overington et al. analysed the US FDA’s Orange Book for primarily 
small-molecule drugs, and the Center for Biologics Evaluation and Research (CBER) website 
for biological drugs, concluding that all current drugs with a known mode of action act 
through 324 distinct molecular drug targets, out of which 226 are human-genome-derived 
proteins, and the remainder are bacterial, fungal, or other pathogenic organism targets. 60 
% of drug targets are located at the cell surface, compared to only ~ 22 % of all proteins in 
the human genome. Another interesting result of this analysis is the relatively constant rate 
of target innovation, with an average rate of first-against target drugs of 5.3 new drugged 
targets per year over the period of 20 years (from 1985 to 2005).5  
It is possible that technological advances will aid the expansion of druggable targets. So far, 
drug discovery projects targeting enzymes have been the most successful, followed by 
GPCRs.1 Most drugs achieve their activity by competing for a binding site on a protein with 
an endogenous small molecule. Their success might be explained by a well-defined active 
site and generally better understood mode of action. Nonetheless, enzyme modulators are 
also easier to identify by biochemical assays since a direct activation/inhibition can usually 
be measured by enzymatic turnover. It is predicted that modern biophysical assays which 
detect direct binding of a small-molecule to a protein will facilitate high-throughput 
screening (HTS) for non-enzymes, such as scaffolding proteins or transcription factors. Their 
lack of obvious binding pockets and/or involvement in protein –protein interactions which 
involve larger contact areas makes them a more challenging target.6 
“The druggable genome” is therefore a term that leaves some ambiguity and is only as big 
as the creativity of drug designers. Drug discovery seems to follow a trend, as exemplified 
21 
 
by the great number of drugs targeting kinases following approval of the Brc-Abl kinase 
inhibitor imatinib.7 Although targeting an enzyme known to be druggable, or with a 
precedent of druggability in its protein family is somehow safe, it limits innovation and a 
“trial and error” approach may be necessary to realize how big the druggable genome 
actually is. 
 
1.1.2. Small molecules and drug likeness 
Orally available drugs are generally small organic molecules, the majority of which follow a 
set of “rules” or “trends” in their chemical structure and physicochemical properties. An 
analysis performed in 1997 of a dataset of 3 000 drugs led to the implementation of “the 
rule of 5” as a set of characteristics required for a small molecule orally available drug. 
Lipinski’s rule of 5 states that “poor absorption or permeation are more likely when there 
are more than 5 H-bond donors (expressed as the sum of OHs and NHs); the Molecular 
weight is over 500; the Log P is over 5 (or MLogP is over 4.5); there are more than 10 H-
bond acceptors (expressed as the sum of Ns and Os”).8 A separate analysis by Veber 
suggested polar surface area (PSA) and the number of rotatable bonds as properties to take 
into consideration as well.9 Yet, drug likeness is much more than this set of rules which are 
focused on oral bioavailability. Drugs that act on the central nervous system and drugs 
which are not intended for oral absorption will have other characteristics. Overington’s 
analysis identified a total of 1 204 small-molecule drugs, out of which only 73 % pass the 
rule of 5.5  
Despite the perception that the rule of 5 would lead to smaller and more lipophilic drugs to 
be designed a 50-year retrospective analysis of molecules published in the Journal of 
Medicinal Chemistry (American Chemical Society) has concluded that the mean and median 
values of a wide range of physical properties of molecules have risen. A decrease of 2 % in 
clogP in the period between 2000 and 2004 was observed, possibly as a result of the rule of 
5 implementation, but it rose again afterwards.10  
 
 
 
22 
 
1.1.3. Chemical probes 
Not all small molecules are designed to be drugs. Binding of a small molecule with 
appropriate physical and chemical properties and high affinity to a certain protein does not 
necessarily make it a potential drug as that target must be associated with a disease 
condition. Nonetheless, many small-molecules can be used as valuable biochemical tools to 
study signalling pathways in vivo and in vitro. These tools are also called chemical probes. 
Frye postulated five principles of a quality chemical probe:11 
 Molecular profiling. In vitro potency and selectivity data which associates with 
cellular or in vivo profile. 
 Mechanism of action. Sufficient mechanistic data versus its intended molecular 
target, which includes dose-dependency in either a cell-based assay or a cell-free 
assay that recapitulates a physiological function of the target. 
 Identity of the active species. Sufficient data to attribute assay results to its intact 
structure or a well-characterised derivative. 
 Proven utility as a probe. Sufficient cellular activity data to confidently address at 
least one hypothesis about the role of the molecular target in a cell’s response to 
its environment. 
 Availability to the academic community with no restrictions in use. 
 
1.1.4. Assay development 
1.1.4.1. Biochemical Assays 
Most assays used in the early stages of drug discovery are performed in vitro and are 
optimised to be able to test a large number of compounds in a relatively easy and 
automated manner, using cheaper technology than that required for in vivo tests. 
Immunoassays, for example, are routinely employed to measure the activity of small 
molecules against enzymes. These require an antibody to specifically bind an antigen and 
commonly have some form of label attached that can easily be detected by means of 
radiation, fluorescence, or luminescence for example. 12 
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Figure 2. General concept of an immunoassay. An antigen can be quantified by reacting with a specific 
antibody and an added labelled antigen which will complete for antibody binding. The labelled antigen – 
antibody complex can then be measured. Less label measured in the assay indicates a higher amount of 
unlabelled antigen present. 
 
1.1.4.2. Biophysical Assays 
Biophysical assays allow the detection of direct binding of a small molecule to its target, 
and can deliver a fast way of compound screening as well as providing information 
regarding binding sites. Many techniques exist which use different physical phenomenon to 
measure drug-target interactions. Some will be briefly described as follows, and detailed 
attention will be given to surface plasmon resonance, the technique employed in the 
research presented in this thesis. 
Isothermal titration calorimetry (ITC) detects small changes in temperature caused by the 
absorption or release of heat upon molecular interactions, allowing for thermodynamics 
measurements to be made.13 The technique produces very accurate values for binding 
affinity, stoichiometry and enthalpy changes. However, it often requires high amounts of 
protein. 
A technique based on fluorescence called fluorescence polarisation (FP) quantifies bound 
ligand by detecting the change in size of the protein-ligand complex. For FP measurements, 
samples are excited with plane polarized light (horizontally or vertically, depending on the 
equipment) at the excitation wavelength of the fluorophore. Emitted light is simultaneously 
measured in the parallel and the perpendicular planes, relative to the excitation source. 
When a rigid and entirely immobile fluorophore is excited by plane-polarized light, it emits 
light in orientations that depend on the angle between the orientations of the absorbing 
and emitting dipoles. If the molecule rotates it will no longer be aligned. The speed at 
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which the ligand tumbles relative to the lifetime of its excited state will determine whether 
rotation of a molecule can be detected – with other conditions constant, the speed of 
tumbling is inversely related to molecular volume. A large molecule is therefore likely to 
retain the same orientation during the interval between absorbing and emitting a photon, 
whereas a smaller one is more likely to re-orient.14  
Nuclear magnetic resonance (NMR) is also a powerful technique which can be used not 
only for molecule characterisation but also for the description of binding events by 
monitoring changes in protein signals as a consequence of ligand interactions. For example, 
15N – 1H HSQC (heteronuclear single quantum coherence) spectrums can be obtained in the 
presence and absence of ligand; each peak corresponds to H-N pairs in the protein and can 
be used to monitor changes in the chemical environment of backbone NH, allowing not 
only detection of ligand binding but also providing binding site information if a residue 
resolved map of the protein is available. Another example of a recent NMR development is 
target immobilised NMR screening (TINS), which uses a single sample of immobilised 
protein to screen an entire fragment library.15 
 
Surface Plasmon Resonance (SPR) 
Surface Plasmon Resonance (SPR) is a biophysical technique that detects direct binding 
between two molecules, including proteins, nucleic acids, lipids, whole cells and small 
molecules. It can provide a wide range of information regarding the biomolecular 
interactions, from the specificity of the interaction to affinity and kinetics. SPR is now 
recognised as a valuable tool to screen and characterise small molecules that modulate the 
activity of a range of targets, including kinases and G protein-coupled receptors (GPCRs).16-
18 The microfluidics system of the biosensor allows the injection of an analyte (small 
molecule, hormone, protein) over an immobilised ligand (protein, nucleic acid, etc.) and the 
optical detector measures the direct binding between the two entities based on the 
difference in refractive index near the surface that occurs as the compound binds, thus 
allowing a real-time and label-free measurement of compound binding to the target (Figure 
3). Added benefits of using SPR-based assays include the ability to screen fragments 
(fragment-based drug design) and the use of separate domains of proteins, which may 
provide information about the location of the binding site.19 Further studies with mutated 
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constructs may also allow additional characterisation of the binding mode when crystal 
structures are not available. 
 
 
Figure 3. General setup of the SPR detection system. 
 
The principles of SPR: 
Surface plasmons are a form of electromagnetic energy and represent electron density 
fluctuations in a conducting metal that can be regarded as equivalent to photons in the 
case of light. The underlying principles of SPR are total internal reflection (TIR) and 
evanescence electric field. TIR occurs when light propagates between two different media 
of different refractive index. Above a critical incidence angle the light is no longer refracted 
but propagates back. When this happens, an electric field intensity called “evanescence 
wave” is formed and when the interface is coated with a thin metal film of gold the 
components of the evanescent field induce electromagnetic surface plasmon waves in the 
metal. The generated evanescence wave penetrates into the sample cell allowing the 
detection of refractive index properties to a distance of about 1 µm from the surface. 
Interactions at the surface of the sensor chip cause a change of the solute concentration 
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and therefore of the refractive index of the medium. The resulting change in the detected 
light angle (Figure 4) is converted into a response signal, where a shift in resonance angle of 
approximately 10-4 degrees corresponds to 1 response unit (RU). An increase in response 
units also directly correlates to an increase in mass at the surface. In the case of protein, 
this has been determined as 1 RU being equivalent to 1 pg/mm2.20-21 
 
 
Figure 4. Difference of light resonance angle at the sensor chip surface as a result of biomolecular interactions 
by SPR. (a) Sensor surface before binding of analyte to the immobilised target; (b) Sensor surface upon binding 
of analyte to the immobilised target. Where ΘI and ΘII correspond to the detected light angle. 
 
Qualitative information obtained from SPR assays: 
The SPR response can be used for simple binding/no-binding assays in which the purpose is 
to determine whether or not there is an interaction between a given analyte and the 
immobilised macromolecule. This kind of assay is usually employed for compound 
screening, to check for compound specificity, or to determine the location of binding sites if 
different protein domains or mutants are immobilised. 
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Quantitative analysis 
 Kinetics 
The kinetics of an interaction consist of the rate at which a complex is formed (association, 
Ka) and the rate at which it decays (dissociation, Kd); and can be determined from the 
information in a sensorgram, the plot of response units over time. The concept is that 
association takes place as the sample passes over the sensor surface and the response in 
the sensorgram increases; and dissociation starts when the sample is replaced by buffer 
and the response decreases (Figure 5).  
 
Figure 5. General overview of a sensorgram. Injection of an analyte increases the signal response from the 
baseline until the binding reaches equilibrium, after which the injection of the analyte stops and the response 
signal decrease as the analyte dissocates form the surface. Injection of a regeneration buffer removes any 
bound material and the signal returns to baseline. 
 
When performing kinetics studies, one may encounter mass transport limitations: the 
amount of analyte that binds to the ligand depends on the amount of analyte that 
effectively reaches the surface where the ligand is bound. The analyte concentration on the 
surface may be depleted and a gradient generated through the liquid layer – this is called 
diffuse mass transport. In any assay it is necessary to establish efficient mass transfer 
between the bulk and the surface. For example, mass transport limitations cause both the 
association and dissociation phases to exhibit slower kinetics, which has direct effects on 
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the information retained from the sensorgram. Therefore, one must account for these 
limitations when analysing the data and include mass transport in the fitting model if 
necessary. 
Two types of kinetics assays can be applied. The conventional approach is to inject the 
analyte at different concentrations with regeneration of the surface between every analysis 
cycle – this is called multicycle kinetics. More recently, another technique has been used in 
which the regeneration step is absent and the sensorgram consists of a titration from low 
to high concentration of analyte – single-cycle kinetics. 
 Affinity 
The affinity of an analyte to the ligand is time-independent and defines how strongly bound 
the complex is. Affinity determines how much complex is formed at equilibrium – steady 
state where association balances dissociation. Affinity can be determined from kinetic 
measurements as for a simple 1:1 interaction, the equilibrium constant KD is the ratio of the 
kinetic rate constants, Kd/Ka. When the association and dissociation rates are too fast to 
determine accurately, affinity can be determined by using the binding information at 
equilibrium if saturation can be observed, and it yields the equilibrium constant KD.  
 Thermodynamics 
Kinetics or affinity measurements can be performed at different temperatures, allowing an 
analysis of the variation of kinetics and affinity constants with temperature and an 
assessment of thermodynamic parameters from the data.22 
 
One-to-one interaction model 
Assuming a one-to-one interaction between a soluble analyte and an immobilised ligand, 
Figure 6 summarises the kinetics of the model system: Molecule B is immobilised to the 
sensor surface, molecule A is transported to the surface in the thin layer flow cell, and the 
concentration of complex AB is measured; A0 represents molecule A in the eluent stream 
and As at the sensor surface. km and k-m describe the flux of molecules to the sensor surface 
and out from the sensor surface; ka and kd are the kinetic association and dissociation 
constants, respectively, and kf and kr are the resulting forward and reverse rate constants 
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that determine the overall rate of the AB complex formation at the surface. The kinetic and 
concentrations parameters calculated by the Biacore software are based on this model.23 
 
Figure 6. One-to-one interaction model at the surface in a flow cell. Where B is immobilised at the sensor 
surface; A is present in the flow system; km and k-m are mass transport rate constants; ka and kd are the rate 
constants for the reaction between A and B, and kf and kr are the overall rate constants in the system. 
 
As mentioned above, the signals at steady-state equilibrium can be used for assay of 
equilibrium-binding constants, whilst the association and dissociation phases can be used 
for kinetic analysis, and may also yield equilibrium-binding constants under proper 
conditions. If a simple one-to-one interaction model applies, then kinetic analysis can 
usually be easily performed, yielding the association rate (kon  or ka) and the dissociation 
rate (koff or kd). Nevertheless, more complex binding interactions often take place for 
instance due to heterogeneity of the surface, mass transport limitations, conformational 
changes or multivalent binding. When binding kinetics data cannot be fitted to a simple 
model or falls outside the detection range of the instrument, steady-state binding data can 
usually be used to determine the equilibrium constant, KD. For an accurate determination of 
KD it is desirable that a range of analyte concentration be used, ranging from well below KD 
up to 10-fold KD. If high concentrations do not lead to saturation of the steady-state 
response this indicates that weaker interactions are taking place, such as binding to 
nonspecific binding sites. 
 
The sensor chip 
The sensor chip is constructed from a thin layer of gold coated with a covalently bound 
matrix of carboxymethylated dextran, a flexible carbohydrate polymer that forms a surface 
layer of approximately 100 nm on the most commonly used sensor chip CM5, and provides 
a means for attachment of molecules (Figure 10).  
30 
 
 
Figure 7. The sensor chip. (a) setup of a sensor chip; (b) carboxylated dextran unit. 
 
The dextran matrix is the environment in which the interaction being studied will occur, 
and gives important properties to the sensor surface. The negative carboxyl groups allow 
electrostatic concentration of positively charged molecules from solution, enabling efficient 
immobilisation from dilute ligand solutions. It provides a defined chemical basis for 
immobilisation of biomolecules using well defined chemistries, and its hydrophobic 
environment is favourable to most solution-based biomolecular interactions. In addition, 
the dextran matrix extends the region where interactions take place to encompass a 
surface layer with a thickness of the same order of magnitude as the penetration depth of 
the evanescent wave.24 
The CM-series sensor chips, which contain the carboxymethylated dextran matrix, permit 
molecule attachment using a variety of chemical methods, exploiting common functional 
groups on the protein such as amino, thiol, and aldehyde groups. Additionally, antibodies 
may also be attached that rely on the specific binding immobilised antibody and the 
antigenic epitope on the ligand (Figure 8a–c and f). In addition to CM5 chips mentioned 
above, other CM chips are available with modified matrixes. CM4 chips have a CM-dextran 
with lower carboxymethylated level than CM5 and are used for low immobilisation levels 
and reduced non-specific binding. CM3 chips have a shorter dextran matrix and used for 
large ligand molecules and particles. If higher binding capacity and higher signal to noise is 
needed, for instance for confident measurements of low molecular weight compounds, a 
CM7 chip can be used, with a higher degree of carboxylation and a denser matrix than 
CM5. 
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For tagged proteins, different immobilisation procedures can be applied. The SA sensor 
chip carries a dextran matrix to which streptavidin has been covalently attached, therefore 
preparing the surface for high affinity capture of biotinylated ligands (Figure 8d); 
polyhistidine-tagged ligands can be captured onto a NTA sensor chip which has a dextran 
matrix with immobilised nitrilotriacetic acid. The NTA molecule chelates metal ions, leaving 
coordination sites free that can bind to polyhistidine tags on recombinant proteins (Figure 
8e). There are additional modified chips available that allow experiments with lipid vesicles 
and liposomes, and even membrane-associated molecules (Figure 8g).  
 
Assay Design 
 Immobilisation  
The available sensor chips provide a variety of means for immobilisation as their surface 
allows for chemical derivatisation.25 The carboxymethylated dextran matrix can be 
modified so that proteins can be covalently attached by taking advantage of the functional 
groups on their amino acid side chains. 
Amine coupling is the most frequently used immobilisation chemistry and can occur 
through lysine residues and the protein N-terminus (Figure 8a). Cysteines can be bound to 
the CM-dextran through their free thiol groups, either by formation of disulphide bridges or 
by covalent reactions with maleimides. Since free thiols are relatively rare, these 
approaches can lead to site-directed, and thus oriented, immobilisation of the target 
(Figure 8b). Carbohydrate molecules and glycoproteins such as antibodies can be 
immobilised through aldehyde coupling on a hydrazine-activated surface. The aldehyde 
groups may be native or introduced by oxidation of cis-diols.  
After immobilisation of a target onto a sensor chip, the immobilization level of the surface 
(measured as a difference in response units) dictates its binding capacity, Rmax.
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Equation 1. Binding capacity of the SPR surface. Where RL is the immobilisation level, S is the stoichiometric 
ratio, Rmax is the maximal response for a certain analyte. 
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Figure 8. Examples of available Biacore sensor chip chemistries. (a) covalent immobilisation through amine 
coupling; (b) covalent immobilisation through thiol coupling; (c) covalent immobilisation through aldehyde 
coupling; (d) capturing through streptavidin – biotin interaction; (e) capturing through NTA – Ni
2+
 - poly-
histidine tag interaction; (f) capturing through antibody – antigen interaction; (g) capture of lipid vesicles and 
liposomes through interaction with immobilised lipophilic residues. 
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 Surface Regeneration 
Surface regeneration consists of the injection of a buffer that will remove any bound 
analyte from the surface to leave it intact for the following cycle of sample injection. 
Optimal conditions are specific for the ligand-analyte configurations, although for protein 
surfaces the most commonly used conditions are low pH (10 mM glycine-HCl at pH 1.5 – 3) 
and ethylene glycol at concentrations up to 100 % for highly hydrophobic interactions. 
Sodium chloride can also be used at a concentration of 1 M to disrupt mostly ionic 
interactions. Regeneration is a critical part of the binding assay since conditions that are 
too mild lead to analyte remaining and a possible carry-over effect, whilst harsh conditions 
might denature the immobisiled protein. Regeneration of the surface is not always 
necessary if the circumstances are such that the analyte dissociates fast enough and all 
analyte may be removed within a reasonable time by simply washing with buffer. 
 Assay conditions and instrument specifications 
Depending on the instrument used, conditions such as temperature and automation of the 
assay can be varied. The work presented here was performed using a Biacore T200. This 
instrument supports the use of 96 and 384-well microplates, allowing medium-high 
throughput screening; the temperature can be set between 4 and 45 °C, and it can detect 
weak binding interaction in the low milimolar (mM) range. The instrument specifications do 
not set a lower limit of molecular weight detection for organic molecules. The 
recommended working ranges for association rate constant (ka) are between 10
3 to 109 M-
1s-1 for proteins and 103 to 5 x 107 M-1s-1 for low molecular weight molecules. Dissociation 
rate constants (kd) of 10
-5 to 1 s-1 are within the typical working range. When setting up an 
assay, all injection times can be specified, such as contact and dissociation between the 
two molecules, regeneration and conditioning steps.26 
 
1.1.5. Compound screening 
A commonly used technique in drug discovery is the screening of large libraries of 
compounds in order to identify those structures which are most likely to bind to a drug 
target. These libraries can be both physical and assessed by means of a biological or 
biophysical assay, as described above, or virtual databases of known structures which are 
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computationally screened. If a biologically active compound for a certain target is already 
known it is possible to search these virtual libraries for similar compounds – this process is 
called a similarity search. The common way of characterizing these molecules is by 
attributing to them a chemical fingerprint, which is simply a list of binary values (0 or 1). 
The molecular access system (MACCS) keys fingerprint for a given structure is based on a 
set of questions about the chemical structure, such as “are there fewer than 3 oxygens?” or 
“is there a ring of size 4?”. The result of this is a list of binary values- either true (1) or false 
(0) and it characterises the molecule. Once the molecules have been represented by such a 
code a Tanimoto coefficient (Equation 2) can be used as a measure of similarity. 
Compounds that have a Tanimoto coefficient value > 0.85 are generally considered similar 
to each other.27  
The positive hits obtained in a virtual screen are not always active but provide a means of 
filtering virtual libraries and usually make experimental screening methods more efficient 
by providing compounds that are more likely to be biologically active. 
  
   
         
 
Equation 2. Tanimoto Coefficiency. Where Na represents the number of features in molecule A, Nb is the 
number of features in B, and Nab is the number of features common to both A and B. 
 
1.1.6. Medicinal chemistry 
The International Union of Pure and Applied Chemistry (IUPAC) defines medicinal chemistry 
as “a chemistry-based discipline, also involving aspects of biological, medical and 
pharmaceutical sciences. It is concerned with the invention, discovery, design, 
identification and preparation of biologically active compounds, the study of their 
metabolism, the interpretation of their mode of action at the molecular level and the 
construction of structure-activity relationships.”28 
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Figure 9. Schematic representation of the disciplines integrating medicinal chemistry. 
 
As represented in Figure 9, medicinal chemistry combines techniques from various fields, 
including structural biology, biochemistry, chemical biology, synthetic chemistry, and 
computational chemistry to design and synthesise biologically active molecule, as well as 
characterising their biological activity and binding interactions to the target. 
Small molecule hits from a drug discovery screen are commonly optimised using medicinal 
chemistry. Firstly, the synthesis of a hit obtained from a virtual screen or a commercial 
library must be investigated and the bioactivity of the synthesised compound assessed. Hit 
to lead optimisation can take place by synthesising analogue compounds which can provide 
insight into the binding mode and functional groups necessary for activity. Understanding 
the binding interactions between a drug and its target can consequently lead to an 
improved design of drugs to be synthesised. A successful drug design is expected to result 
in compounds with improved biological activity and/or physico-chemical properties. 
Synthetic routes are expected to be easily modified, so that a range of analogue 
compounds can be synthesised, employing modern techniques and reagents which are able 
to provide faster, cleaner, and more efficient chemistry. 
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1.1.6.1. Microwave assisted organic synthesis 
Microwave-assisted organic synthesis allows for faster reaction times and can be applied to 
most types of reactions. It is easily reproducible, safe, and evidently allows for the synthesis 
of multiple compounds to be performed in a much shorter time span than thermally driven 
reactions. A basic understanding of the physics behind this process might also allow for an 
improved synthesis. 
A microwave is a form of electromagnetic energy that falls within a frequency of 300 to 
about 300 000 megahertz (MHz). Within this region only molecular rotation is affected, not 
molecular structure. Microwaves couple directly with the molecules in a reaction mixture, 
leading to a rapid increase in temperature, via two fundamental mechanisms: Dipole 
rotation and Ionic conductance. Dipole rotation refers to the alignment of polar molecules 
with the electric field component of the radiation and it is the sympathetic agitation of the 
molecules that generates heat. Ionic conductance occurs when free ions or ionic species 
are present in the substance being heated. Heat generation is due to frictional losses, 
which depends on the size, charge, and conductivity of the ions as well as on their 
interactions with the solvent.29 
Microwave energy is transferred by dielectric loss. The dielectric loss factor (Ɛ’’) and the 
dielectric constant (Ɛ’) of a material are two determinants of the efficiency of heat transfer 
to the sample. Their quotient (Ɛ’’/ Ɛ’) is the dissipation factor (tan δ), high values of which 
indicate ready susceptibility to microwave energy. The Arrhenius equation can be used to 
explain how microwaves increase the rate of reaction. A reaction rate constant (k) is 
dependent on the frequency at which molecules collide, and on whether the molecules are 
properly oriented when they collide (A); and the fraction of those molecules that have the 
minimum energy required to overcome the activation energy barrier (e-Ea/RT). 29 
 
           
Equation 3. Arrhenius equation. Where: k is the rate constant; A is the pre-exponential factor and represents 
the total number of collisions (leading to a reaction or not) per second; T is the temperature; R is the universal 
gas constant; and Ea is the activation energy.  
 
37 
 
Microwave energy will affect the temperature parameter of the equation. An increase in 
temperature causes the molecules to move about more rapidly and consequently leads to a 
greater number of more energetic collisions. Generally, the reaction rate for a microwave-
assisted synthesis doubles for every 10 °C increase in the reaction temperature of a heat-
driven reaction.30 
When developing a new method for microwave synthesis the four most important factors 
to consider are: solvent, temperature, time and power. Most microwave reactions are 
performed in closed systems rather than at atmospheric pressure. This allows solvents to 
be heated up to temperatures that are four times their respective boiling point. The choice 
of solvent is a critical step: the more polar a reaction mixture is the greater its ability to 
couple with the microwave energy, resulting in a faster rise in internal temperature; thus, if 
the reactants are “non-absorbing” the solvent must be polar. A starting point for deciding 
the temperature of the reaction is 10 °C above the temperature used in conventional 
methods, if known. For reactions performed under reflux, the temperature can be set to  
50 °C above the boiling point. Deciding on how long to run a microwave reaction for 
depends on the type of reaction being performed, but a good starting point for pressurized 
reactions is 5-10 min. the amount of power being applied is also important: whilst a low 
power level might not provide successful results, excessive power may cause 
decomposition. 50 watt is generally good for high-absorbance solvents, and 150 watt for 
medium absorbers. If the system is struggling to reach the desired temperature the power 
should be increased. As the reaction reaches its set temperature, the power is reduced so 
that the mixture does not bypass that temperature point. The fast reaction times and small 
scale in which microwave reactions can be performed provide an easy technique for 
development and optimisation of the method.29-30 
 
1.2. Understanding and predicting protein-ligand interactions  
Drug targets have binding sites into which drugs can fit and bind. Most drugs bind to their 
targets by means of intermolecular interactions, which can be experimentally determined 
by analysis of 3D structures or hypothesised by means of theoretical studies using 
computational methods.  
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1.2.1. Intermolecular interactions 
There are several ways in which a drug might interact with its target. The different types of 
intermolecular bonding interactions differ in their bond strengths and depend on the 
structure of the drug and the functional groups that are present  
The actual absolute strengths of the interactions vary depending on the molecules involved 
Table 1 shows the relative strength of some intermolecular interactions and a range of 
their average strength. The strength of covalent bonds is > 80 kcal/mol.31 
 
Table 1. Relative specificity and strength of intermolecular interactions. 
Interaction Specificity31 Strength31-32 
Hydrogen bonding High 0.25 – 40 kcal/mol 
Halogen bonding High 1 – 40 kcal/mol 
Electrostatic Low 5 – 10 kcal/mol 
π – stacking Moderate 5 – 7 kcal/mol 
Hydrophobic Low 1.5 – 2 kcal/mol 
Van der Waals Low < 1 kcal/mol 
 
Each drug may use one or more of these, but not necessarily all of them. Once a lead 
compound is known one must determine which parts of the molecule are important for 
biological activity and which are not. In some cases, x-ray crystallography may be used to 
solve the structure of the compound bound to the target site and then studied using 
molecular modelling software to identify binding interactions and possibly improve these 
by changing the structure of the molecule.  
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1.2.1.1. Ionic interactions 
Ionic or electrostatic interactions take place between groups having opposite charges. 
These interactions are stronger in hydrophobic environments than in polar ones. If an ionic 
interaction is possible between a drug and a protein, this is likely to be the most important 
initial interaction as the drug enters the binding site.32 
 
1.2.1.2. Hydrogen bonds 
Hydrogen bonds vary in strength and occur between an electron-rich heteroatom, which 
contains a lone pair of electrons, and an electron-deficient hydrogen which is usually linked 
to an electronegative atom such as oxygen or nitrogen. Both CO and NH groups from a 
protein can form hydrogen bond interactions. The functional group donating the hydrogen 
to the bond is called a hydrogen bond donor, whilst the group that interacts with the 
hydrogen is called hydrogen bond acceptor. The bond distance is typically between 2.6 and 
3.2 Å and the angle between the donor-hydrogen and the acceptor is generally above 
150 °.33 
 
1.2.1.3. Halogen bonds 
Halogens are commonly added to drugs to provide hydrophobic bulk and/or improve 
ADME properties (absorption, distribution, metabolism, excretion). It has been observed 
that in some cases the organic halides Cl, Br, and I can interact with protein electronegative 
atoms such as O, S, and N. The small size and high electronegativity of fluoride prevents it 
from making halogen bonds. The strength of halogen bonds is similar to that of hydrogen 
bonds.33  
 
1.2.1.4. Orthogonal multipolar interactions 
This type of interaction is characterised by a close orthogonal contact between two dipolar 
functional groups. For example, it has been observed that the CF3 group of the abl kinase 
inhibitor nilotinib forms one interaction orthogonal to an amide besides two further 
contacts to the imidazole NH of a histidine as well as an isoleucine side chain.34  
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1.2.1.5. Hydrophobic interactions 
In a protein-ligand interaction, the amount of protein hydrophobic surface buried upon 
ligand binding is the structural parameter that better correlates with binding affinity. 
Hydrophobic interactions involve the displacement of ordered layers of water molecules 
that surround hydrophobic regions of the molecule.35 This type of interaction is the only 
listed that is entropy driven.31 
 
1.2.1.6. Cation – π interactions 
An ion – dipole interaction can occur when a charged or ionic group in one molecule 
interacts with a dipole in a second molecule. An aromatic ring can interact with an ionic 
group such as a quaternary ammonium ion if the positive charge of the ammonium group 
distorts the π electron cloud of the ring to produce a dipole moment where the face of the 
aromatic ring is electron-rich and the edges are electron-deficient. These interactions can 
be strong on the surfaces of proteins and have rarely been found buried within proteins.36 
 
1.2.1.7. Van de Waals interactions 
Van der Waals interactions involve interactions between hydrophobic regions of different 
molecules. The electronic distribution in neutral regions is never completely even and there 
can be areas of high and low electron densities leading to temporary dipoles. The dipole in 
one molecule can induce dipoles in a neighbouring molecule, leading to weak interactions 
between the two molecules. 
 
1.2.1.8. Repulsive interactions 
Forms of repulsion include proximity and identical charges: if molecules come too close to 
each other their molecular orbitals start to overlap and repel each other; similarly, two 
positively or negatively charged groups are also repelled. 
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1.2.2. Molecular modelling 
The use of molecular modelling comes from a need to represent 3D molecular structures 
such as proteins and DNA in a way that is easy to visualise and therefore easier to 
understand. In medicinal chemistry, molecular modelling is mostly used to study drug-
target interactions, allowing the prediction of binding sites and the more stable binding 
modes. These studies can be performed using the x-ray crystal structure of the target or a 
modelled structure based on homologous proteins with determined structure. 3D 
visualisations of molecular interactions are only made possible through the use of complex 
mathematical equations that follow the laws of classical and quantum physics. The 
computational methods used in molecular modelling can be split into molecular mechanics 
and quantum mechanics. 
 
1.2.2.1. Molecular and Quantum mechanics 
Molecular mechanics (MM) applies classical physics to calculate force fields, a set of 
parameters and mathematical equations involved in how molecules associate. The “force 
field” is therefore a MM equation and its associated atom types, and different force fields, 
are designated for different purposes. 
The basic form of the total energy in a force field includes the energies involved in both 
bonded (covalent) and non-bonded interactions, where bonded energies result from bond 
stretching, angle bending and torsion, and non-bonded interaction include electrostatic 
and Van der Waals interactions (Equation 4). This is a very simplistic representation of a 
force field and non-bonded interactions often value in additional factors such as partial 
covalent bonds including hydrogen bonds, halogen bonds, aromatic bonds, and 
hydrophobic interactions.  
 
 
Equation 4. Total energy in an additive force field. The total energy equals the sum of the energies involved in 
bonded interactions and non-bonded interactions. 
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MM ignores electrons, calculating the energy of the system from the nuclear positions. This 
method is suitable for energy minimization and conformational analysis. Quantum 
mechanics (QM) uses quantum physics to calculate the properties of a molecule by 
considering the interactions between the electrons and the nuclei of the molecule. QM 
methods can be subdivided into two broad categories: ab initio and semi-empirical. ab 
initio calculations are extremely computationally demanding and do not use any stored 
parameters or data, being restricted to small molecules and suitable for measuring 
molecular properties such as molecular orbital energies and coefficients. If calculations 
consider valence electrons only and/or experimental data they can be massively reduced 
and can be carried out on larger molecules. These are known as semi-empirical methods. 
MM and QM provide the basis for molecular dynamics studies, structure alignment and 
docking analysis. 
 
1.2.2.2. Docking  
Molecular dynamics is a program designed to mimic the movement of atoms within a 
molecule and can be carried out on a molecule to generate different conformations, which 
on energy minimisation give a range of stable conformations. 
Genetic and evolutionary algorithms are algorithms programmed to work as biological 
evolution. In molecular modelling, these are designed to produce different binding 
conformations and to carry on an evolutionary process which selects the most stable 
conformations. 
Docking is the process of fitting a molecule into a binding site based on steric and/or 
chemical complementarity. It is used to predict the binding modes and affinities of 
compounds when they interact with their target and can be used to analyse large libraries 
of compounds and/or optimise binding for great ligand affinity. Most approaches consider 
the protein to be rigid and allow the ligand to be flexible. Different algorithms are available 
for protein-ligand docking and commonly used programs are DOCK, FlexX, and  GOLD.37  
The molecular modelling software employed in this project was GOLD 5.1 (from the 
Cambridge crystallographic data centre) and MOE (from chemical computing group). 
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GOLD software 
GOLD (Genetic Optimisation for Ligand Docking) is a genetic algorithm for docking flexible 
ligands into protein binding sites.  
Docking programs usually employ a scoring function to rank ligands according to their 
theoretical affinity. The Goldscore fitness function is optimised for the prediction of ligand 
binding positions rather than the prediction of binding affinities, although some correlation 
may be found. This function is made up of four components: 
 Protein-ligand hydrogen bond energy (external H-bond) 
 Protein-ligand van der Waals (vdw) energy (external vdw) 
 Ligand internal vdw energy (internal vdw) 
 Ligand torsional strain energy (internal torsion) 
Ligand intramolecular hydrogen bond energy (internal H-bond) may be added.  The fitness 
score is taken as the negative of the sum of the component energy terms, so that larger 
fitness scores are better. GOLD optimises the fitness score by using a genetic algorithm. 
Briefly, a population of possible docking solutions is set up at random; each solution is 
encoded as a “chromosome” containing information about the mapping of ligand H-bond 
atoms onto complementary protein H-bond atoms, mapping of hydrophobic points on the 
ligand onto protein hydrophobic points, and the conformation around flexible ligand bonds 
and protein OH groups; each chromosome is assigned a fitness score and the chromosomes 
within the population are ranked according to fitness.38 
 
MOE software 
MOE (Molecular Operating Environment) is a molecular graphics software which also 
performs molecular modelling functions. It has been optimised for structure-based drug 
design, allowing scaffold replacement, docking, conformation analysis, and ligand 
optimisation in pocket. MOE is also used for pharmacophore discovery, quantitative 
structure activity relationships (QSAR), homology modelling and macromolecular 
simulation.39 Aditionally, it provides a series of applications for medicinal chemistry which 
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allow a clear visualisation of non-bonded interaction and protein-ligand interaction 
diagrams, as well as the building of surfaces to define binding site topology.40-41 The 
“Ligand:Protein interaction diagrams” function of MOE provides schematic 2D 
representations of key interactions between proteins and ligands, which aids the analysis 
of docking studies.42 
 
1.3. The guanylate cyclase protein family  
The macromolecular targets explored in this thesis belong to the guanylate cyclase protein 
family. Guanylate cyclases (guanylyl cyclases, GCs) are a family of homologous enzymes 
that exist as a number of isoforms, some of which are membrane-bound, also called 
particulate guanylate cyclases (pGC), while others are soluble (sGC). Both sGC and pGCs 
catalyse the conversion of guanosine triphosphate (GTP) into the second messenger 3’,5’-
cyclic guanosine monophosphate (cGMP) and pyrophosphate (PPi) (Figure 10). Although 
sGC and pGCs share a homologous catalytic domain the mechanisms by which they are 
activated are different: pGCs are stimulated by small peptide hormones, whilst sGC is the 
human receptor for nitric oxide (NO). GTP binds to a single catalytic site in sGC and two 
catalytic sites on pGC.43-44 
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Figure 10. Catalytic mechanism of guanylate cyclase activity. 
 
Membrane- bound guanylate cyclases, GC-A and GC-B, are members of the natriuretic 
peptide receptor family and are also called natriuretic peptide receptor-A (NPR-A) and 
natriuretic peptide receptor-B (NPR-B), respectively. A third receptor for natriuretic 
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peptides, NPR-C, lacks the GC domain.45  Figure 11 summarises the signalling pathways of 
GCs. Natriuretic peptides bind to the extracellular domain of pGCs, catalysing the 
conversion of GTP into cGMP at the intracellular GC domain.  Nitric oxide synthase (NOS) 
catalyses the production of NO from L-arginine. NO binds to the heme nitric oxide/oxygen 
(H-NOX) domain of sGC, leading to the formation of cGMP at the GC domain.46 cGMP is a 
substrate for cGMP-dependent protein kinases47, PDEs48, and gated channels49.   
 
 
Figure 11. Natriuretic peptide receptors and soluble guanylate cyclase domain structure and signaling 
pathway. NOS: nitric oxide synthase; KHD: Kinase homology domain; GC-guanylate cyclase domain; HNOX: 
hydrogen and nitric oxide exchange domain. 
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1.3.1. Natriuretic peptide receptors 
Natriuretic peptides (NPs) are structurally related hormones/paracrine factors that regulate 
vascular homeostasis, fat metabolism and long bone growth. The family of mammalian 
natriuretic peptides is formed by natriuretic peptides type-A (ANP), type-B (BNP) and type-
C (CNP). ANP was the first to be discovered and related to the promotion of sodium and 
water excretion via a cGMP signalling pathway.50 ANP acts mainly as a cardiac hormone 
released from the atria which upon cleavage of proANP into the mature peptide enters the 
coronary sinus and is distributed to its target organs via the circulation. BNP is actively 
produced by the ventricles and unlike ANP, it is not stored in granules but rather 
transcribed as needed in response to cardiac stress states. Levels of both ANP and BNP are 
elevated in patients with congestive heart failure. CNP differs from both ANP and BNP as it 
acts in a paracrine manner. It is the most highly expressed natriuretic peptide in the brain 
but is also expressed in chondrocytes and endothelial cells. CNP is not stored in granules 
and its secretion is increased by growth factors and sheer stress. Its expression in 
neointimal vascular smooth cells is increased in response to vascular injury.45, 51 
NPR-A binds natriuretic peptides at a stoichiometry of 2:1 with a rank preference of ANP>> 
BNP>>CNP. NPR-B is the most active NPR in the failed heart and preferentially binds CNP. 
NPR-C is a non-GC receptor that binds all three NPs.45, 52  
 
1.3.1.1. CNP/NPR-C signalling 
NPR-C was initially thought to function solely as a clearance receptor for the degradation of 
NPs. It was later found to play an important role in the cardiovascular systems and its 
activation has been linked to the smooth muscle hyperpolarisation induced by CNP in 
resistance arteries, where the natriuretic peptide acts as an endothelium-derived 
hyperpolarizing factor (EDHF).53   
NPR-C is coupled to an inhibitory heterotrimeric G protein, Gi, and both the α and βγ 
subunits of this protein mediate a number of important physiological effects. It presents a 
37 aminoacid cytoplasmatic domain that is composed of Gi activator sequences but its 
structure does not resemble the traditional heptahelical G protein-coupled receptor with 
seven transmembrane spanning domains. The 17 aminoacid sequence in the middle region 
of the 37 aminoacid intracellular domain (R469-R485) has been identified as the 
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functionally relevant Gi activator sequence.
54 CNP is a 22 residues peptide circularised by a 
disulphide bond between C6-C22. The peptide binds into a V-shaped cleft formed from the 
homodimer of the receptor. 
Activation of NPR-C in vascular smooth muscle cells activates a potassium conductance 
which leads to hyperpolarisation and relaxation. CNP activation of NPR-C has also been 
shown to inhibit adenylyl cyclase activity leading to a reduction in intracellular cAMP levels 
in cardiac myocytes.54 CNP does not circulate in the blood stream to any great extent, 
except in disease state. CNP mRNA is increased in response to shear stress, pro-
inflammatory cytokines and lipopolysaccharides, and plasma levels of CNP are elevated in 
inflammatory cardiovascular pathologies.55 
CNP is likely to maintain a substantial cytoprotective, anti-atherogenic influence on the 
blood vessel wall and loss of endothelium-derived CNP may be an important contributor to 
the pathogenesis of inflammatory cardiovascular diseases such as atherosclerosis and 
restenosis. The observation that CNP responses are accentuated in the absence of 
endothelium-derived NO leads to the hypothesis that CNP might compensate for 
deficiencies in NO and show anti-atherogenic activity.53  
Studies performed in rat isolated mesenteric arteries showed that blockade of NPR-C 
inhibits CNP- and EDHF- dependent responses, corroborating the role of CNP as an EDHF. 
NPR-C antagonism inhibits the smooth muscle hyperpolarisation associated with EDHF- 
dependent dilation in these arteries, suggesting that the CNP/NPRC signalling might be an 
important target for the treatment of cardiovascular diseases.56 
 
1.3.2. Soluble guanylate cyclase 
sGC domains are conserved within species and have been suggested to be acquired by the 
animal lineage via transfer from bacterial sources.57 GC catalytic domains are homologues 
to the C1 and C2 domains in adenylate cyclase, which converts ATP into 3’,5’-cyclic 
adenosine monophosphate (cAMP) and diphosphate. 
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1.3.2.1. The NO-sGC-cGMP signalling 
NO can be viewed as both a cytotoxic agent and a vital signalling molecule. The 
identification of this diatomic gas as an endothelium-derived relaxation factor rendered it 
of great importance in biological studies.58 NO can easily diffuse through cell membranes 
into target cells and bind to a prosthetic heme group in sGC, leading to a conformational 
change that increases the rate of GTP conversion into cGMP. 
The NO-sGC-cGMP signalling has an important role in regulating blood flow, and in the 
perfusion and function of many organs and tissues. Increased levels of cGMP lead to 
smooth muscle relaxation, inhibition of platelet aggregation and anti-inflammatory effects. 
Reduced bioavailability or responsiveness to NO contributes to the development of 
cardiovascular, pulmonary and hepatic diseases. In contrast, aberrant signalling has also 
been linked to vascular disorders such as hypertension, atherosclerosis and coronary heart 
diseases and has also been shown to occur during sepsis and neurodegenerative 
disorders.59-60 
 
Signalling in the cardiovascular system 
In the vasculature, cGMP is generated by both cytosolic sGC and pGCs. cGMP has a key role 
in the control of vascular tone and blood pressure. Indeed, its primary action is the 
relaxation of vascular smooth muscle and vasodilation.61 Reciprocal regulation of the NO-
sGC-cGMP and NP-pGC-cGMP pathways is evident, such that one cGMP generating system 
may compensate for the dysfunction of the other. For instance, reduced NO-sGC-cGMP 
signalling in patients with cardiovascular risk factors and atherosclerosis may be 
compensated for by increased pGC-derived cGMP.62 
cGMP has also been related to endothelial and VSM growth, endothelial permeability, and 
anti-inflammatory actions. The increase in endothelial permeability mediated by cGMP may 
be involved in ischemia/reperfusion injury. Both NPs- and NO- derived cGMP have anti-
inflammatory activity: whilst NPs prevent immune cell activation, sGC activity appears to 
play an important role in modulating leukocyte adhesion. Moreover, vascular activity of 
cGMP has been correlated to a range of cardiovascular conditions, from systemic and 
pulmonary hypertension to coronary artery disease and atherosclerosis, as well as erectile 
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dysfunction. Thus, modulation of sGC activity is of profound interest in this field and may 
have great potential for therapeutic applications.63 
 
Signalling in the nervous system 
In the brain, sGC acts as a neurotransmitter receptor. The rapid on- and off-kinetics and the 
desensitization profile of activity, combined with variations in the rate of cGMP breakdown, 
provide fundamental mechanisms for shaping cellular cGMP responses and is important in 
decoding NO signals under physiological and pathological conditions.64  
NO-sGC-cGMP signalling has also been implicated in the modulation of synaptic 
transmission and to act in long-term potentiation, one of the major cellular mechanisms 
that underlie the processes of learning and memory65 
Moreover, involvement of cGMP in early differentiation events of embryonic stem cells has 
been proposed. In rats, high cGMP levels promote neural stem cells differentiation to 
neurons whilst reduced cGMP levels promote differentiation to non neuronal (mainly glial) 
cells, which consequently leads to impaired cognitive function. Restoring cGMP levels with 
sildenafil normalizes neural stem cells differentiation.66  
 
sGC and Parkinson’s disease 
NO can mediate neurotoxicity and cause neuronal cell death. The neurotransmitter is 
associated with pathogenic mechanisms involved in multiple neurodegenerative diseases, 
including Parkinson’s Disease (PD). Such mechanisms include excitotoxicity, DNA damage, 
and protein modifications such as nitrosylation and nitration.67 
Recent research has suggested the involvement of NO in PD is due to activation of sGC. PD 
is associated with loss of dopaminergic stimulation to a part of the brain called the 
striatum. Disruption of striatal NO-sGC-cGMP signalling cascades result in profound 
changes in behavioural, electrophysiological, and molecular responses to pharmacological 
manipulations of dopamine and glutamate transmission.68 
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The dopaminergic neurons are responsive for motor control. Therefore, the most common 
symptoms of PD are movement associated including tremors, rigidity, and postural 
unsteadiness. In extreme cases cognitive issues may also arise, leading to memory 
impairment and dementia. Drugs used in the treatment of PD are shown in Figure 12. 
Conventional treatment of PD is based on dopamine replacement with the pro-drug 
levodopa 1 (L-DOPA) in combination with an inhibitor of its peripheral conversion to 
dopamine (carbidopa 2 or benserazide 3). This is however only a symptomatic treatment 
and leads to progressive loss of efficacy with time.69 Thus, alternative treatments are being 
explored that target alternative neurotransmitter systems. 
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Figure 12. Chemical structures of small molecules used in the treatment of Parkinson's Disease and sGC 
inhibitor ODQ. 
 
Studies performed in animal models of PD with a potent sGC inhibitor, ODQ 4, have shown 
that the enzyme could be a new drug target for restoring basal ganglia dysfunction and 
attenuating motor symptoms associated with PD. ODQ 4 reversed the characteristic 
elevations in striatal cGMP levels and reduced the increase in spontaneous firing observed 
in the dopamine-depleted striatum.68 NO-sGC-cGMP signalling is thus a new target for non-
dopamine treatment for PD. 
 
1.3.2.2. Structure and regulation of sGC 
sGC is generally found as a heterodimer composed of a β-subunit (70 kDa) and a larger α-
subunit (77 kDa). The best characterized isoform is the α1/β1 protein, but α2 and β2 subunits 
have also been identified. Each subunit is composed of multiple domains, as represented in 
Figure 13. The H-NOX of sGC is located at the N-terminus, but only the β-subunit presents a 
prosthetic heme group. PAS-like domains are present in both subunits and are thought to 
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direct preferential heterodimer formation. A coiled-coil (CC) bundle is followed by the C-
terminal catalytic domain where turnover of GTP into cGMP occurs.70 GTP binds to the β-
subunit through its purine ring and the cofactor Mg2+, which stabilises the β and γ 
phosphates, binds to acidic residues in the α-subunit.71 
 
 
Figure 13. Schematic representation of the structural organisation of sGC domains. Adapted from 
71
 
 
The heme group on sGC does not bind O2 and CO is only a very weak activator. The binding 
of NO and CO, and discrimination of O2 by sGC has been the subject of great discussion and 
extensively studied using physical-chemical methods. Elucidation of the sGC mechanism 
depends on the understanding of the sGC heme environment and the structural changes 
induced by NO and CO binding to the sGC heme co-factor. UV-vis spectroscopy showed 
that the β1-subunit (1 – 385) contains a five-coordinate, high-spin ferrous heme. Through 
site-directed mutagenesis and spectroscopic approaches it was demonstrated that the 
heme in sGC is coordinated to the proximal Histidine-105 in the β1 subunit. Raman 
characterization of the heme domain showed that in addition to the relatively weak Fe-His 
bond and relatively negative polarity of the distal heme pocket, the lack of hydrogen bond 
formation between a distal residue and oxygen in heterodimeric sGC may significantly 
contribute to the stability of the enzyme under physiological conditions. 72-73 The CO-sGC 
complex on the other hand, was determined to be a six-coordinate with the Fe-His bond 
intact and CO bound on the distal side of the heme.74  
More recent studies have been focused on the desensitization and conformational changes 
associated with sGC activation, which might involve S-nitrosation. For instance, hydrogen-
deuterium exchange mass spectrometry (HDX-MS) has recently been used to map NO-
induced changes in sGC surface accessibility to develop a model of the conformational 
changes that control sGC activity.75  
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The mechanism for sGC regulation by NO is controversial and has been suggested to 
involve both NO binding to the heme and a second NO binding site. The non-heme binding 
site seems to mediate vasodilation by acute NO signals, whereas the tight NO-heme 
complex mediates resting tone in the vasculature. NO has been proposed to act at the non-
heme site of the enzyme in the presence of ATP and GTP, suggesting the presence of 
several allosteric nucleotide-binding sites that regulate NO-heme dynamics and thereby 
catalytic activity.70  
Whilst the crystal structure of the full length sGC remains unknown, structures of the 
catalytic domain heterodimer and β-homodimer have been determined (PDB entries 3uvj 
and 2wz1, respectively).71  Earlier analysis of the crystal structure of the catalytic domain of 
a sGC (CYC12) from the unicellular green algae “Chlamydomonas reinhardtii”, which shares 
40 to 50 % identity with the soluble and membrane-bound GC catalytic domains, has 
shown that it resembles that of adenylate cyclase which was expected due to the sequence 
and functional similarity between them. The structure of the GC catalytic domain differs 
from that of adenylate cyclases primarily in the elements that connect strands and helices, 
and in the less-conserved C-terminal subdomains. It has been suggested that the difficulty 
in crystallizing GC domains in comparison to structurally-related adenylate cyclase may be 
due to an increased intrinsic flexibility in the GC domain.76 
In the catalytic domain of sGC, the α- and β-subunits come together to form a head-to-tail 
dimer (Figure 14). The monomers are highly similar and consist of seven β-sheets and five 
α-helices. The crystal structure has revealed a suble but possible important difference in 
the monomers. An extended β4-β5 hairpin in the α-subunit points away from the β-
subunit, whilst in other cyclase structures it has been shown to be involved in interdomain 
contacts.71 
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Figure 14. Overview of sGC catalytic domain heterodimer crystal structure (PDB ID: 3uvj). a) Heterodimer of 
sGCα and sGCβ catalytic domains; b) Architecture of the α-subunit of the GC catalytic domain; c) Architecture of 
the β-subunit of the GC catalytic domain. Adapted from 
71
 
 
The catalytic domain of human sGC possesses two well-defined binding sites, one site 
responsible for catalysis and one allosteric binding site (also referred to as the 
pseudosymmetric site), which is thought to be able to accommodate small molecules that 
control enzyme activity in a manner similar to forskolin in the binding pocket of adenylyl 
cyclase.71, 77 It has also been proposed that ATP binds to both sites in sGC and inhibits sGC 
activity via competition with GTP, highlighting the potential for allosteric regulation of the 
enzyme.59, 78-79 
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1.3.2.3. Chemical biology tools for sGC 
The first two chemical biology tools available to study sGC activity were YC-1 (5) and ODQ 
4, a stimulator and an inhibitor, respectively. There are currently two compound classes 
known to activate sGC by different mechanisms, one that acts in the absence of NO by 
replacing the heme moiety, such as cinaciguat (BAY 58-2667, 6) and a second class of 
compounds such as the benzylindazole derivative YC-1 (5) which is thought to bind to an 
allosteric site and act synergistically with NO to increase cGMP production.80-81 The 
inhibitor ODQ 4 acts by oxidizing sGC, leading to the formation of an NO-insensitive form of 
the enzyme. 
 
sGC activators 
Small molecules known to activate sGC are represented in Figure 15. YC-1 – like sGC 
stimulators are heme-dependent: they stimulate sGC directly and enhance the sensitivity of 
the reduced enzyme to low levels of bioavailable NO. Some of these compounds are BAY 
41-2272 (7), riociguat (BAY 63-2521, 8), and CFM-1571 (9). Conversely, heme-independent 
compounds do not modulate NO signalling but activate the oxidized or heme-free enzyme 
via binding to the heme pocket and include the compounds cinaciguat 6 and HMR-1766 
(10).  
The activity of YC-1 (5) in the NO-sGC-cGMP pathway was first discovered in human 
platelets, where the compound shows an antiplatelet effect.82 It was then shown to act 
synergistically with NO to increase intracellular cGMP levels in vascular smooth muscle cells 
where it exerts vasorelaxation.83 YC-1 (5) increases the maximal catalytic rate and sensitizes 
the enzyme towards its gaseous activators by binding to an allosteric site on sGC molecules, 
thereby reducing the ligand dissociation rate from the heme group.84-85 It was discovered 
that YC-1 (5) not only activates sGC, but also affects cGMP metabolism, as it inhibits both 
cGMP breakdown in aortic extracts and the activity of PDE isoforms 1 – 5 in vitro. Thus, YC-
1 (5) is a highly effective vasodilator - It combines the functions of a classical 
nitrovasodilator with PDE inhibition of vasoconstriction. However, it shows relatively low 
potency and low selectivity.86-87 
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Figure 15. Chemical structures of known sGC activators. 
 
YC-1 (5) paved the way to the design and discovery of other stimulators such as the 
compound BAY 41-2272 (7). The residues cysteine-238 and cysteine-243 region in the α1-
subunit of sGC had been suggested as the target for this new type of stimulators.88 
Structure-activity relationship (SAR) data for BAY 41-2272 (7) revealed that several 
structurally related compounds relax aortic rings and reveal a long-lasting blood pressure 
lowering affect in rats, showing that these compounds could be valuable for the treatment 
of cardiovascular diseases.89 The activity of sGC stimulators in animal models demonstrated 
potential therapeutic use in a range of diseases from hypertension to heart failure, 
artherosclerosis, restenosis, thrombosis and erectile dysfunction. Optimization of BAY 41-
2272 (7) lead to the discovery of riociguat 8, an sGC activator which has recently been FDA-
approved for the treatment of pulmonary arterial hypertension (PAH) and 
persistent/recurring chronic thromboembolic pulmonary hypertension (CTEPH).90  
The sGC activator cinaciguat 6 resulted from the optimization of a hit obtained in the 
screening of more than 900 000 compounds in a cell-based assay for cGMP. In contrast to 
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the sGC stimulators which act synergistically with NO, cinaciguat 6 shows only an additive 
effect when combined with different concentrations of NO-donors. The mechanistic model 
proposed for the cinaciguat 6-induced enzyme activation shows that the sGC prosthetic 
heme 11 is replaced by the compound. The 2.3 Å crystal structure of the H-NOX•cinaciguat 
complex of the cyannobacteria Nostoc (PDB entry 3l6j) has provided insights into the 
molecular mechanisms of sGC activation by a heme mimetic.91 As represented in Figure 16, 
at a basal state the heme group is coordinated to a histidine residue. Upon NO binding, the 
histidine bond is broken, leading to the conformational change necessary for enzyme 
activation. Cinaciguat 6 either displaces the heme or binds to the apoenzyme, activating 
the enzyme without NO.80  
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Figure 16. Mechanism of action of sGC activator cinaciguat 6. a) chemical structure of the heme in sGC; b) 
activation of sGC via binding of NO to the distal face of the 5-coordinated heme leads to breakage of the 
proximal Fe-Histidine bond; c) activation of sGC by cinaciguat 6 requires displacement of the heme such that 
cinaciguat 6 can now occupy the heme pocket. Adapted from Martin, F et al.
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During oxidative stress, common to vascular disease, sGC is desensitized and degraded 
upon heme loss; cinaciguat 6 activates sGC, protecting heme-oxidised sGC from 
degradation. Phase II clinical trials (COMPOSE programme) for acute heart failure with 
cinaciguat 6 were terminated due to an excess of hypotension and recruitment 
difficulties.92 
 
sGC inhibitors 
As discussed above, a great effort has been put towards the development of small 
molecules activators of sGC. Conversely, the availability of GC inhibitors is scarce and the 
available compounds act on the heme domain, rendering the enzyme unresponsive to its 
natural ligand, NO. ODQ 4 is one such compound and despite not being specific to the 
heme of sGC it has been widely used to study the function of the NO-sGC-cGMP signal 
transduction pathway and was a valuable tool to distinguish signal transduction events 
mediated by sGC from those involving other nucleotide cyclases.93 ODQ 4 reacts with the 
ferrous heme of sGC to yield ferric heme, therefore not affecting the catalytic domain of 
sGC.94  
Current sGC inhibitors show poor selectivity and bioavailability, as they can oxidise other 
heme-containing proteins such as haemoglobin.  
 
1.4. Project aims and thesis overview 
The nitric oxide receptor sGC is a known druggable target and small molecules successfully 
manipulate its activity by different mechanisms. Drugs can activate the enzyme either 
through interaction with its heme site or binding to an allosteric site, showing important 
responses in cardiovascular and pulmonary diseases. On the other hand, inhibition of the 
enzyme has shown promising results in neurodegenerative diseases and sepsis, using 
potent inhibitors which oxidise the heme on sGC making it unresponsive to NO. Although 
many advances have been made in the characterisation of NO-sGC-cGMP signalling 
pathways in the cardiovascular and pulmonary systems, its role and implications in the 
nervous system is not completely understood. 
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The aim of this project was to discover and characterise small molecules capable of 
inhibiting sGC activity through a mechanism different from that of ODQ 4, through binding 
to the catalytic domain of sGC rather than the heme domain, with the view that such 
compounds could be used as a tool to further study the implication of sGC in neurological 
diseases such as PD. The approach followed for the discovery of small molecule inhibitors 
of sGC would include compound screening, organic synthesis, molecular modelling, and 
biochemical and biophysical characterisation of the compounds’ activities and binding to 
sGC through a newly developed SPR assay.  
Chapter 1 gives an overview of target-based drug discovery and the techniques being 
currently employed in the search of small molecule drugs. Moreover, the target of this 
thesis, soluble guanylate cyclase, is introduced.  
A new assay was developed for assessing binding of small molecules to sGC. Thus, the SPR 
instrument used and the assay design approach were firstly validated using the well 
characterised extracellular domain of NPR-C in chapter 2. Binding kinetics and affinity of 
natriuretic peptides type-A and type-C and a known antagonist could be determined and 
compared to literature data. This system would also be used to characterise a subset of 
small molecules designed as NPR-C agonists, and their binding strength analysed alongside 
activity data obtained in vitro. 
In chapter 3, the development of an SPR assay for sGC is described. This assay was 
validated through the characterisation of ATP and GTP binding, as well as the observation 
of binding competition between the nucleotides. Furthermore, the assay was used to 
evaluate the binding of cinaciguat 6, YC-1 (5) and a new subset of sGC activators discovered 
through screening of a small library of YC-1- related compounds synthesised in the Selwood 
laboratory. The assay was developed to allow detection of binding of small molecules to 
the full length sGC and a construct of its catalytic domain, thus providing information 
regarding the domain to which the molecules bind in the enzyme. 
The search for sGC inhibitors started with the screening of commercially available 
compounds using a radioimmunoassay to characterise their activity in vitro. A hit 
compound was selected and fully characterised for biochemical activity and binding affinity 
using SPR. Molecular modelling studies were carried out and a possible binding mode was 
investigated (Chapter 4).  
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Chapter 5 presents a series of compounds analogues of the hit compound. Their design, 
synthesis, and characterisation with regards to sGC inhibition and binding is described. 
A general discussion and conclusions can be found in chapter 6. 
Experimental methods for all chapters and spectroscopic characterisation of synthesised 
compounds are presented in Chapter 7.  
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Chapter 2: Validation of a SPR assay using NPR-C 
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2. Validation of a SPR assay using NPR-C 
2.1. Introduction 
SPR was the biophysical technique used to characterise the interactions between small 
molecules and sGC. The technique had never been used with sGC, thus a new assay had to 
be developed. In order to validate the instrument and the assay design, a different assay 
was initially designed using NPR-C as target. The binding of peptides to NPR-C has been 
extensively characterised before, and it was therefore possible to compare SPR results with 
published data using different biophysical techniques.  
 
2.1.1. NPR-C agonists 
Endothelium derived CNP has been attributed cytoprotective and anti-atherogenic 
functions and it is now established as crucial in the regulation of vascular tone, smooth 
muscle relaxation, activation of leukocytes and platelets and protection against ischaemia-
reperfusion injury.95 The finding that many of the vasoprotective effects of CNP are 
mediated by NPR-C established this signal transduction mechanism as a target for the 
treatment of cardiovascular diseases. Thus, synthetic agonists of NPR-C would serve as 
tools for unravelling the role of CNP/NPR-C regulated pathways and could also be viewed 
as potential therapeutic agents. 
Research at the Selwood and Hobbs groups has led to the design, synthesis, and functional 
characterisation of novel small molecule drug-like compounds that mimic the 
cytoprotective activity of CNP in vitro and in vivo.96 Chemical biology tools used to study the 
activity of NPR-C are shown in Figure 17. 
This drug design process started with a pharmacophore search targeting key interaction 
between CNP and NPR-C of a number of databases, and guided synthesis of new 
compounds followed. Evaluation of the potency of these molecules was first assessed using 
a cell-based screening assay that measured inhibition of Ca2+ influx in primary mesenteric 
artery smooth muscle cells in response to Angiotensin II. Compounds 12 (EC50 = 1.8 µM) 
and 13 (EC50 = 2.8 µM) from a bromo-quinoline series showed the best activity in rat 
isolated mesenteric arteries and were identified as lead agonists for NPR-C. Further 
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modifications obtained by Suzuki coupling resulted in similarly active compounds, 
exemplified by compound 14 (EC50 = 4.8 µM).  
An additional assay was however required, to confirm direct binding of compounds to the 
receptor. In this Chapter, a SPR-based assay is described, which characterises the binding of 
a subset of compounds to NPR-C. The assay was developed with the extracellular domain 
of NPR-C and validated through the characterisation of binding of its natural ligands ANP 
and CNP, which show similar binding affinities to NPR-C in the picomolar range, as well as 
the nanomolar antagonist M372049 (compound 15).56, 97 
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Figure 17. Chemical structures of NPR-C lead agonists and antagonist M372049 (15). 
 
2.1.2. SPR assay design 
The SPR assay presented here has the advantage of detecting direct binding between the 
compounds and the receptor, without the need to label any of the interactants or perform 
competition assays.  
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In principle, there are two major binding experiments that can be performed by SPR to 
characterise drug binding: high-resolution studies give information regarding the kinetics of 
a drug, whilst ranking studies provide qualitative information about binding strength and 
are used to compare binding between compounds. The SPR signals at a single 
concentration are divided by the molecular weight of the compound and multiplied by 100 
to give a normalised response that can be used for comparative purposes.  
The homodimeric extracellular domain of NPR-C presents a number of exposed lysines, 
suggesting it might be possible to immobilise the protein to a chip through amine coupling. 
The basic steps for the assay development and key points to consider are: 
 Determination of optimal pH for protein immobilisation. 
 Assess if enough protein can be immobilised to give a response within the 
detection limits of the system and good signal to noise when analysing small 
molecules. 
 Observation of binding with a natural ligand. 
 Investigation of optimal surface regeneration conditions. 
 Perform binding affinity and kinetics studies with CNP and ANP. 
 Perform binding affinity and kinetics studies with antagonist compound 15. 
 Assess binding with lead compound 13. 
 Characterisation of the binding of a subset of small molecules and how do these 
relate to activity. 
 
2.1.2.1. Immobilisation through amine coupling 
Immobilisation of macromolecules is usually performed from dilute ligand solutions (10 – 
200 µg/mL) in 10 mM buffer, generally sodium acetate. The carboxyl groups are activated 
with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide 
(NHS) to form an activated ester, followed by covalent attachment of ligand by its primary 
amines (lysines and N-terminus). The remaining esters are deactivated with ethanolamine 
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(Figure 18). In order for the reaction with the activated ester to take place the molecule to 
be immobilised must be uncharged and brought in close proximity to the surface by a 
process called preconcentration – this is achieved by electrostatic attraction between the 
opposite charges of the amino groups in the target and the remaining carboxyl groups in 
the dextran. The optimal reaction rate of the EDC/NHS chemistry proceeds around pH 8 
and no reaction occurs below pH 3.5. Therefore, the buffer pH for coupling must be 
optimised experimentally, as it needs to be lower than the isoelectric point (pI) of the 
protein, so that some amines are charged and attracted to the carboxylated dextran, and 
higher than 3.5 to enable efficient covalent attachment. Most proteins can be immobilised 
using a buffer pH between 4 and 5.5. 
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Figure 18. Protein immobilisation through amine coupling using EDC and NHS. The carboxyl groups at the 
sensor surface are activated by EDC and NHS, after which the protein can be covalently bound through the 
primary amines in lysine residues and the N-terminus. 
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2.1.3. Solubility measurements 
A common problem associated with small molecule assays is that organic molecules will 
have different levels of solubility, which may limit their use in certain assay buffers. 
Generally, libraries of compounds are stored as high concentration stock solutions in 
dimethyl sulfoxide (DMSO), and these are diluted in the assay buffer to give a low final 
percentage of DMSO concentration. The Biacore system tolerates low levels of DMSO, as 
do most proteins. However, some compounds may still not be soluble in buffers containing 
only up to 5% DMSO and may give false results in the SPR assay if assay plates and 
sensorgrams are not correctly examined.  
The U.S. Pharmacopeia (USP) uses seven different expressions to define solubility, from 
very soluble to practically insoluble (Table 2).98 
 
Table 2. The USP definition of solubility. 
Description forms 
(solubility definition) 
Parts of solvent 
required for one part 
of solute 
Solubility range 
(mg/ml) 
Solubility 
assigned 
(mg/ml) 
Very soluble (VS) <1 >1000 
1000 
Freely soluble (FS) From 1 to 10 100–1000 
100 
Soluble From 10 to 30 33–100 
33 
Sparingly soluble (SPS) From 30 to 100 10–33 
10 
Slightly soluble (SS) From 100 to 1000 1–10 
1 
Very slightly soluble (VSS) From 1000 to 10,000 0.1–1 
0.1 
Practically insoluble (PI) >10,000 <0.1 
0.01 
 
Previous studies with the NPR-C agonists described here had suggested a difference in 
solubility between the most active compounds 12 and 13, which could have an influence in 
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the biological results obtained. An assay was developed to determine the 
equilibrium/thermodynamic solubility of compounds as shown in Figure 19. The protocol is 
based on the traditional shake flask method and uses LC-MS as the analytical tool to 
determine the concentration of the compounds in a saturated solution at equilibrium. The 
diode array detector is used to quantify the compound by peak integration and the MS 
trace is used to confirm peak identity.  
 
 
Figure 19. General setup for equilibrium solubility measurements. A stock solution is made up in DMSO to a 
concentration of 1mg/mL and diluted with water:methanol for the generation of a calibration curve by LC-MS: 
the MS trace is used to confirm peak identity and the UV-DAD for peak quantification. Aqueous buffer is added 
to a sample of solid material (0.6 to 0.9 mg) and the solution is shaken for 24 h, filtered to remove undissolved 
compound, and the concentration of the sample solution is quantified by LC-MS using the calibration curve. 
 
2.2. Results and Discussion 
2.2.1. SPR assay 
2.2.1.1. Immobilisation 
The calculated pI of the extracellular domain of NPR-C is 5.9. Protein solutions of 30 µg/mL 
were prepared in 10 mM sodium acetate buffers of different pH: 4, 4.5, 5, and 5.5. The 
protein was brought into contact with the sensor chip surface using a contact time of 2 
min, after which it was washed off injecting a short pulse of 50 mM NaOH (Figure 20a). It 
was observed that the lower the pH of the sample the higher the amount of 
preconcentrated protein. Generally, the preconcentration step must give a relative 
response two times higher than the targeted immobilisation level, since not 100 % of the 
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biomolecules attracted to the surface will be successfully immobilised. At pH 5 and 5.5 the 
relative response obtained was only 7.6 and 5.1 kRU, respectively. Therefore, the 
conditions for immobilisation were decided as 30 µg/mL NPR-C in 10 mM sodium acetate 
pH 4.5, which gave a preconcentration of 11.7 kRU.  
The sensor chips used in the Biacore T200 are made of four flow cells where interactions 
can occur. Generally, they are used as pairs and one is used as a reference and the other is 
the active flow cell, where the interactions in the reference flow cell can be either 
unmodified or chemically modified as in the active flow cell, but without addition of the 
biomolecule to be immobilised. This cell is used to control non-specific binding to the 
surface as well as bulk responses obtained from changes in the refractive index of the 
samples injected. In this case, the reference cell was chemically modified with amine 
coupling reagents, in a process called blank immobilisation (Figure 20b). Treatment of the 
active flow cell (Figure 20c) starts with preconcentration of NPR-C at the surface so the 
system estimates the amount of sample to be injected to reach the aimed immobilisation 
level (1); the surface is then washed with 50 mM NaOH to remove any protein aggregated 
at the surface (2); the carboxyl groups of the dextran matrix are activated with a mixture of 
EDC and NHS (3) and then serial injections of the NPR-C sample are performed until the 
aimed immobilisation level is reached (4); blocking of any remaining activated esters is 
performed with ethanolamine (5). 
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Figure 20.Sensorgrams showing the immobilisation of NPR-C. (a) pH scouting; (b) blank immobilisation on 
reference flow cell; (c) Amine coupling immobilisation in active flow cell; where: 1) NPR-C pre-concentration; 2) 
wash with NaOH; 3) EDC/NHS activation; 4) binding of NPR-C; 5) blocking with ethanolamine. 
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2.2.1.2. Surface testing 
In order to assess if NPR-C remains active after immobilisation, a test was performed using 
a high concentration of CNP. First, a blank injection was performed using the assay buffer, 
followed by a 500 nM CNP injection, both using a contact time of 60 sec followed by 120 
seconds of undisturbed dissociation. The sensorgrams in Figure 21 have been zeroed so 
that the response in RU in the y-axis is relative to the baseline before injection and the time 
in the x-axis starts from zero at the time of injection. Figure 21a shows the bulk response 
obtained in the reference flow cel (fc1), where the blue line corresponds to the binding of 
CNP and the orange to the blank sample. The evaluation software allows the subtraction of 
the response obtained in the reference flow cell (fc1) (Figure 21a) from the active flow cell 
(fc2) (Figure 21b), and a reference subtracted sensorgram such as the one in Figure 21c is 
generally used throughout the whole thesis, unless stated otherwise. The blank sample 
serves also as a negative control for binding, which can be subtracted from the sensorgram 
if a bulk response is observed. The resulting sensorgram is therefore a double-referenced 
sensorgram, to represent a more realistic binding which excludes the bulk response and 
noise given by the assay buffer. 
If all binding sites of NPR-C were accessible the Rmax for CNP would be 91 RU. The double-
referenced binding response obtained with CNP gave 72 RU, which indicates 80 % of the 
binding sites are accessible and occupied. 
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Figure 21. Sensorgrams showing CNP binding to NPR-C. (a) Reference flow cell; (b) Active flow cell; (c) 
Reference subtracted sensorgram. 
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2.2.1.3. Surface regeneration 
Regeneration of the surface is not always necessary. If the analyte dissociates quickly 
enough, all analyte may be removed within a reasonable time simply by washing the 
surface the assay buffer. This is evident by observation of the sensorgram, since the 
response returns to baseline after the sample injection.  
CNP shows a very slow dissociation from NPR-C, after 10 min of buffer flow no decrease in 
response units was observed. Thus, regeneration of the surface was necessary for it to be 
reused. Regeneration scouting of the NPR-C surface was performed by testing six repeated 
cycles of CNP binding at 1 nM and regeneration. The results are summarised in Figure 22. 
The solutions tested were 10 mM glycine-HCl at pH 1.5, 2, and 3, 50 mM NaOH, and 1 M 
NaCl. The results were assessed in terms of trends in analyte response and baseline level. 
Glycine-HCl solutions failed to successfully regenerate the surface (Figure 22a–c). As a 
general trend, these solutions failed to remove bound CNP as shown by an increase in 
baseline level and decrease in CNP binding. 50 mM NaOH damaged the NPR-C surface, CNP 
did not bind after a first contact of the protein with NaOH and the baseline level decreased, 
indicating these conditions were too harsh for regeneration (Figure 22d). The use of 1 M 
NaCl as a regeneration solution showed the best results as CNP binding remained constant, 
and only a small increase in the baseline level was observed (Figure 22e). This was 
therefore the solution chosen for regeneration of the NPR-C surface. 
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Figure 22. Regeneration conditions scouting. Binding and baseline levels of six samples monitored upon 
regeneration with (a) glycine – HCl pH 3; (b) glycine – HCl pH2; (c) glycine – HCl pH 1.5; (d) 50 mM NaOH; (e) 1M 
NaCl. 
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2.2.1.4. Binding interactions 
Binding of natriuretic peptides 
The kinetics of binding of CNP and ANP was determined using the single-cycle kinetics 
application of Biacore. A series of five injections of each peptide was performed at 
increasing concentrations (0.25, 0.50, 1, 2, and 4 nM) for 240 seconds each. Upon the last 
injection at 4 nM the binding had reached saturation and dissociation from the surface was 
monitored for 3600 seconds (Figure 23). The association (ka) and dissociation (kd) rates 
were determined by the BIAevaluation software, using a 1:1 binding model, and the 
dissociation constant (KD) was determined by dividing Kd by ka(Table 3). Affinity of the 
peptides to NPR-C measured by SPR is in the picomolar range, as expected considering the 
results previously obtained in cell measurements97 and the main function of the receptor as 
a clearance receptor for natriuretic peptides, which upon binding leads to endocytosis. 
 
Table 3. Kinetics of natriuretic peptides and antagonist binding to NPR-C. where Ka is association rate, kd is the 
dissociation rate, KD is the equilibrium binding constant, and  SE is the standard error) 
Compound ka (1/Ms) SE (ka) kd (1/s) SE (kd) KD (M) 
CNP 4649089 28183.75 1.57E-05 6.68E-08 3.38E-12 
ANP 18523324 321171.6 9.7E-05 1.4E-06 5.24E-12 
M372049 (15) 6333821 96884.88 0.035691 0.000591 5.63E-09 
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Figure 23. Single-cycle kinetics of CNP (a) and ANP (b). The arrows indicate the time points at which the 
peptide was injected into the flow cell and at which concentrations. 
 
Binding of M372049 (15) 
Having validated the SPR assay for binding of two of its biological ligands, the technique 
was tested for the binding of known antagonist M372049 (15), which inhibits NPR-C activity 
in nanomolar concentrations. Its binding to the receptor was measured as having an 
affinity in the range of 6 nM. At low concentrations (0.9 to 7.5 nM) association of the 
compound to the receptor was slow and did not reach equilibrium after 240 seconds, 
whilst at concentrations of 15 nM and higher binding equilibrium was observed after 60 
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seconds. Full dissociation of the compound was observed, as curves returned to baseline 
without the need for a regeneration solution (Figure 24b). 
The activity of M372049 (15) is thought to be due to competition with CNP for binding to 
NPR-C, which was confirmed in this assay. A simple competition experiment was performed 
in which the binding of the antagonist and the natriuretic peptide was measured separately 
as well as in a mixture sample. An overlay of the sensorgrams for binding of CNP at 15 nM, 
M372049 (15) at 30 nM, and a mixture of the two shows that when both compounds are 
present in solution, the resulting binding is less than the sum of the individual binding 
curves, indicating binding competition (Figure 24c). 
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Figure 24. Sensorgrams of M372049 (15) binding to NPR-C. (a) Concentration-dependent binding (0.9 to 60 
nM); (b) Binding competition between M372049 (15)  (30 nM) and CNP (15 nM). 
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Binding of agonists 
A subset of compounds was selected from a library designed and synthesised by former 
members of the Selwood group and their binding strength to NPR-C was tested (Table 4). 
For binding rankings, stock solutions of 50 mM in DMSO were diluted to a final 
concentration of 5 % DMSO in assay buffer. These solutions were injected in triplicates for 
30 seconds, allowing further 30 seconds of undisturbed dissociation. Steady-state binding 
signals were divided by the compounds molecular weight and multiplied by 100, to give a 
molecular weight normalised response. Average values from triplicate injections were 
ranked according to their normalised SPR signal (Figure 25). Finally, the shape of each 
binding curve was examined as exemplified in Figure 26. 
 
 
Figure 25. Ranking of NPR-C agonists binding to NPR-C. 
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Table 4. SAR of NPR-C small molecule agonists. 
N
O O
R1
R2
R3
 
Compound R1 R2 R3 
% inhibition of Ang 
II-induced Ca2+ flux 
(compound 
[1µM])* 
CNP - - - 
100 ± 0 
12 Gly-OtBu Bn Br 
100 ± 0 
13 Gly Bn Br 
95 ± 3 
16 Gly Bn H 
87 ± 4 
17 Val Bn Br 
80 ± 7 
18 Val-OtBu Bn H 
12 ± 4 
19 Phe-OtBu Bn Br 
27 ± 4 
 
Compounds 18 and 19 showed mild or no activity as NPR-C agonists, and they also failed to 
bind significantly to the receptor (. The most active compounds 12 and 13 appear to show 
different binding behaviour, with 13 showing significantly higher binding strength. It was 
noticed however that compound 12 precipitated in solution, so the binding observed does 
not correspond to 50 µM. A follow-up study of the solubility of this compound can be 
found in section 2.2.2. 
Introduction of a valine residue in place of the glycine in R1 did not show significant 
changes in the binding of compound 17 in comparison to 13, and causes only a small 
decrease in activity. Removal of the bromide in the R3 position gave compound 17, which 
retains some activity as an NPR-C agonist and shows high binding to the receptor. 
                                                          
*
 Data obtained from Prof. Adrian Hobbs 
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Compound 14 showed apparent strong binding to the receptor. However, the binding did 
not reach equilibrium and the curve does not return to the baseline after dissociation. This 
behaviour is characteristic of non-specific binding and can be detected by observation of 
the binding sensorgrams (Figure 26b). 
The sensorgrams of compounds that bind to NPR-C show very fast association and 
dissociation, as represented by the curve given by compound 13 in Figure 26c. 
Concentration-dependent binding was observed but binding saturation was not achieved 
when using concentrations up to 150 µM (Figure 27). Thus, it was not possible to obtain 
association and dissociation kinetics or equilibrium binding affinity data.  
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Figure 26. Examples of NPR-C agonist binding sensorgrams. Three categories of binding can be distinguished: 
(a) no binding – compound 12; (b) binding plus non-specific binding – compound 14; (c) specific binding – 
compound 13.  
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Figure 27. Sensorgram of concentration-dependent (1.2 to 150 µM) binding of compound 13. 
 
DMSO correction 
The antagonist M372049 (15) and the small molecule agonists were obtained in stock 
solutions in 100 % DMSO, and diluted to a final concentration of 5 % DMSO in buffer, in 
order to match the concentration of DMSO present in the instrument buffer used. 
However, small differences in DMSO concentration between samples can cause huge 
changes in the bulk signal intensity, therefore compromising the accuracy of the data 
obtained. In order to account for these differences in signal, a calibration procedure can be 
performed by measuring the binding of standard solutions of a range of DMSO 
concentrations, and then plotting the difference in signals between active and reference 
cell against the signal on the reference cell, fitting the data using linear regression. This 
function is already incorporated in both Srubber and BIAevaluation softwares. Sensorgrams 
and binding data presented here were therefore obtained after applying DMSO 
corrections. 
 
2.2.2. Solubility Measurements 
Some compounds showed poor solubility in the assay buffer, even in the presence of 5 % 
DMSO and detergent, and solid could be seen at the bottom of the wells in the assay plates 
after the experiments. This behaviour not only limits the characterisation of these 
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compounds in the presented assay but also indicates their poor solubility may limit their 
use in further drug development. 
The phosphodiesterase 5 (PDE5) inhibitor sildenafil 20 is only slightly soluble in water, has 
high membrane permeability and relatively low bioavailability after oral administration. It 
has been developed as a salt form such as sildenafil citrate, which improves solubility but 
still has a relatively low absolute bioavailability of about 40 % and late onset of action.99 
sildenafil citrate was used in this experiment so that the NPR-C agonists can be compared 
to a drug of known low solubility. 
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Figure 28. Chemical structure of sildenafil 20. 
 
 
Figure 29. Solubility calibration curves for sildenafil 20 and compounds 12 and 13. 
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The solubilities of sildenafil 20 and compounds 12 and 13 were measured in aqueous 
buffer. Standard calibration curves were obtained (Figure 29) and the solubility of the 
compounds measured in 10 mM PBS at pH 7.4. The solubility of sildenafil 20 in 10 mM PBS 
pH 7.4 was determined as 25.9 µg/mL, which puts it in the category of practically insoluble 
(PI). The solubility of compound 12 is below the lower limit of detection and could not be 
measured – by visual inspection, the compound remains in suspension in buffer throughout 
the 24h shaking process. In comparison, the solubility of the acid analogue 13 was 
calculated as 491.6 µg/mL, putting it one grade above sildenafil in qualitative terms, as very 
slightly insoluble. 
 
Table 5. Calculated solubility of sildenafil 20 and compounds 12 and 13. 
Compound UV peak area 
Solubility 
(µg/mL) 
Solubility 
(µM) 
 
Sildenafil 31.4 25.9 0.04 
 
12 Not detected <10.0 <0.02 
 
13 685 491.6 1.18 
 
 
2.3. Summary 
NPR-C signalling through CNP binding has been shown to regulate vascular homeostasis, 
which can be inhibited by M372049 (15), an NPR-C antagonist. The Selwood group has 
developed a series of drug-like small molecules which mimic CNP activity and serve as NPR-
C agonists in the absence of CNP. An SPR assay was developed in which the extracellular 
domain of NPR-C can be immobilised onto a CM5 sensor chip though amine coupling. The 
system has been validated by analysing the binding behaviour of natriuretic peptides type-
C and type-A to the receptor, as well as its known antagonist. Their binding kinetics and 
affinity were determined and binding competition was observed between CNP and 
M372049 (15), confirming the activity of the antagonist is through binding to the CNP site, 
as originally designed. Binding of a subset of NPR-C agonists was measured as well, and 
observation of the sensorgrams allows the characterisation of these compounds as binding, 
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non-binding, and binding non-specifically. Some compounds showed poor solubility in the 
assay buffer, limiting their characterisation in this assay. Equilibrium solubility of 
compounds 12 and 13 was determined alongside sildenafil 20, a PDE5 inhibitor with poor 
solubility and bioavailability. It was not possible to determine the solubility of compound 
12 as it was below the lower limit of the detection of the LC-MS instrument used. 
Compound 13 showed better solubility and should consequently be the agonist used for 
follow-up studies. 
The SPR assay developed in this chapter provided data which is comparable to literature 
information about NPR-C behaviour. Thus, the experiments presented serve to validate the 
SPR instrument and methodology employed in the assay design. 
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Chapter 3: Discovery and characterisation of drug-
like sGC activators 
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3. Discovery and characterisation of drug-like sGC activators 
3.1. Introduction 
3.1.1. The binding mode of sGC activators 
There are currently two compound classes known to activate sGC by different mechanisms, 
one that acts in the absence of NO by replacing the heme moiety, such as cinaciguat 6 and 
a second class of compounds such as the benzylindazole derivative YC-1 (5) which is 
thought to bind to an allosteric site and act synergistically with NO to increase cGMP 
production.91  YC-1 (5) is also capable of inhibiting sodium channels in a voltage-dependent 
manner, and it was used as the starting point for the design of a library of sodium channel 
modulators.82, 100-101 Thus, cross-screening of this library of compounds against sGC was 
performed.  
The mechanisms by which small molecules activate enzymes differ in many ways from 
those that apply to inhibitors and it can be challenging not only to discover activators but 
also to understand their mode of action. Activators commonly bind to an allosteric binding 
site and require lower doses than inhibitors to cause an effect.102 Current biochemical 
characterisation of sGC modulation by small molecules is performed by measuring cGMP 
levels by radioimmunoassays and biophysical characterisation of the enzyme can also be 
performed using spectroscopic methods such as Raman spectroscopy and electron 
paramagnetic resonance.73, 103 These methods provide a great deal of information regarding 
the activity of the enzyme in the presence and absence of small molecules, but give limited 
evidence about the binding strength and binding sites of these molecules. A biophysical 
method such as surface plasmon resonance would allow the detection of direct binding of 
small molecules to sGC and would complement the biochemical characterisation of such 
compounds. 
 
3.1.2. SPR assay design 
The large heterodimeric structure of sGC can make it particularly challenging to detect 
binding of low molecular weight compounds using SPR. Whilst higher concentrations of 
protein on the sensor chip provide a higher signal to noise ratio, a denser surface is also 
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prone to higher non-specific binding and hindrance of the binding site. We evaluated if a 
construct of the α1β1 catalytic domain of sGC could be used as a model for the detection of 
binding to sGC. The catalytic domain of sGC (sGCcat) is easier to manipulate in an SPR assay 
as its smaller size (~50 kDa) allows the use of a less dense surface (lower immobilisation 
level), which reduces steric effects and non-specific electrostatic binding whilst still 
providing a high enough signal to noise ratio. Furthermore, comparison of binding between 
full-length and sGCcat would allow the determination of the domain to which the 
compounds are binding. 
The assay development steps were similar to the ones described in chapter 2, section 2.1.2. 
Validation of the assay could be performed using ATP and GTP, and the use of both protein 
constructs would confirm whether the compounds are binding to the catalytic domain of 
the enzyme or not. 
 
3.2. Results and Discussion 
3.2.1. Screening for sGC activators 
The screening of the library of YC-1 (5) analogues took place in two phases: the library was 
firstly virtually screened for compounds with certain substructures; followed by a 
biochemical evaluation of their activity.  
 
3.2.1.1. Virtual screening 
Virtual screening was performed using Pipeline Pilot, a program that allows the search, 
analysis and generation of data in numeric, textual, chemical, or biological formats using a 
range of scripts and filters, and integrating various other programs. This allows data to be 
input into a pipeline in a certain format and retrieved in another format of choice. The 
protocol used in this screening is shown in Figure 30. A small database of 41 compounds 
was input into the pipeline and compounds that did not pass the Lipinski’s rule of five were 
filtered out. Three substructure searches were followed.  
Some compounds virtually selected were not physically available. Those available were 
subsequently evaluated for biological activity. The core structure of these compounds is 
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made of an indazole substituted in the 3-position with a 1,2,4-oxadiazole. The main 
variations in the selected compounds were the substituent groups in the N1 and N2 
positions of the indazole (R1) and the groups in the 3-position of the oxadiazole. The first 
substructure search retrieved compounds which had a free amine group in the 3-position 
of the oxadiazole and a benzyl group in the N1 position of the indazole. This search resulted 
in compounds 21, 23, and 25, which vary only in the groups and positions of substituents in 
the benzyl group. The second search retained the free amine group in the oxadiazole and 
allowed a greater variation at N1 and N2 of the indazole, resulting in compounds 22, 24, 26, 
27, and 28. Finally, more diversity was allowed by selecting compounds with a tert-butyl 
carbamate group in the 3-position of the indazole and further substituents in the benzyl 
group at N1 of the indazole, of which compounds 29 and 30 were available. 
 
Figure 30. Pipeline Pilot protocol. A compound library of 41 compounds was filtered to keep only those which 
pass Lipinski’s rule of five, keeping 34 compounds. Three substructures were searched and selected compounds 
were further evaluated. 
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Table 6. Chemical structures of sGC activators. 
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3.2.1.2. Biochemical evaluation 
The activity of the selected compounds was evaluated using a radioimmunoassay which 
measures the amount of cGMP produced. Evaluation was performed using the well 
characterised bovine lung sGC as well as human recombinant protein. In this assay, the 
protein is treated with 1 mM MgGTP and 100 µM of compound. cGMP produced is solely 
due to the activation of the enzyme by the compound since no additional NO is included. 
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The results obtained with the different proteins show only small variations in activity. In the 
bovine lung sGC assay compounds 22, 23, 24, 25, 28, and 29 do not produce more cGMP 
than a control sample containing no compound (~ 1 pmol/ng protein). Compounds 21, 27, 
and 30 successfully stimulated the enzyme to convert GTP into cGMP. Comparatively, the 
human recombinant protein showed increased activity and in addition to compounds 21, 
27, and 30, also compound 24 substantially activated the enzyme. 
 
 
Figure 31. Biochemical activation of sGC by selected compounds. a) activation of bovine lung sGC; b) activation 
of human recombinant sGC. Assays performed in the presence of 1mM MgGTP and absence of added NO. 
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3.2.2. Biophysical assay development 
3.2.2.1. Protein immobilisation 
Immobilisation of sGC was performed using amine coupling through lysine residues as 
previously described. pH scouting was originally performed at different protein 
concentrations (Table 7). This consisted of preconcentrating the protein on the sensor chip 
at concentration of 30, 50, and 200 µg/mL at pH 4, 4.5, 5, and 5.5. pH 5.5 worked well in all 
concentrations. In general, protein immobilisation was performed using 30 µg/mL sGCcat in 
10 mM sodium acetate pH 5.5, except for experiments that required a high immobilisation 
level for which 200 µg/mL sGCcat in 10 mM sodium acetate pH 5.5 was used. 
Immobilisation was performed in the presence of MgATP and MgGTP, to protect binding 
sites so that lysines in these sites were not used for coupling to the dextran. 
Immobilisation of full-length sGC was performed similarly to the catalytic domain of the 
enzyme. It required however a lower pH (4.5) of immobilisation buffer in order to achieve 
successful pre-concentration at the surface of the sensor chip. 
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 Table 7. pH scouting for sGCcat immobilisation. 
Protein concentration 
(ug/mL) 
pH 
Relative Response (RU) 
30 
5.5 
8, 109 
5 
5, 406 
4.5 
6, 265 
4 
-112 
50 
5.5 
14, 748 
5 
20, 964 
4.5 
26, 681 
4 
26, 700 
200 
5.5 
56, 062 
5 
33, 846 
4.5 
24, 441 
4 
16, 150 
 
3.2.2.2. Buffer optimisation 
Buffer scouting was performed in order to select the most appropriate buffer solution to 
use in experiments for nucleotide binding. The most commonly used buffers in Biacore 
assays are either HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) based or PBS 
(phosphate buffer saline). HEPES was selected for this assay as it gave higher binding 
response with ATP than PBS. NaCl is present in the buffer to mimic physiological conditions 
and reduce nonspecific binding to the protein, and a small concentration of dithiothreitol 
(DTT) was also added to avoid oxidation of cysteine residues. Upon observation that 
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MgGTP shows higher binding that the nucleotide in the absence of cofactor Mg2+, MgCl2 
was added to the running buffer at a concentration of 10 mM. Surfactant P20 was also 
included to reduce adsorption of hydrophilic molecules to the flow system surfaces. In 
experiments performed with the full length enzyme, NaCl was present in the buffer at a 
concentration of 300 mM, in order to reduce non-specific binding responses. 
 
3.2.3. Binding of nucleotides 
Binding of both nucleotide triphosphates (NTPs), ATP and GTP, to the immobilised proteins 
in the SPR assay was observed at physiological concentrations, whilst binding of cGMP only 
shifted from the baseline at concentrations higher than 1 mM (Figure 32). Surface 
saturation could not be observed, as NTPs are known to aggregate at concentrations higher 
than 1 mM.104 Moveover, ligands could be binding to a second site. Binding curves were 
fitted to a nonlinear curve model that considers binding plus linear non-specific binding. 
The fit was consistent with GTP binding to one binding site (n = 1) and ATP binding more 
than one site (n = 1.2) (Figure 33). The KD values obtained are only apparent and since ATP 
binds to both sites the value obtained is an apparent cumulative affinity, as determination 
of two separate binding affinities could not be achieved. 
The conformation of the catalytic domain of sGC is thought to change significantly upon 
activation and “open” and “closed” states have been suggested. Although it is not possible 
to know in which conformation the protein was immobilised, binding of ATP and GTP 
shows that binding sites are accessible. 
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Figure 32. Sensorgrams of nucleotides binding to the catalytic domain of sGC. (a) ATP; (b) GTP; (c) cGMP. 
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Figure 33. Fitting curves for ATP (a) and GTP (b) binding to the catalytic domain of sGC. 
 
3.2.4. ATP and GTP binding site competition 
ATP is known to regulate sGC activity and it has been hypothesised it does so through 
allosteric binding and/or competition with GTP. In order to confirm the immobilised protein 
could mimic its behaviour in functional assays, a competition assay was designed in which 
competition between ATP and GTP was assessed. In the SPR competition assay, the binding 
of the nucleotides was measured at five different concentrations, where the NTPs were 
present alone or in a mixture sample. If the two compounds were binding to separate sites, 
the response obtained with a mixture sample would be the same as the sum of binding 
responses when the NTPs are alone in solution (Figure 34 a – c). However, it was observed 
that binding of the two NTPs injected in solution together is lower than the sum of their 
individual binding levels (Figure 35). Thus, the information obtained in the competition 
assay, together with the observation that ATP binds more than one site in sGC, suggests the 
regulation of nucleotide binding to sGC involves the binding of ATP to the 
pseudosymmetric site of sGC’s catalytic domain, combined with a competition between 
ATP and GTP to the catalytic site of the enzyme (Figure 34d). 
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Figure 34. Proposed mechanism for ATP and GTP competition measured by SPR. If GTP and ATP do not 
compete for a binding site the response obtained with both compounds in solution (c) will be the the sum of 
their individual binding responses (a) and (b); If the nucleotides compete for one or more binding sites the 
response obtained with both compounds in solution will be lower than the sum of their individual responses 
(d). 
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Figure 35. GTP and ATP competition assay 
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3.2.5. Binding of activators 
Both proteins tolerated DMSO concentrations of up to 5 % which allowed binding of the 
small molecules to be evaluated using this system. The binding level of all compounds was 
measured at 100 µM (Figure 36). 
YC-1 (5) demonstrated strong binding to both proteins indicating that the YC-1 (5) binding 
site is located in the catalytic domain, consistent with previous investigations (Figure 37a 
and b).105 In contrast, the heme mimetic cinaciguat 6 which is known to bind to the H-NOX 
domain showed higher binding to the full length sGC than to the catalytic domain, 
appearing to bind to sGCcat non-specifically, as per analysis of the sensorgrams (Figure 37 c 
and d).  
Compounds 21 and 23 are close analogues, differing only in the position of a methyl group, 
and both give a high binding response to sGC in the SPR assay, similarly to YC-1 (5) itself. 
The 2-methylbenzyl-substituted indazole 23 does not activate the enzyme in the 
biochemical assay. Replacement of the methyl group in the 4-position of compound 21 by a 
methoxy group in compound 25 not only renders the compound inactive but also prevents 
it from binding to the enzyme in the SPR assay. Further variations at the N1 substituted 
indazole include a 5-methylisoxazole in compound 27 and an ethanone in compound 28. 
The latter showed low binding to sGC and no activity in the biochemical assay. Compound 
27 on the other hand, activated the enzyme and also showed binding in the SPR assay to a 
lower extent than compound 21. The tert-butyl carbamate substituted (1,2,4-oxadiazol-3-
yl)methanamines 29 and 30 vary in the substituents at the N1 of the indazole core. The 5-
ethylbenzo[d][1,3]dioxole compound 30 is capable of activating sGC and shows significant 
binding to the enzyme, whilst the N-(4-ethylphenyl)acetamide compound 29, despite 
showing higher binding than 30 is inactive in the biochemical assay. The acetamide group, 
which is both a hydrogen bond donor and acceptor, might contribute to a higher binding 
affinity, but this is not necessarily required for activity. Three compounds (22, 24, and 26) 
were selected in which the indazole core was substituted at the N2 position, and whilst 
compounds 22 and 24 showed strong binding to sGC they did not exhibit any biological 
activity.  
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Figure 36. Binding response of selected compounds to sGC measured by SPR. a) Binding to the catalytic 
domain; b) Binding to full-length human recombinant sGC. 
 
 
  
1
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Figure 37. Sensorgrams for binding of YC-1 (5) (a, b) and cinaciguat 6 (c, d) to catalytic domain and full-length sGC, repectively. 
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The binding of the indazoleoxadiazole compounds to the full length sGC correlates with the 
binding to the catalytic domain construct, providing evidence that the binding site for this 
class of compounds is at the catalytic domain of sGC (Figure 38a). This is most likely at the 
pseudosymmetric site, as previously suggested by structural models of YC-1 (5) interaction 
with the catalytic core of sGC.105 No correlation was observed between binding level and 
lipophilicity (ClogP) of the compounds (Figure 38b).  
 
 
Figure 38. Correlation between compound binding to full length and catalytic domain sGC (a) and between 
compound binding to catalytic domain and clogP (b). 
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3.3. Summary 
An SPR assay was developed in which binding can be detected to two constructs of sGC, full 
length, and catalytic domain. The SPR assay detects binding alone and is not expected to 
correlate with biochemical activation and based on the data obtained this does not occur. 
However, binding may be a pre-requisite for activity and we did not observe biochemical 
activation without binding.  
The results presented here provided further evidence that the so-called NO-independent 
sGC activators act through binding to an allosteric site on the catalytic domain of the 
enzyme. The assay was performed to evaluate a library of YC-1 (5) related compounds and 
discovered some new indazoleoxadiazole activators as a result. The α1β1 sGC catalytic 
domain construct used in this assay can therefore be used as a model for sGC binding in 
further SPR-based studies, which can provide a simple direct method to enable fragment-
based drug design and inhibitor screening. 
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Chapter 4:  Discovery and characterisation of small 
molecule inhibitors of sGC 
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4. Discovery and characterisation of small molecule 
inhibitors of sGC 
4.1. Introduction 
Inhibition of sGC activity can be attained by discrete mechanisms such as reduction of NO 
availability, and competition with NO or GTP for binding. Reduced availability of NO can be 
caused mainly by inhibition of nitric oxide synthase106 or by reaction with radical species. In 
cells, the direct effects of NO are more than just interaction with metal complexes such as 
the heme in sGC. NO also plays a key role in response to oxidative stress, a hallmark of 
certain cardiovascular diseases which is characterised by excessive production of reactive 
oxygen species, such as superoxide (O2
·-). Superoxide can react with NO to form 
peroxynitrite (ONO2
-), a powerful oxidant that may cause cell damage and death. This leads 
to a reduced bioavailability of NO, and superoxide is sometimes referred to as a sGC 
inhibitor.  
Figure 39 shows small molecules that inhibit sGC activity, and the mechanisms by which 
these act are represented in Figure 40. 
The small molecule LY83583 (31) leads to inhibition of sGC activity by generating 
superoxide.107 Scavenging of superoxide can be performed by superoxide dismutase (SOD), 
an enzyme that catalyses the dismutation of superoxide into oxygen (O2) and hydrogen 
peroxide (H2O2), thus maintaining NO availability and sGC activity.
108-109  
Small molecules such as ODQ 4, the 8-bromo analogue NS2028 (32), and related 
compounds are potent direct inhibitors of sGC which act through oxidation of the ferrous 
heme into ferric heme, thus preventing binding of NO.110-112 However, such compounds lack 
in vivo selectivity, as they also oxidise other heme-containing proteins, such as 
haemoglobin.  
Calmidazolium 33 has shown direct inhibition of isolated guanylate and adenylate cyclases 
by a mechanism that is not competitive with the natural ligands, ergo suggesting binding to 
allosteric sites. Calmidazolium 33 is a potent antagonist of calmodulin, a calcium-binding 
messenger protein which acts as a calcium sensor and signal transducer.  Additionally, it 
has shown direct modulation of the Ca2+/Mg2+-ATPase and store-operated calcium 
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channels.113-114 This suggests calmidazolium 33 is a promiscuous inhibitor which may target 
several proteins. 
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Figure 39. Chemical structures of inhibitors of sGC activity 
 
 
 
Figure 40. Schematic representation of different mechanisms for inhibition of sGC activity. 
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Since ATP and GTP analogues are known to compete with GTP for binding to sGC in 
addition to regulating enzyme activity through an allosteric site, these are also sometimes 
referred to as sGC inhibitors.115-116  
This chapter will explore the search for a new direct inhibitor of sGC, which does not act 
through the formation of the superoxide radical, or oxidation of the heme, achieved by 
screening of commercial libraries of compounds. Moreover, the synthesis and biochemical 
and biophysical characterisation of a selected hit will also be investigated.  
 
4.2. Results and discussion 
4.2.1. Compound screening 
N.B. The results presented in section 4.2.1. took place before start of the PhD in the Selwood 
and Garthwaite labs. Virtual screening was performed by Dr. Paul Gane and Prof. David 
Selwood. Biochemical evaluation of all compounds reported in this thesis was performed by 
Prof. John Garthwaite and Kathryn Hampden-Smith (unless stated otherwise). 
 
Previous studies with the anti-convulsant drug lamotrigine 34 have shown increased NO-
stimulated cGMP levels in cerebellar slides, suggesting a direct correlation with sGC.117 
Additional experiments with lamotrigine analogues 35 and 36 took place in the Garthwaite 
lab and it was discovered that contrary to lamotrigine 34, the selected analogues 35 and 36 
were mild inhibitors of sGC activity. Thus, these compounds were used as the starting point 
for the search of new inhibitors of sGC. 
The core structure of lamotrigine 34 consists of a 6-phenyl-1,2,4-triazine ring system. In 
analogues 35 and 36 the 1,2,4-triazine ring is substituted by a pyrimidine, which was the 
ring used in the substructure searched (A).  
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Figure 41. Chemical structure of lamotrigine 34 and analogues 35 and 36. 
 
Virtual screening was performed by similarity searches using MACCS fingerprints at 85 and 
75 % Tanimoto of commercial libraries. Biochemical evaluation of selected compounds 
took place using purified rat lung guanylate cyclase (α1β1) and diethylamine NONOate 
(DEA/NO) 37 as the NO donor at 1 µM. DEA/NO spontaneously dissociates into NO in a pH-
dependent process, with a half-life of 2 min at 37 °C pH 7.4. Enzyme activity was 
determined by measuring cGMP production using a standard cGMP [3H] radioimmunoassay 
system.118  
N N
N
O
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H2N
 
            37 
Figure 42. Chemical structure of diethylamine NONOate (DEA/NO). 
 
The initial structure searched (structure A) resulted in circa 500 structures available, out of 
which 16 were selected by hand based upon diversity, molecular size, and availability. 
Compounds 38 and 42 showed inhibition of isolated enzyme activity by 51 %. A subsequent 
search was performed based on substructure B. Available compounds were filtered using 
PipelinePilot to select the 50 most diverse compounds. The symmetrical disubstituted 
[1,2,5]oxadiazolo[3,4-b]pyrazines compounds 39 and 43 were the most active of this 
library, with an sGC inhibition of 90 %. A search for substructure C resulted in the discovery 
of the symmetrical substituted quinoxaline compound 40 (73 % inhibition). A final library 
screening took place by searching for N2,N3-diphenylquinoxaline-2,3-diamines 
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(substructure D), leading to the finding of compound 41, which showed 99 % inhibition of 
sGC activity.  
Further studies were conducted with compounds 40 and 41 which allowed the 
determination of their half-maximal inhibitory concentration (IC50), summarised in Table 8. 
In general, compound 41 was more potent than compound 40. Both compounds also 
showed inhibition of sGC activity stimulated by the activator cinaciguat 6, in the absence of 
added NO, proving they are not acting through competition with NO.  
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Figure 43. Chemical structures of virtually screened substructures and hit compounds. 
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Table 8. Biochemical activity of hit compounds 40 and 41. 
 
Most compounds had no effect on basal or forskolin-stimulated adenylyl cyclase (data not 
shown). The activity of compounds 40 and 41 was also tested on particulate GCs, using 
purified rat lung membranes in the presence of 10 µM ODQ 4 to inhibit NO-activated sGC. 
cGMP generation was measured after stimulation of pGC with ANP. The sGC inhibitors also 
showed inhibition of pGC-generated cGMP, indicating they are acting through the GC 
domain of the enzyme. 
 
4.2.2. The synthesis of substituted quinoxalines 
Some N2,N3-diphenylquinoxaline-2,3-diamines (substructure D) were reported as 
antimalarial agents in the late 1940’s and their synthesis was based on the displacement of 
the chlorides in 2,3-dichloroquinoxalines with anilines at temperatures that ranged 
between 140 and 160°C for several hours. 119-120 
More recent literature has reported the synthesis of N2,N3-diphenylquinoxaline-2,3-
diamines using microwave-assisted organic synthesis, which massively decreases reaction 
times, as shown in Scheme 1, with the reaction between 2,3-dichloro-6-nitroquinoxaline 44 
GC activator 
Compound 40            
IC50 (µM) ± SE 
Compound 41            
IC50 (µM) ± SE 
DEA/NO 
10 nM 241.9 ± 21.3 
24.3 ± 1.5 
0.3 nM 195.8 ± 11 
25.7 ± 0.7 
cinaciguat 6 
1 µM 79.8 ± 4.3 
36.5 ± 39.5 
20 nM 64.4 ± 12.2 
24.5 ± 4.2 
ANP 
1 µM 100.9 ± 10.6 
24.6 ± 13.0 
10 nM 62.4 ± 10.2 
20.7 ± 2.5 
basal 80.9 ± 15.0 
14.5 ± 2.2 
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and (E)-3-(3-aminophenyl)acrylic acid 45 for 30 min at 160 °C, giving compound 46 with a 
35 % yield (Scheme 1).121 
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Scheme 1. Pd-catalysed synthesis of a substituted N
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-diphenylquinoxaline-2,3-diamine.
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4.2.3. Synthesis of hit compound 41 
The hit compound 41 was selected for further characterisation. Firstly, a synthetic route 
was desired that would allow a fast synthesis of compounds that could be obtained with 
high degrees of purity for biological analysis. The synthesis of compound 41 is not 
described in the literature. However, considering available literature of analogue 
compounds122, it was proposed that it could be obtained by reaction of commercially 
available 2,3-dichloro-6-nitroquinoxaline 44 with 4-aminophenol 47. Synthesis of 
compound 41 was not attempted using the Pd-catalysed synthesis described in Scheme 1 
as it was initially performed before the publication of such method. Instead, a method was 
optimised for the synthesis of these compounds via nucleophilic aromatic substitution 
mechanism (SNAr) (Scheme 2) 
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Scheme 2. SNAr mechanism for the synthesis of compound 41. 
 
A small set of reaction conditions was tested (Table 9) for the synthesis of compound 41, 
using microwave irradiation at 150 Watt. The initial solvent chosen for this reaction was N-
methyl-2-pyrrolidone (NMP). NMP is a polar aprotic solvent, a medium-absorber of 
microwave irradiation with a high boiling point of 215 °C, and dissolves most organic 
compounds, making it a preferred solvent in microwave synthesis. Reaction number 1 took 
place at 160 °C for 5 min. The microwave system did not take long to reach the set 
temperature (3:33 min). The presence of the desired product was shown by liquid 
chromatography-mass spectrometry (LC-MS) before aqueous work-up and the identity of 
the product was confirmed by NMR after purification by flash column chromatography. In 
order to optimize the reaction conditions, a few variables were changed. First, as the 
aqueous work-up initially used was long and the compound seemed to crystallize in water, 
crystallization and filtration were performed instead of an aqueous extraction. This was 
however not successful as NMP was not completely removed from the substance during 
the washes nor separated in the column. It was also noted that an increase in reaction time 
to 10 min did not improve the yields obtained. Replacement of the solvent NMP by 
acetonitrile (MeCN), another polar aprotic solvent and medium absorber was investigated. 
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The maximum temperature achieved with this solvent was 120 °C, and it took 
approximately 11 min to reach. Analysis of the crude compounds suggested the presence 
of a side product, possibly the mono-substituted compound, in small quantities, which did 
not occur with NMP. The experimental procedure followed in reaction 1 was the one which 
allowed a faster reaction and a more pure compound. In comparison to the microwave-
assisted method described in the literature, the method presented here is faster, taking 
only 5 min whilst the Pd-catalysed method takes 30 min, and does not require the use of a 
catalyst, giving a much cleaner reaction. 
 
Table 9. Reaction conditions for the synthesis of compound 41. 
N
N
Cl
ClO2N
 
44 
 
 
OH
NH2  
47 
 
 
 
N
N
NH
NHO2N
OH
OH  
41 
 
Reaction 
number 
Solvent 
Temp. 
(° C ) 
Time† 
(min) 
Workup 
Result 
1 NMP 160 5 (+ 3.33) Aq. extraction 
60 % yield 
2 NMP 160 5 (+ 3.22) Crystallisation 
Impurities present 
3 NMP 160 10 (+ 3.22) Aq. extraction 
60 % yield 
4 MeCN 120 5 (+ 11:05) 
Solvent 
evaporation 
Longer reaction time; 
Possible side product 
with [M+H]+=317 
5 MeCN 120 5 (+ 11:00) Aq. extraction 
                                                          
†
 Time in brackets corresponds to the time needed by the Microwave to reach the desired 
temperature. 
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Figure 44. Spectroscopic characterisation of compound 41. a) 
1
H NMR: The four singlets between 9.0 and 9.4 
ppm correspond to the two OH protons (two more downfield peaks) and the two NHs; the peak at 8.18 ppm 
correspond to the H in the carbon labelled as 6 in the quinoxaline ring, and it is coupled to the other H proximal 
to NO2 at 8.01 ppm (J = 2.6 Hz). This is in turn coupled to the vicinal proton which resonates at 7.51 ppm (J = 8.9 
Hz). The peak at 7.64 ppm integrates to 4 protons, the protons closer to the NHs in both phenol rings, and the 
remainder 4 protons closer to the OH groups appear at 6.83 ppm. b) High resolution mass spectrum: The major 
peak at m/z 390.1205 corresponds to [M+H]
+
. 
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4.2.4. Biochemical characterisation of synthesised compound 41 
The activity of the synthesised compound 41 was evaluated in a simplified assay using four 
concentration points (3, 10, 30, 100 µM). A new assay was employed using bovine lung 
purified sGC. The compounds were tested in the presence of 1 mM MgGTP and 30 nM 
DEA/NO for 2 min. Superoxide dismutase (SOD) was included in the assay at 1000 units/mL 
to account for possible enzyme inhibition due to superoxide radical. The synthesised 
compound showed an IC50 of 70 µM, only slightly more potent than the commercial 
compound (IC50 = 90 µM), possibly due to a higher degree of purity. 
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Figure 45. Comparison of biochemical activity between commercial and synthesised compounds 41. 
 
4.2.5. Characterisation of the binding of compound 41 to sGC 
The binding of compound 41 to sGC was characterised using SPR. The equilibrium affinities 
of the ligand to the full-length sGC and two constructs of the catalytic domain, a wild-type 
form and a mutant form, were compared. The mutated protein has the amino acid 
substitutions G476C and C541S in the β-subunit (GUCY1B3) and was generated to engineer 
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a disulphide bond between the α and β subunits and prevent a disulphide bond between 
the β-subunits in order to preferentially obtain heterodimers, which allowed the 
generation of heterodimer crystals and subsequently the determination of their structure 
by x-ray crystallography.71  
Binding of compound 41 was measured at six different concentrations and equilibrium 
dissociation constants (KD) were obtained by fitting to a steady-state binding equation, 
considering one binding site (Equation 5), or a model that takes into account non-
stoichiometric binding (Equation 6). 
 
      
     
 
  
 
   
 
  
 
 
Equation 5. Model for one-to-one binding interaction. Where Resp corresponds to the response in RU 
obtained by SPR at a concentration C, Rmax is the maximal response obtained and KD is the equilibrium 
dissociation constant. 
 
     (    
  
  
   
 )       
Equation 6. Model for non stoichiometric binding interaction. Where Resp corresponds to the response in RU 
obtained by SPR at a concentration C, Rmax is the maximal response obtained, KD is the equilibrium dissociation 
constant, kns is the dissociation constant for additional binding site, and n is the number of binding sites. 
 
Two types of sensor chip were used in this experiment. GE Healthcare recommends the use 
of a CM7 chip to measure binding of small molecules. This chip has a higher degree of 
dextran carboxylation, allowing a higher degree of protein immobilisation at the surface 
which in turn is expected to give higher response levels and a greater signal to noise ratio. 
This chip was used to immobilise the wild type catalytic domain of sGC and the full length 
enzyme. The wild type sGCcat was also immobilised onto a CM5 chip, alongside the mutant 
sGCcat for comparison. Sensorgrams are shown in Figure 46. 
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Figure 46. Sensorgrams of compound 44 binding to different immobilised constructs of sGC. a) wild-type sGCcat on a CM7 chip; b) wild-type sGC on a CM5 chip; c) full-length sGC on a CM7 
chip; d) mutant sGCcat on a CM5 chip. 
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The equilibrium dissociation constant (KD) of compound 41 was similar for all surfaces (ca 
10 – 30 µM). Dose-response plots are shown in Figure 47 and calculated KD summarised in 
Table 10. At higher concentrations of compound 41, the binding responses obtained in the 
full-length enzyme were higher than the theoretical maximal response (Rmax) possible for 
one binding site, as calculated by Equation 5. This may indicate that the compound is 
binding to a second site, possibly non-specifically. Non-specific binding had also been 
observed with nucleotides in chapter 2, and it is possible that due to the high molecular 
weight of enzyme (~ 150 kDa) there may be other sites where small molecules could bind. 
Thus, a different model was employed to calculate the binding affinity of compound 41 to 
the full length enzyme, which takes into account non-specific binding (Equation 6). Using 
this model, the Rmax was fixed at 78 RU, the number of binding sites was determined as 1.3 
and the calculated KD was slightly smaller than that obtained when employing a one 
binding site model. Analysis of the sensorgrams obtained with the wild type sGCcat in the 
CM5 chip suggests binding saturation is achieved at 32 and 64 µM, but the response 
obtained at a concentration of 128 µM is again higher. Thus, the model for non-
stoichiometric binding gives a better line fitting, with Rmax fixed at 23 RU. 
 
Table 10. Calculated equilibrium dissociation constants for compound 41. 
Immobilised enzyme 
 
Rmax 
One-to-one binding model 
KD (µM) 
Non-stoichiometric 
binding model 
 
KD (µM) n 
 
sGCcat – wild type 
(CM7 chip) 
155 16.8 ± 3.9   
 
sGCcat – wild type 
(CM5 chip) 
85 32.7 ± 10.1 11.5 ± 1.1 1.3 ± 0.1 
 
sGC full length 
(CM7 chip) 
78 19.4 ± 2.1 10.3 ± 0.7 1.3 ± 0.2 
 
sGCcat – mutant 
(CM5 chip) 
77 11.4  ± 1.8  
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Figure 47. Dose-response plots of compound 41 binding to sGC. a) wild-type sGCcat on a CM7 chip; b) wild-
type sGC on a CM5 chip; c) full-length sGC on a CM7 chip; d) mutant sGCcat on a CM5 chip. Lines in blue were 
fitted to a one-to-one binding model, whilst lines in red were fitted to a non-stoichimetric binding model. 
 
4.2.6. Docking studies 
Co-crystallisation of the catalytic domain of sGC with the inhibitor 41 has been attempted 
by Dr. Charles Allerston at the structural genomics consortium in Oxford, and the group of 
Dr. Alun Coker at the Royal Free in UCL. At the time of writing, co-crystals had been 
obtained but a high resolution structure had yet to be solved. Thus, a possible binding 
mode was investigated by molecular modelling, using the available crystal structure of a 
mutated catalytic domain of sGC. This mutated enzyme was used in the SPR studies 
reported in section 4.2.5, and since the binding affinity of compound 41 to this enzyme was 
identical to the wild-type enzyme, it can be concluded that the mutated residues do not 
influence the binding of the inhibitor and the crystal structure can be used for docking 
purposes.  
As discussed in chapter 3, the catalytic domain of sGC shows two sites at the interface of 
the α- and β-subunits that can accommodate small molecules: the GTP binding site, and an 
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allosteric regulatory binding site referred to as the pseudosymmetric site (Figure 48). The 
two sites are different, and small molecules can bind to only one or both sites, thus 
showing a 1:1 or 1:2 binding ratio. 
 
 
Figure 48. Cartoon representation of the catalytic domain of sGC (pdb entry 3uvj). Where the α-subunit is 
represented in green and the β-subunit in orange. The molecular surfaces depicted represent the GTP and 
pseudosymmetric binding sites, and are coloured according to lipophilicity, where the hydrophilic surface is 
coloured in pink, the lipophilic in bright green, and neutral in white.  
 
Compound 41 was docked into the pseudosymmetric site of sGC and possible binding 
modes were analysed based on their Goldscore fitness. The Goldscore fitness function is a 
dimensionless score that gives an indication of how good the binding pose is, and is used as 
a comparative term. In general, the higher the score, the better the docking result is likely 
to be. 
A superimposition of all the resulting binding modes obtained with the inhibitor shows that 
with the exception of one mode that is docked at a more exposed surface, most binding 
modes are similarly docked at buried pockets at the interface of the two subunits. Five out 
of nine binding poses show only slightly variances in the angle of the phenol rings and the 
nitro group (Figure 49). 
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Figure 49. Superimposition of the binding poses of compound 41 in the pseudosymmetric site of sGC. a) All 
binding poses docked at pseudosymmetric site of sGC with protein suface; b) Zoomed image of five similar 
binding poses, without protein surface represented. 
 
The binding pose with the highest Goldscore (57.86) shows four key interactions with the 
receptor: one oxygen of the nitro group may act as H-bond acceptor for two backbone NHs, 
being the only interaction with residues of the β-subunit; the two NH groups attached to 
the quinoxaline may act as H-bond donors for the side chain of a glutamic acid; one OH can 
act as a H-bond donor; and a π-cation interaction is suggested between a charged lysine 
and one of the aromatic rings (Figure 50 and Table 11). In similar docking poses obtained 
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with compound 41, it is possible by small angle variations of the rotatable bonds that the 
other OH group would also act as H-bond donor to residues in proximity. In addition, the 
lysine and arginine residues present in the site could show π-cation interactions with other 
aromatic rings of the ligand. 
 
 
Figure 50. Highest ranking docking pose of compound 41 into the pseudosymmetric site of sGC. a) and b) 
Cartoon representation of compound 41 docked into the pseudosymmetric site of sGC; b) 2D representation of 
the ligand interactions between the compound and the residues of sGC. 
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Table 11. Possible interactions between compound 41 and sGC and their respective distances obtained by 
docking. 
Ligand 
Receptor 
Interaction 
Distance (Å) 
Atom Residue Chain 
N 10 OE1 GLU526 A H-donor 
3.28 
N 11 OE1 GLU526 A H-donor 
3.38 
N 11 OE2 GLU526 A H-donor 
2.82 
O 28 O PRO592 A H-donor 
2.48 
O 12 N GLN535 B H-acceptor 
3.02 
O 12 N ARG536 B H-acceptor 
3.31 
6-ring NZ LYS524 A π-cation 
3.63 
 
4.3. Summary 
sGC inhibitors currently used as biochemical tools to investigate the pathologies associated 
with sGC overactivity lack selectivity or bioavailability, limiting their use in vivo and further 
development as potential therapeutic agents. In this chapter, a new inhibitor of sGC has 
been presented. The small molecule, compound 41, resulted from a series of screening 
experiments initially based on analogues of the anti-convulsing drug lamotrigine which 
showed mild sGC inhibition.  
Compound 41 inhibits purified bovine lung sGC with an IC50 of 24 µM in the presence of 10 
nM NO, and with an IC50 of 37 µM when the enzyme is stimulated with 1 µM cinaciguat 6, 
in the absence of added NO. Inhibition of membrane-bound pGCs was also observed in 
purified rat lung membranes which had been treated with ODQ 4 to inhibit cGMP 
production by sGC. Compound 41 inhibited pGC activity with an IC50 value of 25 µM in the 
presence of 1 µM ANP. This indicates that the small molecule is not acting through 
oxidation of the heme, but rather targeting the catalytic domain of the enzyme. 
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Further characterisation of the binding of compound 41 was carried out using the SPR assay 
previously developed for the detection of binding of compound to sGC, described in 
chapter 3. A comparison was performed between the binding of the inhibitor to the full-
length enzyme, the wild type catalytic domain and the mutated catalytic domain whose 
crystal structure has been solved. An additional experiment was performed to compare the 
results obtained with the standard CM5 chip and the CM7 chip, which has a higher degree 
of carboxylation and allows higher immobilisation levels. In general, the binding affinity of 
compound 41 was similar for all immobilised proteins and chips (KD = 11 – 33 µM). The CM7 
chip gave slightly better sensorgrams with the wild type catalytic domain than the CM5 
chip, with a lower degree of non-specific binding. 
A simple route to the synthesis of the inhibitor 41 was developed using microware-assisted 
organic chemistry, which takes place through nucleophilic aromatic substitution in a polar 
aprotic solvent, without the need for the addition of catalysts or long reaction times. The 
synthesised compound showed similar activity to the commercially available material in a 
biochemical assay.  
Co-crystallisation of sGC with a bound compound has yet to be achieved. In order to 
hypothesise a binding mode and consider the interactions that may take place between 
compound 41 and the receptor, docking studies were performed using the available crystal 
structure of a mutated catalytic domain of sGC, to which binding of the inhibitor had been 
observed by SPR. The inhibitor was successfully docked into the pseudosymmetric site of 
the receptor and it is possible that the interactions between the compound and the 
receptor include hydrogen bonds and π-cation interactions. 
In summary, compound screening led to the identification of a new inhibitor of sGC which 
binds to the catalytic domain of the enzyme, possibly at the pseudosymmetric site, and 
may establish intermolecular interactions with both subunits of sGC. 
 
  
124 
 
 
 
 
 
 
 
Chapter 5: Design, synthesis and characterisation 
of small molecules as potential sGC inhibitors 
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5. Design, synthesis and characterisation of small molecules 
as potential sGC inhibitors 
5.1. Introduction 
In the previous chapter, the discovery of a new class of inhibitors of sGC was described, and 
the biochemical activity and biophysical binding of hit compound 41 was explored. Given 
that a crystal structure of the drug-target complex could not be obtained, it was necessary 
to synthesise and characterise a small library of analogues in order to explore the binding 
role of the different groups present in the molecule and seek more potent compounds. The 
activity of synthesised compounds was evaluated using a simple biochemical assay that 
allows the calculation of enzyme percent inhibition by selected compounds at 100 µM. 
Their binding to the catalytic domain was measured using SPR, also at a single 
concentration.  
 
5.1.1. Design rationale for analogues of compound 41 
In order to understand the functionality of the groups present in compound 41, a series of 
analogues was designed and synthesised with small variations in their structure, as 
summarised in Figure 51. Compound 41 is composed of a quinoxaline scaffold with a nitro 
group in the 6-position of the heterocycle and joined to two phenols via secondary amines 
which serve as linkers. Variations in this structure involved the replacement of p-phenols by 
m-phenols and other substituted benzenes (substructure E), replacement of the nitro 
group (substructure F), removal of the NH linker (substructure G), and reduced symmetry 
of the compounds by mono-substituted quinoxalines (substructure H).  
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Figure 51. Substructures of compounds analogues of compound 41 to be synthesised. 
 
5.2. Results and discussion 
N.B. Compounds 53, 60, 61, 70, and 71 were synthesised by Revathy Selvarajah, at the time 
a MChem student from the Department of Chemistry. 
 
5.2.1. Replacement of phenols 
A series of compounds was synthesised and tested in which the p-phenol rings were 
replaced by other substituted aromatic rings. Their structure, synthetic yield, percent 
inhibition, and binding response to sGCcat are summarised in Table 12. 
A common strategy in drug design is to change the position of substituents. In the case of 
compound 41 it would be possible that by changing the position of the hydroxyl group a 
stronger hydrogen bond could be formed by creating a more favourable contact with the 
receptor, thus increasing the activity of the inhibitor. Compound 48 was synthesized in 
which the hydroxyl group was in the meta-position. This compound also inhibits the activity 
of sGC and binds strongly to the receptor. 
Hydroxyl groups are commonly encountered in drugs due to their involvement in hydrogen 
bonding: the oxygen atom can act as a H-bond acceptor and the hydrogen as a H-bond 
donor. Testing the activity of the methoxy analogue, compound 49, could give some insight 
into the mechanism by which the compound is interacting with sGC. On one hand, if the 
proton of the original hydroxyl group is involved as a H-bond donor and is removed, the 
activity of the compound should be lowered. However, if the oxygen atom is acting as a H-
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bond acceptor, since it is still present in the methoxy analogue, the compound would 
remain active. Compound 49 showed no activity and no binding to sGC, confirming the 
hydroxyl group acts as H-bond donor and is required for activity. Removal of the hydroxyl 
group resulted in compound 50, which also showed no activity or significant binding. 
Many compounds in medicinal chemistry derive from peptides or polypeptides, and amide 
bonds are therefore present in the many lead compounds. Amides are likely to interact 
with binding sites through hydrogen bonding – primary and secondary amides have N-H 
groups that can act as H-bond donors, whilst the carbonyl oxygen atom can act as H-bond 
acceptor and has the potential to form two hydrogen bonds. Two acetamide analogues of 
compound 41 were synthesized: one in the para- position, compound 51, and the other in 
the meta- position, compound 52. Neither of the compounds showed activity or significant 
binding to sGC.  
The insertion of fluorides in aromatic rings can lead to higher metabolic stability, when 
compared to hydroxyl groups. These are however not able to form halogen bonds, and the 
fluoride-containing compound 53 showed no significant binding or activity against sGC. 
Indoles and indazoles are classical isosteres of phenol and have been shown not only to 
provide stronger interactions but also to improve metabolic stability.123 In this case, 
replacement of the phenol by an indazole was preferred over indole, as its ClogP is lower, 
and compound 54 was synthesised. However, it showed no significant inhibition of sGC, 
and its binding to the enzyme could not be determined by SPR since the compound showed 
poor solubility in the assay buffer. Compound 54 cannot establish the same contacts as 
compound 41 when docked into the structure of sGC, and it generally docks into the 
opposite side of the pseudosymmetric binding site. 
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Table 12. SAR of compounds where p-phenols have been substituted. 
 
N
NO2N NH
NH
R1
R2
R1
R2
 
Compound 
number 
R2 R2 % yield 
sGC 
% inhibition 
sGCcat binding 
Norm. Response 
(RU) 
 
41 OH H 60 56.2 ± 22.4 14.40 ± 1.72 
 
48 H OH 75 41.4 11.61 ± 0.76 
 
49 OCH3 H 40 0.8 0.99 ± 0.28 
 
50 H H 70 14.0 2.55 ± 0.21 
 
51 NHCOCH3 H 25 -8.7 0.84 ± 0.33 
 
52 H NHCOCH3 50 9.0 2.99 ± 1.01 
 
53 F H 61 -41.0 1.88 ± 1.78 
 
54 2-CHNNH-3 25 -12 
 - 
 
5.2.2. Replacement of the nitro group 
The electron-withdrawing nitro group commonly presents as a challenge in drug design. 
Nitro-aromatics are commonly associated with toxicity, but identifying suitable 
replacements has proven difficult. For example, in the development of the Bcl-XL inhibitor 
ABT-737 (55), an aromatic nitro group was replaced successfully by a 
trifluoromethylsulfone group; whilst in the development of inhibitors of the murine double 
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minute 2 (MDM2)-p53 protein-protein interaction, the same replacement rendered the 
compound inactive. 124  
NN
O
NHS
O
O
O2N
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N
S
Cl
 
     55 
Figure 52. Chemical structure of the Bcl-XL inhibitor ABT-737. 
 
The nitro group in compound 41 was replaced by a series of groups, their activity and 
binding was also investigated. A series of 6-substituted-2,3-dichloroquinoxalines was 
synthesised, since they were not commercially available. Further modifications included 
the reduction of the nitro to a primary amine, and the conversion of an acyl chloride into 
an amide.  
 
5.2.2.1. Synthesis of 6-substituted-2,3-dichloroquinoxalines 
2,3-dichloroquinoxalines (57, 59, 61, 63) were obtained by chlorination of 2,3-
dihydroquinoxalines (56, 58, 60, 62) using thionyl chloride with a catalytic amount of 
dimethyl formamide (DMF). The precursor 2,3-dihydroquinoxalines were in turn obtained 
by condensation of 1,2-phenylenediamines with oxalic acid, following known protocols125 
(Scheme 3). 
NH2
NH2
OHO
OHO N
N OH
OH N
N Cl
Cl
R R R4N HCl
reflux, 2 hrs
SOCl2, DMF
reflux, 2 hrs  
R = CF3 56, 50 %  R= CF3 57, 67 %  
 CN 58, 59 %   CN 59, 67 %  
 Cl 60, 85 %   Cl 61, 72 %  
 COOH 62, 84 %   COCl 63, 66 %  
Scheme 3. Synthesis of 2,3-dichloroquinoxalines.  
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The 2,3-dihydroquinoxalines are effectively chlorinated by the intermediate formidinium 
chloride salt , also known as the Vilsmeier reagent, which results from the reaction of DMF 
with thionyl chloride (Scheme 4). In the first step, DMF attacks thionyl chloride, and the 
chloride ion leaves. The resulting cation undergoes nucleophilic attack by the chloride ion, 
forming a tetrahedral intermediate, whichintermediate collapses with the loss of sulphur 
dioxide and chloride ion. At this point, the Vilsmeier reagent forms an intermediate with 
the quinoxaline-2,3-diol by nucleophilic attack. Rearrangement of the intermetiade species 
leads to regeneration of DMF, which acts as a good leaving group, allowing for an efficient 
chlorination of the the quinoxaline.. The generated gases, SO2 and HCl, leave the reaction 
vessel. 
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Scheme 4. Proposed mechanism for DMF catalysed chlorination with thionyl chloride. 
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5.2.2.2. Amide formation from acyl chloride 
The acyl chloride 63, was converted into a methylamide 64 by reaction with methylamine. 
Upon reaction with 3- and 4-aminophenols, the resulting analogues 73 and 74 were tested 
for sGC inhibition. It was proposed that if the nitro group is acting as a H-bond acceptor, its 
substitution by a carbonyl group could retain that interaction, which was observed in the 
docking studies. Although compound 74 showed strong binding to the receptor, neither of 
the compounds showed inhibition in the biochemical assay. 
 
N
N
Cl
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Cl
Cl  
                       63 
 
CH3NH2
EtOH
DCM
24 hrs, r.t.
(35 %)  
 
N
N
N
H
O
Cl
Cl 
          64 
Scheme 5. Synthesis of 2,3-dichloro-N-methylquinoxaline-6-carboxamide 64. 
 
5.2.2.3. Reduction of the nitro group  
Reduction of nitro groups may take place under different mechanisms, including 
hydrogenation, electron transfer, and hydride reductions. 
Reduction of aromatic nitro compounds by hydride is not straightforward Though aliphatic 
nitro compounds are relatively easy to reduce with lithium aluminium hydride (LiAlH4), 
reduction of nitrobenzene gives the azo compound (Ph-N=N-Ph), not the aniline.126-127 The 
most common metal counterion for hydride reducing agents are lithium and sodium. 
Nonetheless, alternative metal borohydrides can be generated with metals of higher ionic 
potential (such as Mg, Ca, Ba, and Sn) which may give better yields to the reduction of 
some functional groups.  
Tin (II) chloride (SnCl2) selectively reduces nitro groups into amines via a series of electron 
transfers.128-129 In the Selwood lab, it has previously been found that a combination of SnCl2 
and sodium borohydride (NaBH4) has given better results for the reduction of nitro groups 
than the use of SnCl2  alone. NaBH4 does not reduce nitro groups in aqueous or alcoholic 
solutions, but it has been found to do so in the presence of transition metals. For instance, 
reduction of 1-chloro-4-nitrobenzene takes place in the presence of copper (II) 
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acetylacetonate and it has been proposed to follow the simple pathway benzene – 
nitrosobenzene – phenylhydroxylamine – aniline, rather than producing the condensation 
intermediates azoxy- and azo-benzene.130 Reduction of the nitro group in compound 41 
into an amine took place by reaction with tin (II) chloride dihydride and NaBH4 in ethanol. 
In the proposed mechanism (Scheme 6), Sn2+ coordinates with the nitro, allowing the first 
hydride attack to the nitrogen. Similarly to the copper (II) reaction described above, nitroso 
and hydroxylamine intermediates would be formed.  
Formation of the amine (65 % yield) was confirmed by 1H NMR, where the NH2 broad peak 
can be seen at 5 ppm (Figure 53). 
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Scheme 6. Proposed mechanism for nitro reduction with NaBH4 and SnCl2. 
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Figure 53. 
1
H NMR of compound 75. The broad peak at 5.06 ppm corresponds to the NH2 in the 6-position of 
the quinoxaline, confirming successful reduction of the nitro groups. The NH2 group also causes the quinoxaline 
protons to be more shielded thus appearing at lower ppm compared to compound 41. 
 
5.2.2.4.  Characterisation of final compounds 
The 6-substituted-2,3-dichloroquinoxalines described in sections 5.2.2.1 and 5.2.2.2 were 
reacted with 3-aminophenol and/or 4-aminophenol and the final compounds were tested 
for sGC binding and inhibition.  Removal of the nitro group renders the compound inactive 
(compound 65) although it still binds strongly to the receptor. This suggests the binding 
observed is not greatly influenced by the group in the 6-position of the quinoxaline, but it is 
however necessary for activity. Substitution of the nitro by other electron withdrawing 
groups gave similar results (Table 13). Insertion of amine, chloro and nitrile groups also 
resulted in compounds which bind to the receptor but do not inhibit the enzyme activity. 
Conversely, insertion of a trifluoromethyl group resulted in active compounds (compounds 
66 and 67) that do not bind to the receptor so strongly.  
The reaction of 2,3-dichloroquinoxaline-6-carbonyl chloride 63 with 3-aminophenol 
resulted in nucleophilic attack on the carbonyl as well, yielding the compound 72, which did 
not show significant activity or binding. 
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Table 13. SAR of compounds where the nitro group has been substituted. 
N
N
NH
NHR1
R2
R2
R3
R3
 
Compound 
number 
R1 R2 R3 % yield 
sGC 
% inhibition 
sGCcat binding 
Norm. Resp. 
(RU) 
41 NO2 OH H 60 56.2 ± 22.4 14.40 ± 1.72 
65 H OH H 50 -28 12.43 ±  0.13 
66 CF3 OH H 83 44.4 6.38 ± 0.47 
67 CF3 H OH 83 21.1 2.96 ± 0.46 
68 CN OH H 86 -31 4.46 ± 1.98 
69 CN H OH 94 -57 10.46 ± 0.53 
70 Cl OH H 79 -6 9.72 ± 0.49 
71 Cl H OH 79 -11 9.01 ± 0.42 
72 CONH-(3-OH)-Ph OH OH 31 16 3.96 ± 0.34 
73 CONHCH3 OH H 72 -19 1.11 ± 0.30 
74 CONHCH3 H OH 75 -54 9.58 ± 0.29 
75 NH2 OH H 61 -24 9.85 ± 0.22 
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There is no clear correlation between binding and inhibition in this series of compounds. In 
general, removal of the nitro group or its substitution by other electron-withdrawing or 
carbonyl groups resulted in compounds which are still capable of binding the receptor, as 
observed by SPR, but only the trifluoromethyl-substituted compounds 66 and 67 were 
active in a functional assay. It is possible the inactive compounds are more stable at a 
conformation different from that of the active compounds, thus binding to the receptor in 
a different way, and docking of compounds shows it is possible for some compounds to fit 
at different ends of the binding site. Nonetheless, due to such a structural similarity 
between the compounds and their electronic behaviour, they would be expected to show 
similar binding behaviours.  
 
5.2.2.5. Trifluoro-substituted inhibitors with reduced toxicity 
As mentioned above, the use of nitro groups in drugs should be limited, as they are 
commonly associated with in vivo toxicity. Nitro-aromatic compounds can be metabolised 
into nitroso compounds and hydroxylamines, both of which present toxicity. Nitroso 
aromatics bind haemoglobin and can cause methemoglobinemia, whilst aromatic 
hydroxylamines may covalently modify DNA via electrophilic nitrinium formation.131-132  
 
 
Figure 54. Reductive pathways involved in the metabolism of nitroaromatics. Addapted from Smith, G.
131
  
 
The introduction of fluorides is common in medicinal chemistry since many approved 
pharmaceuticals are fluorinated. Fluorinated compounds may improve bioavailability by 
increasing stability to metabolism.133 Thus, since the fluoromethylated compound 66 
showed significant inhibition of sGC activity, this compound would be preferred for follow-
up assays over the nitro compound 41. Both compounds can be similarly docked into 
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sGCcat. The stronger binding observed by SPR of compound 41 to the receptor may be due 
to a potential H-bond between the nitro group and backbone amines. This however does 
not seem to be necessary for activity (Figure 55). 
 
 
Figure 55. Superimposition of compounds 41 and 66 binding to the pseudosymmetric site of sGC. Compound 
41 (green) is docked with a Goldscore of 57.86 and the depicted pose for compound 66 (pink) has a Goldscore 
of 54.49.  
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5.2.3. Synthesis of mono-substituted quinoxalines 
It was found that the reaction of 6-nitroquinoxaline 44 with N-(2-aminophenyl)acetamide 
76 was unfavoured, as the ortho-substituted aniline is sterically hindered and prevents the 
displacement of a second chloride. The resulting compound is therefore mono-substituted 
and is obtained in very low yields (16 %). The reaction could result in two possible isoforms 
in which the nitro group of compound 78 could be in the 6- or 7- position of the 
quinoxaline. Analysis by LC-MS shoes only one major product with m/z [M-H]- = 356 and it 
is not possible to confirm which isoform was formed. 
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Scheme 7. Synthesis of compound 78. 
138 
 
 
Figure 56. LC-MS spectrum of compound 78. (a) Chromatograph showing only one product with r.t. at 7.96 
min; (b) Mass spectrum with [M-H]
-
 (m/z 356.00) ion observed.  
 
5.2.4. Improved synthesis of mono-substituted quinoxalines by Buchwald 
– Hartwig aryl amination 
The Buchwald-Hartwig amination is a cross-coupling reaction of an aryl halide with an 
amine using a palladium catalyst, a ligand, and a strong base, to form a C – N bond.134-135 
This is a versatile technique as various palladium based catalysts are available and new 
ligands are constantly being developed to optimise the systems used for specific groups of 
organic molecules. A system using Pd2(dba)3 as precatalyst, the bidentate Xantphos as the 
ligand, and Cs2CO3 as base, has been widely used for coupling of aryl halides and amides.
136 
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The method can also be applied under microwave conditions, which increase the rate of 
reaction and retains high yield.137 It was investigated if this method could be employed to 
the coupling of 6-nitroquinoxaline 44 with the sterically hindered N-(2-
aminophenyl)acetamide 76. The reaction was carried out under microwave irradiation for 
30 min at 120 °C, using dioxane as the solvent. The apparent yield of 40 % was indeed 
greater than the one obtained by nucleophilic aromatic substitution. In both cases 
however, it was not possible to obtain the desired compound with a great degree of purity. 
The use of the same conditions for the synthesis of compound 41 did not result in a greater 
yield (50 %) than that obtained by nucleophilic aromatic substitution (60 %). 
The proposed mechanism for this cross-coupling reaction (Scheme 8) starts with the 
oxidative addition (I) of 6-nitroquinoxaline 44 to the palladium catalyst generated by the 
precatalyst Pd2(dba)3 with the ligand Xantphos. Coordination (II) of the aniline to the 
catalyst takes place through its lone pair of electrons in the free amine. A base mediated 
palladium-amine bond formation (III) takes place, followed by reductive elimination (IV) in 
which the C-N bond is formed, to yield compound 78. 
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Scheme 8. Proposed mechanism for Buchwald-Hartwig cross-coupling reaction. 
 
The addition of a methyl group in the 3-position of 4-aminophenol did not provide enough 
bulk for the reaction with 6-nitroquinoxaline 44 to result in a mono-substituted compound. 
Instead, compound 79 was obtained with 66 % yield. Surprisingly, the Buchwald-Hartwing 
cross-coupling proceeded via coupling of the quinoxaline with the hydroxyl group rather 
than the amine, possible because the amine was more hindered and the oxygen could 
coordinate with the catalyst more easily (Scheme 9). This was confirmed by 1H NMR, where 
the characteristic peak for a primary amine (4.92 ppm) can be observed (Figure 57). 
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Scheme 9. Synthesis of compounds 79 and 80. 
 
 
Figure 57. 
1
H NMR of compound 80. The peak at 8.77 ppm correspond to the H in the carbon in between the 
NO2 and the pyrazine ring, and it is coupled to the other H proximal to NO2 at 8.41 ppm (J = 2.6 Hz). This is in 
turn coupled to the vicinal proton which resonates at 7.89 ppm (J = 9.2 Hz). The peak at 6.92 ppm corresponds 
to the proton next to the methyl group and it is coupled to the H on the opposite side of the O at 6.88 ppm (J = 
2.7 ppm), which is in turn coupled to the vicinal H at 6.67 ppm (J = 8.5 Hz). The NH2 peak is seen at 4.92 ppm 
and the peak for the methyl group at 2.07 ppm. 
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The disubstituted analogue of compound 41, compound 79, bound strongly to the receptor 
but did not show enzyme inhibition. Neither of the mono-substituted compounds showed 
strong binding to sGC, but compound 80 inhibited its activity (Table 14). 
 
 Table 14. Characterisation of compounds 78 - 80. 
Compound number % yield 
sGC              
% inhibition 
sGCcat binding   
Norm. Response (RU) 
41 60 56.2 ± 22.4 14.40 ± 1.72 
78 40 5 2.37 ± 0.60 
79 66 -18 10.43 ± 0.08 
80 26 41 2.86 ± 0.65 
 
5.2.5. Asymmetrically substituted quinoxalines 
The reaction of 2,3-dichloroquinoxalines with meta- or para-substituted anilines results in a 
bisubstitution of the quinoxaline by the aniline, giving compounds which are highly 
symmetrical. It is however possible that only one aminophenol in the active compounds 
(41, 66, 67) is required for activity, and that a different substitution on the vicinal carbon 
could take place, thus improving the activity or physico-chemical properties of the 
molecules.  
Two asymmetrically substituted compounds were designed in which the solubilising groups 
piperazine and morpholine were introduced. The designed compounds would be expected 
to retain the key interactions with the receptor, whilst the reduced planarity and symmetry 
would be expected to increase their solubility.138 
The quinoxaline was made symmetrical with the insertion of a second nitro group, in order 
to reduce the number of potential products. Nitration of 6-nitroquinoxaline-2,3-diol 81 was 
carried out in the presence of potassium nitrate and sulphuric acid. Formation of the nitric 
acid takes place by solvation of potassium nitrate in sulphuric acid. Subsequent reaction of 
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nitric acid with sulphuric acid leads to the formation of the nitronium ion which is used in 
the electrophilic aromatic substitution of quinoxaline (Scheme 10). 
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Scheme 10. Proposed mechanism for the nitration of 2,3,-dichloro-6-nitroquinoxaline. 
 
The progress of this reaction was monitored by LC-MS analysis, until consumption of the 
starting material was observed, after 48 hrs. The resulting 6,7-dinitroquinoxaline-2,3-diol 
82 was then chlorinated to give 2,3-dichloro-6,7-dinitroquinoxaline 83 (Scheme 11). 
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Scheme 11. Synthesis of 2,3-dichloro-6,7-dinitroquinoxaline 83. 
144 
 
5.2.5.1. Synthesis of a piperazine-containing compound 
Introduction of a piperazine in place of a hydroxyl group lead to compound 87, which could 
potentially establish an additional H-bond since the piperazine would be protonated at 
neutral pH. 
4-(4-methylpiperazin-1-yl)aniline 86  was obtained by a two-step process which started 
with the Eschweiler-Clarke methylation of 1-(4-nitrophenyl)piperazine 84 under microwave 
irradiation, using a literature method139, followed by nitro reduction using sodium 
borohydride and tin (II) chloride. This methylation step took place to avoid reaction of the 
piperazine with the quinoxaline. 
4-(4-methylpiperazin-1-yl)aniline 86 was reacted with 4-aminophenol and 2,3-dichloro-6,7-
dinitroquinoxaline 83 and the resulting compound 87 was purified by reverse phase flash 
column chromatography (Scheme 12). In addition to the desired asymmetrically 
substituted compound 87, the reaction also proceeds via formation of symmetrically 
substituted compounds with both anilines used as starting material. Due to the similar 
polarity of the three compounds, it was not possible to successfully separate them by 
normal phase column chromatography, but separation was possible using C-18 columns 
and a water/methanol solution as the mobile phase. 
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Scheme 12. Synthetic route to compound 87. 
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5.2.5.2. Synthesis of a morpholine-containing compound 
A 4-phenylmorpholine was inserted instead of a second phenol (Scheme 13). The 
purification of compound 89 was complex and required preparative HPLC purification after 
reverse phase flash column chromatography (Figure 58). Preparative HPLC uses the same 
principle as analytical HPLC, except that in preparative HPLC the sample goes from the 
detector into a fraction collector, rather than into waste. This purification technique is 
considered lengthy and expensive when compared to traditional methods such as flash 
column chromatography and crystallisation and its use is therefore restricted for the 
separation of small quantities of compound. In this case, only 2 mg were obtained, which 
was enough for biological testing. NMR characterisation was not possible due to the small 
amount obtained, but compound identity was confirmed by accurate mass spectrometry. 
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Scheme 13. Synthesis of 4-(3-(2-morpholinophenylamino)-6,7-dinitroquinoxalin-2-ylamino)phenol 89. 
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Figure 58. Monitoring the purification of compound 89 by liquid chromatography and mass spectrometry. (a) 
Chromatograph of the crude material, where the peat at r.t. 8.69 min corresponds to compound 89; (b) 
Chromatograph obtained after reverse phase column chromatography, where the peak highlighted in yellow 
was recovered by preparative HPLC; (c) High resolution mass spectrum of compound 89 after purification. 
[M+H]
+
 (m/z 503.15) ion observed. 
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5.2.6. Removal of the NH linker 
A small set of compounds were obtained in which the NH linker was removed. These 
molecules are smaller and less flexible, and could potentially bind to deeper pockets in the 
receptor. 
The available 4-substituted-1,2-diamines were condensed with commercially available 1,2-
bis(3-methoxyphenyl)ethane-1,2-dione 90 and its demethylated analogue 91 using 
microwave irradiation. Demethylation of 1,2-bis(3-methoxyphenyl)ethane-1,2-dione 90 
was achieved using HBr in AcOH, using a literature method (Scheme 14). 140 141  
 
O
O
O
O  
90 
48% HBr
AcOH
reflux, 36 hrs
(60 %)  
 
O
O
OH
OH  
91 
Scheme 14. Demethylation of 1,2-bis(3-methoxyphenyl)ethane-1,2-dione 91. 
 
In general, hydroxyl-substituted compounds showed stronger binding to the receptor than 
the methoxy analogues. Conversely, methoxy analogues showed higher inhibition (Table 
15). Hydroxyl groups are strong H-bond donors, and may direct the compounds into a 
binding mode that is not favourable for inhibition. The methoxy analogues showed mild 
inhibition of sGC, and since they are very structurally different from the initial hit 
compound 41 they are expected to bind to the receptor in a different mode. 
 
148 
 
O
O
O
O
R2
R2
NH2
NH2
R1
N
NR1
O
O
R2
R2
MeOH 9:1 AcOH
5 min, 160 °C
W
 
Scheme 15. Synthesis of 2,3-diphenylquinoxalines. 
 
Table 15. SAR of2,3-diphenylquinoxalines. 
Compound 
number 
R1 R2 % yield % inhibition 
Norm. Response 
(RU) 
41 - 60 56.2 ± 22.4 14.40 ± 1.72 
92 CF3 OCH3 89 33 2.09 ± 0.21 
93 CN OCH3 99 30 0.42 ± 0.25 
94 Cl OCH3 99 38 -0.34 ± 0.54 
95 F OCH3 89 39 1.09 ± 0.43 
96 CF3 OH 99 -46 10.95 ± 0.50 
97 CN OH 89 -21 8.44 ± 0.37 
98 Cl OH 99 -9 6.90 ± 0.46 
99 F OH 81 -36 5.52 ± 0.33 
 
Docking of these compounds into the pseudosymmetric site of sGC suggests they are 
indeed binding to a deeper pocket of the pseudosymmetric site (Figure 59a). The binding 
conformations of the two trifluoromethyl-substituted compounds 92 and 96 in the binding 
site show the trifluoromethyl groups at differents ends, and since 96 shows strong binding 
in the SPR assay but no activity, it is possible that as suggested, the strong H-bond possible 
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between the hydroxyl groups is rendering the compound at a conformation that is not 
favourable for inhibition (Figure 59b). On the other hand, compound 92 could be binding 
by structural complementarity, not necessarily establishing any strong H-bonds, but still 
inducing a conformational change that renders the enzyme inactive.  
 
 
Figure 59. Docking of compounds 92 and 96 into the pseudosymmetric site of sGC. a) compounds 92 (yellow) 
and 96 (orange) bind to a deep pocket in the pseudosymmetric site of the enzyme; b) superimposion of the 
conformations with highest Goldscores of compounds 92 (yellow, goldscore 59.80) and 96 (orange, goldscore 
54.73). 
 
5.2.7. The role of superoxide dismutase in the biochemical assay 
The biochemical assay used to test the activity of compounds reported in this chapter was 
developed and performed by the group of Prof. John Garthwaite (UCL). The assay used 
isolated purified bovine lung sGC, which was activated by the NO donor diethylamine 
NONOate, in the presence of GTP and the cofactor Mg2+. Since some of the early reported 
inhibitors such as LY83583 (31) were found to inhibit enzyme activity by the formation of 
superoxide radicals, superoxide dismutase (SOD) was included in the assay buffer to 
prevent possible false positives that could result from the formation of superoxide. SOD is 
the general term given to metalloproteins which, as suggested by the name, dismutase 
superoxide into oxygen and peroxide. They are therefore considered antioxidants, and are 
commonly used in biochemical assays as radical scavengers. It was found that the activity 
of some initial hits reported in chapter 4 decreased in the presence of SOD, including that 
of compound 41 (data not shown).  
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Given that most analogues of compound 41 with at least one phenol ring showed binding 
to the enzyme in the biophysical assay it is surprising that only the trifluoromethyl 
substituted compounds showed significant inhibition of the enzyme. It should be noted 
that these compounds were only tested once. In addition, the activity of compound 41 
varied significantly (56.2 ± 22.4 % inhibition) in the different assays performed, since the 
compounds were tested on different occasions, depending on their availability.  
The last set of compounds tested were the N-methylquinoxaline-6-carboxamide derivatives 
73 and 74, and the asymmetrically substituted 6,7-dinitroquinoxalines 87 and 89. The 
activity of the compounds was measured in the presence and absence of SOD. Additionally, 
basal activity was also assessed by measuring the production of cGMP in the absence of 
added NO (Figure 60). ‡ 
 
 
Figure 60. The activity of compounds 41, 73, 74, 87, and 89 in the presence and absence of SOD. 
 
                                                          
‡
 This set of experiments was performed by me and Prof. John Garthwaite. 
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It has been proposed that superoxide can be formed by reaction of DMSO and NaOH, both 
of which are present in the assay, with oxygen.142 Yet, this has been controlled for as the 
compounds were tested alongside a control blank sample. No stimulation of sGC was 
observed in the absence of added NO. In the presence of 30 nM NO, cGMP production was 
observed in the presence and absence of SOD. All small molecules tested inhibited cGMP 
production to some extent in the absence of SOD, yet, when SOD was present only 
compound 41 showed enzyme inhibition.  
SOD has a well-defined binding site formed at the dimer interface which has been shown to 
accommodate small molecules. 143-144 Moreover, SOD is a target for selective killing of 
cancer cells by oestrogen derivatives.145  
This suggests the compounds reported here may be binding to SOD, which is present at 
high concentration in the assay buffer (0.1 mg/ mL), thus not acting on sGC. This could be 
investigated by a biophysical assay that would compare the affinity of the small molecules 
to SOD and sGC. Additionally, to confirm activity of the compounds, they could be tested in 
the presence of a different radical scavenger, such as the small molecule Tempol 100 
(Figure 61), which has been shown as effective as SOD in metabolising superoxide in 
cells.146 At the time of writing this hypothesis had not been tested. 
N
OH
O
Tempol  
            100 
Figure 61. Chemical structure of the SOD mimetic Tempol 100. 
 
5.3. Summary 
In this chapter, the synthesis, biochemical activity and binding of a series of compounds 
based on compound 41 were described. Replacement of some of the functional groups 
present in the structure of the inhibitor has given useful information regarding its binding 
mode. One or both of the phenol rings are H-bond donors, and variations in these rings are 
not well tolerated. The position of the hydroxyl group can be changed whilst retaining 
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binding strength and activity. However, other groups have rendered the compound inactive 
and reduced its binding strength. 
Changes in the 6-position of the quinoxaline have resulted in compounds which have high 
affinity to the receptor, but only the trifluoromethyl compounds have shown significant 
inhibition of the enzyme. Nonetheless, the replacement of the nitro group by a 
trifluoromethyl would be very beneficial if the metabolism of the compounds is taken into 
consideration, since nitroaromatics are often metabolised into toxic compounds which may 
cause DNA damage. 
The mono-substituted quinoxalines 78 and 80 showed only weak binding to the receptor 
but compound 80 showed mild inhibition of sGC, whilst the asymmetrically substituted 
compounds 87 and 89 inhibited sGC in the absence of SOD, but had no effect once SOD was 
included in the assay. A small set of 2,3-bis(3-methoxyphenyl)quinoxalines also presented 
mild inhibition of sGC activity. 
It is possible that the inhibitors presented bind to the catalytic domain of sGC inducing a 
conformational change, or “locking” the enzyme in a basal conformation, that is not 
favourable to activation by NO or GTP binding. This hypothesis considers the simple model 
of sGC activation which consists of NO binding to the heme inducing a conformation 
change that leads to binding of GTP and its conversion into cGMP.  
As discussed, the available biochemical assay used to assess the activity of the synthesised 
compounds is a highly artificial method, and it is proposed that a different functional assay 
could supplement the information reported here. A cell-based assay, if available, would 
provide a more accurate functional characterisation of this small library of compounds. 
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6. General conclusions 
Target-based drug discovery has the advantage of a known mechanism of drug action at a 
very early stage of development, ergo allowing the prediction of possible side effects and 
how to avoid them. If the exact binding mode of the drug to the target is known, by means 
of a crystal structure, it is often possible to improve drug-target interactions providing 
drugs with higher affinity to the target, potency and selectivity. Nonetheless, when a crystal 
structure is not available, it is still possible to obtain a great deal of information regarding 
binding affinity and the drug’s binding site using other biophysical techniques. 
Biophysical techniques such as SPR have in the past decade greatly facilitated target-based 
drug discovery. The technique can be used throughout the whole process of drug discovery 
from target identification to preclinical profiling. It has been extensively used in high 
throughput screening and structure-activity relationships. 
In this thesis, information obtained from SPR experiments has been used in all results 
chapters (Chapters 2 – 5). In chapter 2, the technique was validated using the NPR-C as a 
target. Characterisation of the receptor interaction with its natural ligands, CNP and ANP, 
was consistent with the information available in the literature and the assay was optimised 
to allow the characterisation of binding of a peptide antagonist and a small set of small 
molecule agonists. Confirmation that the small molecules do in fact bind to this target has 
established NPR-C as a druggable target. In addition, further characterisation of the most 
potent compounds was carried out by analysis of their binding behaviour to the receptor 
and problems with aqueous solubility, allowing the selection of a lead compound for 
further drug development. 
The main target of this thesis was sGC, a dimeric heme-containing enzyme which was 
already known to be druggable. Although small molecule activators of sGC have been 
known for over three decades, there have been no conclusive studies regarding their 
binding site, since a crystal structure is not available. Nonetheless, studies with mutated 
enzymes and molecular modelling had suggested different binding sites. The SPR assay 
presented here is to our knowledge the first SPR assay developed to detect binding to sGC, 
and it has provided further information to locate the binding site of these small molecules 
at the catalytic domain of the enzyme, possibly at an allosteric site, the pseudosymmetric 
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binding site.  Screening of a small library of compounds synthesised in the Selwood lab also 
resulted in the discovery of new enzyme activators. 
Screening of commercially available compounds against sGC resulted in the discovery of 
the first class of compounds that inhibit the activity of the enzyme through allosteric 
regulation, rather than oxidation of the heme. The hit compound 41 was thoroughly 
characterised biochemically and biophysically, and it was observed that the small molecule 
binds to the catalytic domain of enzyme, preventing conversion of GTP into cGMP (Figure 
62). Activity of compound 41 was also observed in cells in the lab of Prof. Garthwaite (data 
not shown). 
The synthesis of a small set of analogues was achieved using microwave-assisted organic 
synthesis, and the novel compounds were obtained using short synthetic routes with 
medium to high yields and high purity, suitable for biochemical evaluation. All compounds 
synthesised were ranked according to their binding strength, giving insight into the 
functional groups which are relevant for binding to the receptor.  
 
Figure 62.Schematic representation of the inhibition of sGC activity through binding of a small molecule to an 
allosteric site on the catalytic domain of the enzyme. 
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A radioimmunoassay was employed to assess the biochemical activity of sGC in the 
presence of all compounds and allowed the identification of compound 66 as an improved 
analogue of the hit compound 41. The replacement of the nitro group by a trifluoromethyl 
group would have advantages in the metabolism of the small molecule, as metabolites of 
nitro-aromatics are known to be toxic. 
N
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47 % sGC inhibition 44 % sGC inhibition
41 66
 
Figure 63. Chemical structures of most potent sGC inhibitors. 
 
Compound 66 is hereby proposed as a useful tool to further elucidate the signalling 
pathways regulated by sGC. An inhibitor that targets the catalytic domain of the enzyme 
would have advantages over the use of heme-binders, which have already proven 
limitations such as lack of selectivity and bioavailability. A more suitable tool is required to 
study for example the role of sGC in Parkinson’s disease, as it has been proposed as an 
alternative target for the treatment of the condition. 
 
6.1. Future work 
The biochemical assay employed showed several limitations in the assessment of 
compound activity. A key point noted was that the activity of the hit compound varied 
significantly on different days. Moreover, the presence of SOD significantly decreased the 
activity of the compounds. Thus, a significant amount of work remains to be done to 
accurately assess the activity of the inhibitors synthesised. It would be interesting to re-test 
all compounds in the absence of SOD, as well as assess their effect on SOD, as it is possible 
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the compounds are also binding to the metalloprotein and having an inhibitory/activating 
effect. A cell based assay would also complement this investigation. 
The pseudosymmetric site of sGC was explored using molecular modelling software. It is a 
relatively large site at the dimer interface which can accommodate small molecules. Due to 
the large size of this site, it is possible that compounds bind to different ends or pockets of 
the site, which could lead to compounds binding but not having a biochemical effect. It is 
proposed that the binding of inhibitors would stabilise the enzyme into an inactive 
conformation, thus preventing cyclisation of GTP into cGMP. Collaborators at UCL are also 
interested in this regulatory site and will continue with the crystallisation studies aiming to 
obtain a high resolution structure of the compound bound to the enzyme. It has been 
determined by SPR that the inhibitors bind to the catalytic domain of the enzyme, and 
since conditions for crystallisation of this isolated domain are already known, it would 
theoretically be possible to obtain a co-crystal of the drug-protein. The crystal structure 
would therefore allow a structure-based drug design, which could ultimately lead to more 
potent compounds. 
Further evaluation of compounds 41 and 66 in cell-based assay would be useful to assess 
the quality of these compounds as chemical probes. 
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7. Experimental methods 
7.1. General methods 
Human NPR-C was purchased from OriGene (Rockville, USA), CNP was purchased from 
Bachem (UK) Ltd. M372049 was a gift from AstraZeneca. NPR-C agonists were synthesised 
by the Selwood lab as reported in literature.147 Full-length human recombinant guanylyl 
cyclase α1β1 (soluble) was obtained from Enzo lifesciences (catalogue number ALX-201-
177). YC-1 (5) was purchased from Cayman Chemical. BAY 41-2272 (7) was purchased from 
Santa Cruz Biotechnology. Biacore consumables were purchased from GE Healthcare (UK), 
including buffer stock solutions. All other reagents used were obtained from Sigma. 
 
7.1.1. SPR 
Surface plasmon resonance (SPR) experiments were performed with a Biacore T200 
instrument at 25 °C. Data processing and analysis were performed using BIAevaluation 
software and Scrubber2. All sensorgrams were double referenced by subtracting the 
response in a reference flowcell and a blank sample, and injection spikes were removed. 
Where specified, data obtained were corrected for molecular weight differences by 
dividing each relative response value by the molecular weight of the corresponding sample 
and multiplying it by 100 (Normalized Response = Relative Response/Molecular weight x 
100). 
 
7.1.1.1. SPR immobilisation via amine coupling 
The carboxymethyl-modified dextran matrix of the chip was activated by injecting a 
solution containing 0.2 M (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride 
(EDC) and 50 mM N-hydroxysuccinimide (NHS) for 7 mins. The protein was injected in short 
pulses until the target level was reached and the surface free esters were blocked by 
injecting 1 M ethanolamine for 7 min. The upstream flowcell used as a reference was 
treated with EDC and NHS for 7min and blocked with ethanolamine for 7 min (blank 
immobilisation). 
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7.1.2. Biochemical assay for sGC activity 
Briefly, soluble guanylate cyclase (5 ng/ml) was incubated with 50 mM Tris, 0.3 mM MgCl, 
100 µM EGTA, 0.045 % BSA, and 1000 units/mL SOD at pH 7.4 and 1 mM MgGTP at 37 °C. 
Compounds were added at 100 µM prior to DEA/NO at 30nM when evaluating enzyme 
inhibition. To test for enzyme activation in the absence of NO, no DEA/NO was added. 
cGMP generation was allowed to proceed for two minutes, after which aliquots were 
withdrawn and inactivated by boiling in 50 mM Tris, 4 mM EDTA buffer. cGMP formation 
was measured by a standard radioimmunoassay.  
 
7.1.3. Chemistry 
Starting materials were either commercially available or synthesized according to methods 
reported in the literature. 1H and 13C NMR spectra were recorded on a Bruker AMX-300 or a 
Bruker AMX-500 spectrometer. Chemical shifts are reported as ppm relative to TMS 
internal standard. Mass spectra were recorded on a Fisons VG70-SE spectrometer (EI, FAB) 
or an Agilent 6100 Series LC-mass spectrometer using C-18 or C-4 columns. Microwave 
reactions were carried out using a CEM Discover microwave. 
 
7.2. Chapter 2 methods 
7.2.1. SPR 
7.2.1.1. Buffer preparation 
Running buffer for experiments without DMSO was prepared by diluting a 10x stock 
solution of HBS+ from GE Healthcare, to give a final composition of 10 mM HEPES, 150 mM 
NaCl, 0.05 % Surfactant P20. 
To prepare running buffer with 5 % DMSO, firstly a 1.05x HBS+ buffer was prepared, 
followed by addition of DMSO to give a final composition of 10 mM HEPES, 150 mM NaCl, 
0.05 % Surfactant P20, 5 % DMSO. 
 
 
161 
 
7.2.1.2. Immobilisation of NPR-C 
NPR-C (25 µg/mL in 10 mM sodium acetate pH 4.5) was covalently attached to a CM5 chip 
via amine coupling. A surface density of 2700 RU was used for measurements with 
natriuretic peptides and the NPR-C antagonist M372049, and a density of 5200 RU for 
measurements with NPR-C agonists. 
 
7.2.1.3. Antagonist and agonist sample preparation 
Compounds were initially prepared as 50 mM stock solutions in DMSO. SPR samples were 
prepared by firstly diluting the DMSO samples with 20 parts of 1.05x HBS+. The correct 
concentration was then obtained by further dilution with 1x HBS, 5 % DMSO.  
 
7.2.1.4. High-resolution CNP and ANP binding 
Sequential injections of the natriuretic peptide at 0.25, 0.50, 1, 2, and 4 nM were 
performed at a flow rate of 30 µL/min for 240 sec each concentration, followed by a 
dissociation time of 3600 sec. Binding site saturation was observed and the surface was 
regenerated by two injections of 1M NaCl for 200 sec each. Kinetic parameters were 
calculated assuming a simple 1:1 (Langmuir) binding. 
 
7.2.1.5. High-resolution binding of M372049 (15) 
Binding of M372049 (15) was measured at 7 concentrations (0.94, 1.88, 3.75, 7.5, 15, 30, 
60 nM) in duplicate. Injection time was of 120 sec followed by undisturbed dissociation for 
600 sec, during which curves returned to baseline. A needle wash with 50 % DMSO was 
performed between each sample and a DMSO calibration cycle was performed to correct 
for variances in DMSO concentration between samples. Kinetic parameters were calculated 
assuming a simple 1:1 binding. 
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7.2.1.6. High resolution binding of agonist compound 13 
Concentration dependent binding of compound 13 was measured at 8 concentrations 
(1.17, 2.34, 4.70, 9.38, 18.75, 37.50, 75, 150 µM) in duplicate. Injection time was of 30 sec 
followed by undisturbed dissociation for 30 sec, during which curves returned to baseline. 
A needle wash with 50 % DMSO was performed between each sample and a DMSO 
calibration cycle was performed to correct for variances in DMSO concentration between 
samples. Kinetic constants (rapid on/off rates) fall outside the instrument’s limits of 
detection. 
 
7.2.1.7. Binding of NPR-C agonists 
Injections of compounds at 50 µM were performed in triplicate with an association time of 
30 sec and dissociation of 30 sec, during which time curves returned to baseline. The 
surface was washed with running buffer and the needle washed with 50 % DMSO between 
samples. A DMSO calibration was performed to account for variations in DMSO 
concentration between samples and running buffer. Sensorgrams and all results were 
normalised for molecular weight variances by dividing the relative responses by the 
compound molecular weight and multiplying it by 100. 
 
7.2.2. Solubility measurements 
7.2.2.1. Generation of standard solubility curves 
Stock solutions with a concentration of 1000 µg/mL were prepared by dissolving the solid 
compound in DMSO. The resulting solutions were dissolved with a mixture of water and 
methanol (1:1) to make up standard solutions of 500, 250, 100, 50, 25, and 10 µg/mL. The 
standard solutions were analysed by LC-MS and the concentration plotted against the peak 
area to obtain a calibration curve.  
 
7.2.2.2. Measurement of compound solubility in buffer 
Two solutions were prepared in which the solid compound (0.7 to 0.9 mg) was dissolved in 
1 mL of 10 mM PBS pH 7.4 and shaken for 24 hrs. After 24 hrs, 500 µL were removed, 
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filtered through 0.22 µm and analysed by LC-MS. The average area of the peak 
corresponding to the compound was fitted into the equation for the calibration curve and 
the concentration determined  
 
7.3. Chapter 3 Methods 
7.3.1. Protein expression and purification 
sGCcat was a gift from Charles Allerston (Structural Genomics Consortium, Oxford). Protein 
expression and purification was performed as previously described except that the protein 
was finally buffer exchanged in to 50 mM HEPES, pH 7.5, 300 mM NaCl, 5 % glycerol, in 
order to make it ameanable to amine-coupling.71  
 
7.3.2. SPR 
7.3.2.1. Buffer preparation. 
Running buffer for experiments without dmso was prepared by diluting a 10x stock solution 
of HBS-EP+ from GE Healthcare and adding DTT and MgCl2, to give a final composition of 10 
mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.05 % v/v Surfactant P20, 1 mM DTT, and 
10 mM MgCl2. To prepare running buffer with 5 % DMSO, the assay buffer was prepared as 
described above and 5 % DMSO was added. For experiments performed with full-length 
sGC, running buffer contained a concentration of 300 mM NaCl in its final composition. 
 
7.3.2.2. Immobilisation of sGC α1β1 catalytic domain (sGCcat) 
sGCcat (30 µg/mL in 10 mM sodium acetate buffer at pH 5.5 containing 1 mM DTT, 1 mM 
ATP, 1 mM GTP, and 3 mM MgCl2) was covalently bound to a CM5 sensor chip via an amine 
coupling method  
 
 
164 
 
7.3.2.3. Immobilisation of full length human recombinant sGC 
Full length enzyme (50 µg/mL in sodium acetate buffer at pH 4.5 containing 1 mM DTT, 2 
mM ATP and 3 mM MgCl2) was covalently bound to a CM5 sensor chip via an amine 
coupling method. 
 
7.3.2.4. High-resolution binding of ATP, GTP, and cGMP 
The equilibrium binding of nucleotides at 8 different concentrations (0.1 to 3 mM) was 
measured in duplicates using an injection and dissociation times of 30 sec each. The 
running buffer did not contain DMSO. 
 
7.3.2.5. Binding of small molecules 
Binding of compounds was measured at 100 µM. Injection time was for 30 sec followed by 
undisturbed dissociation for 30 sec were curves returned to baseline. A needle wash with 
50 % DMSO was performed between each sample and a DMSO calibration cycle was 
performed to correct for variations in DMSO concentration between samples by a standard 
method.148 Every sample was measured in triplicate. 
 
7.4. Chapter 4 methods 
7.4.1. Virtual screening  
(Conducted by Paul Gane in the Selwood lab.) 
Similarity searching using MACCS fingerprints at 85 and 75 % Tanimoto similarity was 
performed in 2007 using the following databases: Abinitio, Acros, Actimol, Akos/Akl, 
,Akox/Akx, Akos/Owh, Asinex, Chembridge, Chemstar, LifeChemicals, 
MoscowMedChemLabs, Pharmeks, Sigma, SPECS, Vitas/Dah, Vitas/Stk. The available 
structures were selected by hand based upon diversity, molecular size, and apparent 
availability. 
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7.4.2. Particulate guanylate cyclase assay 
(Conducted by the Garthwaite lab) 
Purified rat lung membranes (20 µg protein/200 µL) were incubated in Tris buffer with 10 
mM phosphocreatine, 10 units/mL creatine phosphokinase, and 10 µM ODQ to inhibit NO-
activated GC. The reaction took place with 0.3 mM MgCl, 0.5 mM MgATP, and 1 mM 
MgGTP, at 37 °C. 1 µM ANP was added to activate pGC and cGMP penetration allowed to 
proceed for 10.5 – 12.5 min. Generated cGMP was measured by a standard 
radioimmunoassay. 
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7.4.3. Synthesis 
4,4'-((6-nitroquinoxaline-2,3-diyl)bis(azanediyl))diphenol (41) 
N
NO2N Cl
Cl
NH2
N
N NH
NH
O2N
OH
OH
OH  
2,3-dichloro-6-nitroquinoxaline (24.4 mg, 0.10 mmol) and 4-aminophenol (43.6 mg, 0.40 
mmol) were transferred into a 10 ml microwave vial containing a stirrer bar and NMP (1 
mL). The mixture was stirred at 160°C for 5 min under microwave irradiation. The residue 
was taken up in water (5 mL) and extracted with ethyl acetate (3 x 5 mL). The organics were 
washed with water (3 x 5 mL) and brine (3 x 5 mL), dried over Mg2SO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography using a 
methanol gradient of 3 to 10 % in DCM to give the name compound as a red powder (24.0 
mg, 60 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.37 (s, 1H, OH), 9.31 (s, 1H, OH), 9.26 (s, 1H, NH), 9.07 (s, 
1H, NH), 8.18 (d, J = 2.5 Hz, 1H, ArH), 8.01 (dd, J = 8.9, 2.5 Hz, 1H, ArH), 7.64 (dd, J = 10.9, 
8.9 Hz, 4H, 4 x ArH), 7.51 (d, J = 8.9 Hz, 1H, ArH), 6.83 (d, J = 8.9 Hz, 4H, 4 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ 154.2 (ArC), 153.8 (ArC), 143.2 (ArC), 142.6 (ArC), 141.5 
(ArC), 140.6 (ArC), 135.3 (ArC), 130.7 (ArC), 130.3 (ArC), 125.4 (ArCH), 123.7 (ArCH), 123.2 
(ArCH), 120.1 (ArCH), 118.6 (ArCH), 115.5 (ArCH), 115.2 (ArCH). 
HRMS-ES (m/z): [M + H]+ calculated for C20H16N5O4, 390.1202; found, 390.1205. 
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7.4.4. SPR 
7.4.4.1. Immobilisation 
The catalytic domain of sGC (sGCcat) and full-length enzyme were immobilised as described 
in section 3. The mutated catalytic domain sGC was immobilised using the same conditions 
as the wild type sGCcat.  
The immobilisation level of sGCcat was 11386 RU on the CM5 chip and 20683 RU on the 
CM7 chip. 
The immobilisation level of the mutated sGCcat on a CM5 chip was 10891 RU. 
The immobilisation level of the full length sGC on a CM7 chip was 20683 RU. 
 
7.4.4.2. High resolution binding of compound 41 
Binding of compound 41 was measured at 6 concentrations (4, 8, 16, 32, 64, and 128 µM). 
Injection time was 30 sec followed by undisturbed dissociation for 60 sec, during which 
time curves returned to baseline. A needle wash with 50 % DMSO was performed between 
each sample. Kinetic parameters were calculated assuming a simple 1:1 binding model, and 
a binding model considering non-specific binding, where specified. 
 
7.4.5. Molecular modelling 
7.4.5.1. Small molecule preparation 
3D coordinates were added to the 2D molecules by adding hydrogens and performing 
energy minimization using the force field MMFF94x in the MOE software. Files were saved 
as mol2 files. 
 
7.4.5.2. Binding site mapping 
The crystal structure of the catalytic domain of sGC (pdb entry 3uvj) was imported into the 
MOE software and binding sites were selected using the “site finder” functionality of the 
software. The two biggest sites (432 and 461 Å), corresponded to the GTP binding site and 
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the pseudosymmetric site, respectively, as concluding by visualisation of the residues 
known to be involved in GTP binding. 
 
7.4.5.3. Protein preparation 
The pdb file was analysed and missing residue side chains were added to the structure. 
 
7.4.5.4. Docking 
Docking took place using Gold 5.1. Using the standard wizard setup, hydrogens were 
added. The binding site was selected by importing the list of residues obtained in 7.4.5.2. 
The fitness function selected was GOLDSCORE and the genetic algorithm search was 
performed at medium speed. 
 
7.5. Chapter 5 methods 
7.5.1. General methods 
7.5.1.1. Method A: 
The quinoxaline and aniline (1:4) were transferred into a 10 mL microwave vial containing a 
stirrer bar and NMP (1 mL). The mixture was stirred at 160°C for 5 min under microwave 
irradiation. The residue was taken up in water (5 mL) and extracted with ethyl acetate (3 x 
5 mL). The organics were washed with water (3 x 5 mL) and brine (3 x 5 mL), dried over 
Mg2SO4, filtered and concentrated in vacuo. 
 
7.5.1.2. Method B 
The 4-substituted-1,2-diamine and 1,2-bis(3-methoxyphenyl)ethane-1,2-dione (or 1,2-
bis(3-hydroxyphenyl)ethane-1,2-dione) (1:1) were dissolved in 9:1 methanol-acetic acid 
(1.5 mL) and reacted under microwave irradiation for 5 min at 160 °C. Upon cooling, the 
solvent was evaporated under reduced pressure and the residue purified by flash column 
chromatography using a solvent gradient of 10-50 % ethyl acetate in cyclohexane. 
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7.5.1.3. Method C 
A solution of oxalic acid in 4 N HCl (5 mL) was added to a stirring solution of the diamine (1 : 
1) in 4N HCl (15 mL) and the reaction mixture was refluxed for 2hrs. The solution was 
cooled to room temperature and the precipitate filtered by suction, washed with water and 
freeze-dried. 
 
7.5.1.4. Method D 
N,N-dimethylformamide (0.01 eq.) was added to a solution of 2,3-dihydroxyquinoxaline-6-
carbonitrile in thionyl choride (5 mL) and stirred under reflux for 2 hrs. The reaction 
mixture was cooled to room temperature and concentrated under vacuum. Water (10 mL) 
was added to the solid on an ice bath and the slurry was stirred for 30 min at room 
temperature, after which the solid was filtered and washed with water. The precipitate was 
taken up in a minimum amount of DCM and filtered through a silica column and eluted 
with DCM. 
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7.5.2. Synthesis§ 
3,3'-((6-nitroquinoxaline-2,3-diyl)bis(azanediyl))diphenol (48) 
N
NO2N Cl
Cl
NH2
N
N NH
NH
O2N
OH
OH
OH
 
2,3-Dichloro-6-nitroquinoxaline (48.8 mg, 0.20 mmol) and 3-aminophenol (87.2 mg, 0.80 
mmol) were reacted following method A. The crude material was purified by flash 
chromatography using ethyl acetate and cyclohexane (50 : 50) to give the named 
compound as a red powder (57.0 mg, 75 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.50 (s, 1H, OH), 9.48 (s, 1H, OH), 9.41 (s, 1H, NH), 9.24 (s, 
1H, NH), 8.32 (d, J = 2.6 Hz, 1H, ArH), 8.11 (dd, J = 9.0, 2.6 Hz, 1H, ArH), 7.66 (d, J = 2.0 Hz, 
1H, ArH), 7.64 (d, J = 9.0 Hz, 1H, ArH), 7.51 (t, J = 7.3 Hz, 1H, ArH), 7.27 (dd, J = 18.4, 8.0 Hz, 
2H, 2 x ArH), 7.22 – 7.16 (m, 2H, 2 x ArH), 6.54 (ddd, J = 17.0, 8.0, 1.5 Hz, 2H, 2 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 155.89, 155.55, 143.29, 143.23, 142.52, 141.43, 135.29, 
132.27, 131.87, 125.53, 123.46, 122.95, 120.18, 118.80, 113.95, 55.25, 55.22. 
HRMS-ES (m/z): [M + H]+ calculated for C22H16N5O4, 390.1202; found, 390.1189. 
 
 
 
 
 
 
                                                          
§
 Compounds 53, 60, 61, 70, and 71 were synthesised by Revathy Selvarajah in the Selwood lab. 
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N2,N3-bis(4-methoxyphenyl)-6-nitroquinoxaline-2,3-diamine (49) 
N
NO2N Cl
Cl
NH2
N
N NH
NH
O2N
O
O
O  
2,3-Dichloro-6-nitroquinoxaline (24.4 mg, 0.10 mmol) and 4-methoxyaniline (49.2 mg, 0.40 
mmol) were reacted following method A. The crude material was purified by flash 
chromatography using an ethyl acetate gradient of 0 to 50 % in cyclohexane to give the 
named compound as a red powder (15.0 mg, 40 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.39 (s, 1H, NH), 9.20 (s, 1H, NH), 8.21 (d, J = 2.6 Hz, 1H, 
ArH), 8.04 (dd, J = 8.9, 2.6 Hz, 1H, ArH), 7.82 – 7.74 (m, 4H, ArH), 7.54 (d, J = 8.9 Hz, 1H, 
ArH), 7.05 – 6.99 (m, 4H, ArH), 3.78 (s, 6H, 2 x OCH3). 
13C NMR (126 MHz, d6-DMSO) δ 155.9 (ArC), 155.6 (ArC), 143.3 (ArC), 143.2 (ArC), 142.5 
(ArC), 141.4 (ArC), 135.3 (ArC), 132.3 (ArC), 131.9 (ArC), 125.5 (ArCH), 123.5 (ArCH), 122.9 
(ArCH), 120.2 (ArCH), 118.8 (ArCH), 113.9 (ArCH), 55.3 (OCH3), 55.2 (OCH3). 
HRMS-ES (m/z): [M + H]+ calculated for C22H20N5O4, 418.1515; found, 418.1531. 
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6-nitro-N2,N3-diphenylquinoxaline-2,3-diamine (50) 
Literature compound.149 
N
NO2N Cl
Cl
NH2
N
N NH
NH
O2N
 
2,3-Dichloro-6-nitroquinoxaline (48.8 mg, 0.20 mmol) and aniline (74.4 mg, 0.80 mmol) was 
reacted using method A and purified by flash chromatography using an ethyl acetate 
gradient of 10 to 50 % in cyclohexane to give a yellow powder (49.0 mg, 70 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.51 (s, 1H, NH), 9.34 (s, 1H, NH), 8.27 (d, J = 2.2 Hz, 1H, 
ArH), 8.07 (dd, J = 8.8, 2.2 Hz, 1H, ArH), 7.95 – 7.85 (m, 4H, 4 x ArH), 7.62 (d, J = 8.8 Hz, 1H, 
ArH), 7.47 – 7.39 (m, 4H, 4 x ArH), 7.20 – 7.09 (m, 2H, 2x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 143.7 (ArC), 143.1 (ArC), 142.4 (ArC), 141.2 (ArC), 139.4 
(ArC), 139.1 (ArC), 135.2 (ArC), 128.8 (ArCH), 125.9 (ArCH), 123.9 (ArCH), 123.4 (ArCH), 
121.6 (ArCH), 121.1 (ArCH), 120.5 (ArCH), 119.2 (ArCH).  
HRMS-ES (m/z): [M + H]+ calculated for C20H16N5O2, 358.1304; found, 358.1305. 
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N,N'-(((6-nitroquinoxaline-2,3-diyl)bis(azanediyl))bis(4,1-
phenylene))diacetamide (51) 
N
N Cl
Cl
NH2
N
N NH
NH
HN
HN
O2N O2N
HN
O
O
O  
2,3-Dichloro-6-nitroquinoxaline (48.8 mg, 0.20 mmol) and N-(4-aminophenyl)acetamide 
(120 mg, 0.80 mmol) were reacted following method A. The crude material was purified by 
flash chromatography using a methanol gradient of 0 to 5 % in DCM to give the named 
compound as a red powder (23.0 mg, 25 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.97 (s, 1H, NH), 9.96 (s, 1H, NH), 9.52 (s, 1H, NH), 9.33 (s, 
1H, NH), 8.28 (d, J = 2.4 Hz, 1H, ArH), 8.06 (dd, J = 8.9, 2.4 Hz, 1H, ArH), 7.83 (dd, J = 13.6, 
8.9 Hz, 4H, 4 x ArH), 7.67 – 7.57 (m, 5H, 5 x ArH), 2.05 (d, J = 4.9 Hz, 6H, 6 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 168.1 (Ar-NH-CO-CH3), 168.0 (Ar-NH-CO-CH3), 143.5 (ArC), 
143.1 (ArC), 142.3 (ArC), 141.3 (ArC), 135.5 (ArC), 135.3 (ArC), 134.5 (ArC), 134.1 (ArC), 
125.7 (ArCH), 122.1 (ArCH), 121.6 (ArCH), 120.4 (ArCH), 119.4 (ArCH), 119.3 (ArCH), 118.9 
(ArCH), 23.9 (Ar-NH-CO-CH3). 
HRMS-ES (m/z): [M + H]+ calculated for C24H22N7O4, 472.1733; found, 472.1750. 
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N,N'-(((6-nitroquinoxaline-2,3-diyl)bis(azanediyl))bis(3,1-
phenylene))diacetamide (52) 
N
N Cl
Cl
NH2
N
N NH
NH
O2N O2N
N
H
O
H
N
O
N
H
O
 
2,3-Dichloro-6-nitroquinoxaline (122 mg, 0.50 mmol) and N-(3-aminophenyl)acetamide 
(300 mg, 2.00 mmol) were reacted following method A. The crude material was purified by 
flash chromatography using ethyl acetate and cyclohexane (50 : 50) as eluent to give the 
name compound as a red powder (117.0 mg, 50 %). 
1H NMR (500 MHz, d6-DMSO) δ 10.02 (s, 2H, 2 x NH), 9.62 (s, 1H, NH), 9.44 (s, 1H, NH), 8.46 
– 8.32 (m, 3H, 3 x ArH), 8.12 (dd, J = 8.8, 2.0 Hz, 1H, ArH), 7.71 – 7.60 (m, 3H, ArH), 7.36 – 
7.25 (m, 5H, 5 x ArH), 2.09 (s, 3H, CH3), 2.08 (s, 3H, CH3). 
13C NMR (126 MHz, d6-DMSO) δ 168.4 (Ar-NHCOCH3), 139.7 (ArC), 135.1 (ArC), 128.8 
(ArCH), 125.9 (ArCH), 120.6 (ArC), 119.2 (ArCH), 116.3 (ArCH), 115.8 (ArCH), 114.5 (ArCH), 
114.1 (ArCH), 112.2 (ArCH), 111.6 (ArC), 109.1 (ArC), 24.1 (Ar-NHCOCH3). 
HRMS-ES (m/z): [M + H]+ calculated for C24H22N7O4, 472.1733; found, 472.1733. 
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N2,N3-bis(4-fluorophenyl)-6-nitroquinoxaline-2,3-diamine (53) 
N
NO2N Cl
Cl
NH2
N
N NH
NH
O2N
F
F
F  
2,3-Dichloro-6-nitroquinoxaline (24.4 mg, 0.10 mmol) and 4-fluoroaniline (48.0 µl, 0.40 
mmol) were reacted following method A. The crude material was purified by flash 
chromatography using a ethyl acetate gradient of 10 to 50 % in cyclohexane to give the 
named compound as an orange powder (24.0 mg, 61 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.52 (s, 1H), 9.36 (s, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.07 (dd, J 
= 8.9, 2.4 Hz, 1H), 7.92 (ddd, J = 13.8, 8.9, 5.0 Hz, 4H), 7.60 (d, J = 8.9 Hz, 1H), 7.31 – 7.23 
(m, 4H). 
HRMS-ES (m/z): [M + H] calculated for C20H14N5O3F2, 394.1116; found, 394.1123. 
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N2,N3-di(1H-indazol-6-yl)-6-nitroquinoxaline-2,3-diamine (54) 
N
NO2N Cl
Cl
NH2
N
N NH
NH
O2N
N
NH
NH
N
N
NH
 
2,3-Dichloro-6-nitroquinoxaline (48.8 mg, 0.20 mmol) and 1H-indazol-6-amine (106.4 mg, 
0.80 mmol) we reacted using method A and purified by flash chromatography using a 
methanol gradient of 0 to 10 % in DCM to give an orange powder (21.0 mg, 25 %). 
1H NMR (300 MHz, d6-DMSO) δ: 13.04 (s, 1H, NNH), 12.98 (s, 1H, NNH), 9.78 (s, 1H, NH), 
9.60 (s, 1H, NH), 8.68 (s, 1H, ArH), 8.47 (s, 1H, ArH), 8.36 (d, J = 2.6 Hz, 1H, ArH), 8.17 (dd, J 
= 9.0, 2.6 Hz, 1H, ArH), 8.03 (d, J = 5.4 Hz, 2H, 2 x ArH), 7.79 (dd, J = 8.7, 4.4 Hz, 2H, 2 x ArH), 
7.66 (d, J = 9.0 Hz, 1H, ArH), 7.51 – 7.39 (m, 2H, 2 x ArH).  
13C NMR (126 MHz, d6-DMSO) δ 143.7 (ArC), 143.4 (ArC), 142.6 (ArC), 141.2 (ArC), 140.5 
(ArC), 140.4 (ArC), 137.7 (ArC), 137.3 (ArC), 135.2 (ArC), 133.4 (ArC), 133.4 (ArC), 125.8 
(ArCH), 120.5 (ArCH), 120.4 (ArCH), 119.6 (ArCH), 119.4 (ArCH), 119.2 (ArCH), 116.5 (ArCH), 
116.0 (ArCH), 101.66 (ArCH), 100.67 (ArCH). 
HRMS-ES (m/z): [M + H]+ calculated for C22H16N9O2, 438.1427; found, 438.1425. 
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6-(trifluoromethyl)quinoxaline-2,3-diol (56) 
Literature compound.150  
OHO
OHO
NH2
NH2
F3C
N
N OH
OH
F3C
 
4-Trifluoromethyl-o-phenylenediamine (528 mg, 3.0 mmol) was reacted with oxalic acid 
(1.97 mg, 3.3. mmol) using method C to give the named compound as a brown powder 
(340 mg, 50 %). 
1H NMR (500 MHz, d6-DMSO) δ: 12.17 (s, 1H, OH), 12.06 (s, 1H, OH), 7.41 (d, J = 8.3 Hz, 1H, 
ArH), 7.38 (s, 1H, ArH), 7.26 (d, J = 8.3 Hz, 1H, ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 155.2 (ArC), 154.9 (ArC), 129.0 (ArC), 126.1 (ArC), 125.2 
(ArCH), 123.2-122.9 (m, Ar-CF3), 119.7 (ArCH), 115.8 (ArCH), 111.8 (ArC-CF3). 
MS-EI (m/z): [M]- calculated for C9H4F3N2O2, 229.1363; found 229.00. 
 
2,3-dichloro-6-(trifluoromethyl)quinoxaline (57) 
Literature compound.150 
N
N OH
OH
F3C
N
N Cl
Cl
F3C
 
The reaction with 6-(trifluoromethyl)quinoxaline-2,3-diol (330 mg, 1.76 mmol) was carried 
out using method D to give the name compound as a white solid (268 mg, 67 %). 
1H NMR (500 MHz, d6-DMSO) δ: 8.52 (d, J = 0.9 Hz, 1H, ArH), 8.29 (d, J = 8.8 Hz, 1H, ArH), 
8.20 (dd, J = 8.8, 1.9 Hz, 1H, ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 147.5 (ArC), 146.7 (ArC), 141.4 (ArC), 139.2 (ArC), 131.2 
(ArC-CF3 or Ar-CF3), 130.9 (ArC-CF3 or Ar-CF3), 129.8 (ArCH), 127.0 (ArCH), 126.0 (ArCH). 
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2,3-dihydroxyquinoxaline-6-carbonitrile (58) 
Literature compound.150 
OHO
OHO
NH2
NH2
N
N
N OH
OH
N
 
3,4-Diaminobenzonitrile (399 mg, 3 mmol) was reacted with oxalic acid (1.97 mg, 3.3. 
mmol) using method C to give the named compound as a purple powder (330 mg, 59 %) 
1H NMR (500 MHz, d6-DMSO) δ: 12.21 (s, 1H, OH), 12.08 (s, 1H, OH), 7.50 (d, J = 8.2 Hz, 1H, 
ArH), 7.39 (s, 1H, ArH), 7.21 (d, J = 8.2 Hz, 1H, ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 155.12 (ArC), 154.76 (ArC), 129.85 (ArC), 126.85 (ArC), 
126.36 (ArCH), 118.69 (Ar-CN), 118.28 (ArCH), 115.99 (ArCH), 104.54 (ArC-CN). 
MS-EI (m/z): [M]- calculated for C9H4N3O2, 186.1478; found 186.10. 
 
2,3-dichloroquinoxaline-6-carbonitrile (59) 
Literature compound.150 
N
N OH
OH
N
N
N Cl
Cl
N
 
The reaction with 2,3-dihydroxyquinoxaline-6-carbonitrile (330 mg, 1.76 mmol) was carried 
out using method D to give the named compound as a white solid (264 mg, 67 %). 
1H NMR (500 MHz, d6-DMSO) δ: 8.76 (s, 1H, ArH), 8.25 (s, 2H, ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 147.8 (ArC), 146.9 (ArC), 141.6 (ArC), 139.2 (ArC), 133.9 
(ArCH), 132.7 (ArCH), 129.6 (ArCH), 117.7 (Ar-CN), 113.7 (ArC-CN). 
MS-EI (m/z): [M + Na+] calculated for C9H3Cl2N3Na, 247.0372; found 247.30. 
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6-chloroquinoxaline-2,3-diol (60) 
Literature compound.150 
OHO
OHO
NH2
NH2
Cl
N
N OH
OH
Cl
 
4-Chlorobenzene-1,2-diamine (570.36 mg, 4.0 mmol) was reacted with oxalic acid (396.18 
mg, 4.4 mmol) using method C to give the named compound as a tan powder (668 mg, 85 
%). 
1H NMR (500 MHz, d6-DMSO) δ: 11.97 (s, 1H), 11.96 (s, 1H), 7.11 (s, 2H), 7.10 (s, 1H). 
 
2,3,6-trichloroquinoxaline (61) 
Literature compound.150 
N
N OH
OH
Cl
N
N Cl
Cl
Cl
 
The reaction with 6-chloroquinoxaline-2,3-diol (658 mg, 3.3 mmol) was carried out using 
method D to give the named compound as a yellow solid (555 mg, 72 %). 
1H NMR (500 MHz, d6-DMSO) δ: 8.21 (d, J = 2.3 Hz, 1H), 8.10 (d, J = 9.0 Hz, 1H), 7.96 (dd, J = 
9.0, 2.3 Hz, 1H). 
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2,3-dihydroxyquinoxaline-6-carboxylic acid (62) 
Literature compound.151 
OHO
OHO
NH2
NH2 N
N OH
OH
O
HO
O
HO
 
3,4-Diaminobenzoic acid (913 mg, 6.0 mmol) was reacted with oxalic acid (594 mg, 6.6 
mmol) using method C to give the named compound as a pink powder (1.035 g, 84 %). 
1H NMR (500 MHz, d6-DMSO) δ: 12.50 (s, 1H, OH), 12.39 (s, 1H, OH), 8.04 (s, 1H, ArH), 7.97 
(d, J = 6.5 Hz, 1H, ArH), 7.51 (d, J = 6.5 Hz, 1H, ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 166.7 (Ar-COOH), 155.3 (ArC), 155.0 (ArC), 129.3 (ArC), 
125.4 (ArC), 125.2 (ArC), 124.4 (ArCH), 116.4 (ArCH), 115.2 (ArCH). 
MS-EI (m/z): [M - H]]   calculated for C9H5N2O4, 205.1479; found 205.10. 
 
2,3-dichloroquinoxaline-6-carbonyl chloride (63) 
Literature compound.152 
N
N OH
OH
O
HO
N
N Cl
Cl
O
Cl
 
The reaction with 2,3-dihydroxyquinoxaline-6-carboxylic acid (1.0 g, 4.85 mmol) was carried 
out using method D to give the named compound as a white solid (841 mg, 66 %). 
1H NMR (500 MHz, d6-DMSO) δ: 8.44 (dd, J = 2.6, 1.5 Hz, 1H, ArH), 8.29 (dd, J = 8.7, 1.5 Hz, 
1H, ArH), 8.09 (d, J = 8.7 Hz, 1H, ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 166.1 (Ar-COOCl), 146.7 (ArC), 145.9 (ArC), 141.8 (ArC), 
139.3 (ArC), 133.2 (ArC), 130.8 (ArCH), 129.3 (ArCH), 128.4 (ArCH). 
MS-EI (m/z): [M + H]+ calculated for C9H3Cl2N2O2, 242.0396; found 242.90. 
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2,3-dichloro-N-methylquinoxaline-6-carboxamide (64) 
N
N Cl
Cl
O
Cl
N
N Cl
Cl
O
N
H
 
Methylamine solution (33 wt. % in absolute ethanol, 256 µL) was added to DCM (3 mL) on 
ice and the resulting mixture was added to a solution of 2,3-dichloroquinoxaline-6-carbonyl 
chloride 63, (261 mg, 1 mmol) in DCM (3 mL) whilst stirring at room temperature. The 
mixture was stirred at room temperature overnight after which it was diluted with DCM (10 
mL) and washed with saturated sodium bicarbonate (3 x 10 mL) and brine (3 x 10 mL). The 
organics were dried over MgSO4, filtered, and the solved evaporated. The crude compound 
was purified by flash column chromatography using a gradient of 30 to 60 % ethyl acetate 
in cyclohexane to yield the named compound as a white powder (89 mg, 35 %). 
1H NMR (500 MHz, d6-DMSO) δ: 8.84 (s, 1H, NH), 8.48 (s, 1H, ArH), 8.29 (d, J = 8.6 Hz, 1H, 
ArH), 8.14 (d, J = 8.6 Hz, 1H, ArH), 2.85 (d, J = 3.7 Hz, 3H, CH3). 
13C NMR (126 MHz, d6-DMSO) δ: 165.0 (ArC), 146.0 (ArC), 145.6 (ArC), 141.1 (ArC), 139.6 
(ArC), 136.8 (ArC), 129.9 (ArCH), 128.1 (ArCH), 126.6 (ArCH), 26.5 (CH3). 
MS-EI (m/z): [M] calculated for C10H7Cl2N3O, 256.089; found 255.90. 
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4,4'-(quinoxaline-2,3-diylbis(azanediyl))diphenol (65) 
N
N Cl
Cl
NH2
N
N NH
NH
OH
OH
OH
 
2,3-Dichloroquinoxaline (39.8 mg, 0.20 mmol) and 4-aminophenol (87.2 mg, 0.80 mmol) 
were reacted following method A and purified by flash column chromatography using an 
ethyl acetate gradient of 10 to 50 % to give the named compound as a yellow powder (35.0 
mg, 50 %). 
1H NMR (500 MHz, d6-DMSO) δ 9.21 (s, 2H, 2 x OH), 8.71 (s, 2H, 2 x NH), 7.61 (d, J = 8.7 Hz, 
4H, 4 x ArH), 7.42 (dt, J = 7.3, 3.4 Hz, 2H, 2 x ArH), 7.23 (dd, J = 6.1, 3.4 Hz, 2H, 2 x ArH), 6.79 
(d, J = 8.7 Hz, 4H, 4 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ 153.2 (ArC), 141.4(ArC), 136.2(ArC), 131.5(ArC), 125.0 
(ArCH), 124.4(ArCH), 122.8(ArCH), 115.1(ArCH). 
HRMS-ES (m/z): [M + H]+ calculated for C20H17N4O2, 345.1352; found, 345.1347. 
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4,4'-((6-(trifluoromethyl)quinoxaline-2,3-diyl)bis(azanediyl))diphenol (66) 
N
NF3C Cl
Cl
NH2
N
N NH
NH
F3C
OH
OH
OH  
2,3-Dichloro-6-(trifluoromethyl)quinoxaline (52.8 mg, 0.20 mmol) and 4-aminophenol (87.2 
mg, 0.80 mmol) were reacted following method A. The crude material was purified by flash 
chromatography using an ethyl acetate gradient of 30 to 70 % in cyclohexane to give the 
named compound as a red powder (68.0 mg, 83 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.34 (s, 1H, OH), 9.32 (s, 1H, OH), 9.03 (s, 1H, NH), 8.96 (s, 
1H, NH), 7.68 (s, 1H, ArH), 7.65 – 7.59 (m, 4H, 4 x ArH), 7.55 (d, J = 8.5 Hz, 1H, ArH), 7.47 
(dd, J = 8.5, 1.8 Hz, 1H, ArH), 6.84 – 6.78 (m, 4H, 4 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 170.3 (ArC), 153.8 (ArC), 153.6 (ArC), 142.8 (ArC), 142.3 
(ArC), 138.7 (ArC), 135.7 (ArC), 131.0 (ArC), 130.8 (ArC), 125.8 (ArCH), 123.4 (ArCH), 123.2 
(ArCH), 121.9 (ArCH), 119.9 (ArCH), 115.2 (ArCH). 
HRMS-CI (m/z): [M+H]+ calculated for C21H16F3N4O2, 413.12199; found, 413.120133. 
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3,3'-((6-(trifluoromethyl)quinoxaline-2,3-diyl)bis(azanediyl))diphenol (67) 
N
NF3C Cl
Cl
NH2
N
N NH
NH
F3C
OH
OH
OH
 
2,3-Dichloro-6-(trifluoromethyl)quinoxaline (52.8 mg, 0.20 mmol) and 3-aminophenol (87.2 
mg, 0.20 mmol) were reacted following method A. The crude material was purified by flash 
chromatography using a ethyl acetate gradient of 30 to 70 % in cyclohexane to give the 
named compound as a red powder (68.0 mg, 83 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.49 (s, 1H, OH), 9.46 (s, 1H, OH), 9.18 (s, 1H, NH), 9.12 (s, 
1H, NH), 7.81 (s, 1H, ArH), 7.67 (d, J = 8.4 Hz, 1H, ArH), 7.61 – 7.56 (m, 2H, 2 x ArH), 7.50 (d, 
J = 2.5 Hz, 1H, ArH), 7.26 (dd, J = 11.6, 9.0 Hz, 2H, 2 x ArH), 7.18 (td, J = 8.4, 2.5 Hz, 2H, 2 x 
ArH), 6.57 – 6.46 (m, 2H, 2 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 157.6 (ArC), 142.5 (ArC), 142.0 (ArC), 140.7 (ArC), 138.5 
(ArC), 135.5 (ArC), 129.3 (ArCH), 126.2 (ArCH), 123.5 (ArC), 122.3 (ArCH), 120.6 (ArC), 112.0 
(ArCH), 111.7 (ArCH), 110.5 (ArCH), 110.2 (ArCH), 108.3 (ArCH), 108.0 (ArCH). 
HRMS-CI (m/z): [M + H]+ calculated for C21H16F3N4O2, 413.12199; found, 413.121732. 
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2,3-bis((4-hydroxyphenyl)amino)quinoxaline-6-carbonitrile (68) 
N
N Cl
Cl
NH2
N
N NH
NH
OH
OH
OH
N N
 
2,3-Dichloroquinoxaline-6-carbonitrile (112 mg, 0.50 mmol) and 4-aminophenol (218 mg, 
1.20 mmol) were reacted following method A. The crude material was purified by flash 
chromatography using a ethyl acetate gradient of 30 to 70 % in cyclohexane to give the 
named compound as a red powder (158.0 mg, 86 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.76 (s, 1H, OH), 9.73 (s, 1H, OH), 9.56 (s, 1H, NH), 9.43 (s, 
1H, NH), 8.25 (s, 1H, ArH), 8.04 (dt, J = 8.8, 3.2 Hz, 4H, 4 x ArH), 7.93 (ddd, J = 11.1, 8.3, 2.3 
Hz, 2H, 2 x ArH), 7.24 (dt, J = 8.8, 3.2 Hz, 4H, 4 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 153.9 (ArC), 153.7 (ArC), 142.9 (ArC), 142.3 (ArC), 139.6 
(ArC), 136.0 (ArC), 130.8 (ArC), 130.5 (ArC), 129.3 (ArCH), 126.5 (ArCH), 125.9 (ArCH), 123.6 
(ArCH), 123.2 (ArCH), 119.5 (ArC-CN), 115.19 (ArCH), 115.17 (ArCH), 105.6 (ArC-CN). 
HRMS-CI (m/z): [M + H]+ calculated for C21H16N5O2, 370.13040; found, 370.129541. 
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2,3-bis((3-hydroxyphenyl)amino)quinoxaline-6-carbonitrile (69) 
N
N Cl
Cl
NH2
N
N NH
NH
OH
OH
OH
N N
 
2,3-Dichloroquinoxaline-6-carbonitrile (67.2 mg, 0.30 mmol) and 3-aminophenol (130.8 mg, 
1.20 mmol) were reacted following method A. The crude material was purified by flash 
chromatography using a ethyl acetate gradient of 30 to 70 % in cyclohexane to give the 
named compound as a red powder (104.0 mg, 94 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.47 (s, 1H, OH), 9.42 (s, 1H, OH), 9.27 (s, 1H, NH), 9.16 (s, 
1H, NH), 7.93 (d, J = 1.7 Hz, 1H, ArH), 7.66 – 7.57 (m, 2H, 2 x ArH), 7.53 (s, 1H, ArH), 7.49 (s, 
1H, ArH), 7.30 – 7.24 (m, 2H, 2 x ArH), 7.18 (dd, J = 14.3, 8.0 Hz, 2H, 2 x ArH), 6.57 – 6.47 
(m, 2H, 2 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 157.6 (ArC), 142.6 (ArC), 142.0 (ArC), 140.6 (ArC), 140.3 
(ArC), 139.3 (ArC), 135.8 (ArC), 129.7 (ArCH), 129.3 (ArCH), 127.0 (ArCH), 126.3 (ArCH), 
119.3 (Ar-C), 112.1 (ArCH), 111.8 (ArCH), 110.8 (ArCH), 110.4 (ArCH), 108.4 (ArCH), 108.1 
(ArCH), 106.4 (ArC-CN).  
HRMS-CI (m/z): [M + H]+ calculated for C21H16N5O2, 370.13040; found, 370.129114. 
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4,4'-((6-chloroquinoxaline-2,3-diyl)bis(azanediyl))diphenol (70) 
N
NCl Cl
Cl
NH2
N
N NH
NH
Cl
OH
OH
OH  
2,3,6-Trichloroquinoxaline (46.7 mg, 0.20 mmol) and 4-aminophenol (87.3 mg, 0.80 mmol) 
were reacted following method A. The crude material was purified by flash 
chromatography using an ethyl acetate gradient of 0 to 50 % in cyclohexane to give the 
named compound as a yellow powder (30.0 mg, 79 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.24 (s, 1H), 9.23 (s, 1H), 8.87 (s, 1H), 8.81 (s, 1H), 7.65 – 
7.55 (m, 4H), 7.45 – 7.37 (m, 2H), 7.22 (dt, J = 8.6, 2.1 Hz, 1H), 6.83 – 6.76 (m, 4H). 
13C NMR (126 MHz, d6-DMSO) δ: 153.51 (ArC), 153.45 (ArC), 141.97 (ArC), 141.61 (ArC), 
137.03 (ArC), 134.97 (ArC), 131.18 (ArC), 131.09 (ArC), 128.04 (ArC), 126.35 (ArCH), 124.25 
(ArCH), 123.73 (ArCH), 123.07 (ArCH), 123.04 (ArCH), 115.14 (ArCH). 
HRMS-ES (m/z): [M + H] calculated for C20H16N4O2Cl, 379.0962; found, 379.0927. 
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3,3'-((6-chloroquinoxaline-2,3-diyl)bis(azanediyl))diphenol (71) 
N
NCl Cl
Cl
NH2
N
N NH
NH
Cl
OH
OH
OH
 
2,3,6-Trichloroquinoxaline (46.7 mg, 0.20 mmol) and 3-aminophenol (87.3 mg, 0.80 mmol) 
were reacted following method A. The crude material was purified by flash 
chromatography using an ethyl acetate gradient of 0 to 60 % in cyclohexane to give the 
named compound as a yellow powder (30.0 mg, 79 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.39 (s, 2H), 9.03 (s, 1H), 8.98 (s, 1H), 7.58 – 7.49 (m, 3H), 
7.48 (s, 1H), 7.33 (dd, J = 8.7, 2.3 Hz, 1H), 7.23 (s, 2H), 7.16 (td, J = 8.0, 1.7 Hz, 2H), 6.50 (d, J 
= 8.0 Hz, 2H). 
13C NMR (126 MHz, d6-DMSO) δ: 157.58 (ArC), 141.66 (ArC), 141.25 (ArC), 140.92 (ArC), 
140.83 (ArC), 136.82 (ArC), 134.79 (ArC), 129.22 (ArCH), 128.78 (ArC), 126.72 (ArCH), 
125.03 (ArCH), 124.05 (ArCH), 111.55 (ArCH), 110.06 (ArCH), 107.83 (ArCH). 
HRMS-ES (m/z): [M + H] calculated for C20H16N4O2Cl, 379.0962; found, 379.0940. 
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N-(3-hydroxyphenyl)-2,3-bis((3-hydroxyphenyl)amino)quinoxaline-6-
carboxamide (72) 
N
N Cl
Cl
NH2
N
N NH
NH
OH
OH
OH
O
Cl
O
HN
OH
 
2,3-Dichloroquinoxaline-6-carboxylic acid (243 mg, 1.0 mmol) and 3-aminophenol (436 mg, 
4.0 mmol) were reacted following method A. The crude material was purified by flash 
chromatography using a ethyl acetate gradient of 30 to 70 % in cyclohexane containing 1 % 
acetic acid to give the named compound as a red powder (148.0 mg, 31 %). 
1H NMR (500 MHz, CDCl3) δ: 10.19 (s, 1H, Ar-CONH-Ar), 9.12 (s, 1H, NH), 9.04 (s, 1H, NH), 
8.15 (d, J = 1.9 Hz, 1H, ArH), 7.87 (dd, J = 8.5, 1.9 Hz, 1H, ArH), 7.60 (d, J = 8.5 Hz, 1H, ArH), 
7.51 (dt, J = 8.5, 1.9 Hz, 2H, 2 x ArH), 7.33 (t, J = 1.9 Hz, 1H, ArH), 7.29 – 7.23 (m, 2H, 2 x 
ArH), 7.20 – 7.09 (m, 4H, 4 x ArH), 6.56 – 6.48 (m, 3H, 3 x , ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 172.5 (Ar-CONH-Ar), 165.5 (ArC), 157.5 (ArC), 157.3 (ArC), 
142.0 (ArC), 141.6 (ArC), 140.9 (ArC), 140.7 (ArC), 140.2 (ArC), 138.3 (ArC), 135.2 (ArC), 
131.0 (ArC), 129.4 (ArCH), 129.3 (ArCH), 125.1 (ArCH), 124.9 (ArCH), 124.2 (ArCH), 111.9 
(ArCH), 111.8 (ArCH), 111.4 (ArCH), 110.8 (ArCH), 110.4 (ArCH), 110.2 (ArCH), 108.1 (ArCH), 
108.0 (ArCH), 107.7 (ArCH). 
HRMS-EI (m/z): [M] calculated for C27H21N5O4, 479.1588; found, 479.1600. 
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2,3-bis((4-hydroxyphenyl)amino)-N-methylquinoxaline-6-carboxamide (73) 
N
N Cl
Cl
NH2
N
N NH
NH
OH
OH
N
H
O
N
H
O
OH
 
2,3-Dichloro-N-methylquinoxaline-6-carboxamide (25.7 mg, 0.10 mmol) and 4-
aminophenol (43.6 mg, 0.40 mmol) were reacted following method A. The crude material 
was purified by flash chromatography using an ethyl acetate gradient of 20 to 70 % in 
cyclohexane to give the named compound as a yellow powder (29.0 mg, 72 %). 
1H NMR (500 MHz, d6-DMSO) δ 9.26 (s, 1H, OH), 9.25 (s, 1H, OH), 8.89 (s, 1H, Ar-NH), 8.82 
(s, 1H, Ar-NH), 8.44 (q, J = 4.5 Hz, 1H, Ar-CONHCH3), 7.94 (d, J = 2.0 Hz, 1H, ArH), 7.71 (dd, J 
= 8.4, 2.0 Hz, 1H, ArH), 7.63 (d, J = 8.4 Hz, 4H, 4 x ArH), 7.43 (d, J = 8.4 Hz, 1H, ArH), 6.86 – 
6.77 (m, 4H, 4 x ArH), 2.77 (d, J = 4.5 Hz, 3H, Ar-CONHCH3). 
13C NMR (126 MHz, d6-DMSO) δ 166.5 (Ar-CONHCH3), 153.5 (ArC), 153.4 (ArC), 142.2 (ArC), 
141.9 (ArC), 138.2 (ArC), 137.2 (ArC), 135.4 (ArC), 131.3 (ArC), 131.1 (ArC), 130.0 (ArCH), 
124.6 (ArCH), 123.8 (ArCH), 123.1 (ArCH), 115.1 (ArCH), 26.3 (Ar-CONHCH3). 
HRMS-EI (m/z): [M] calculated for C22H19N5O3, 401.1488; found, 401.1481. 
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6,7-bis((3-hydroxyphenyl)amino)-N-methyl-2-naphthamide (74) 
N
N Cl
Cl
NH2
N
N NH
NH
OH
OH
OH
N
H
OO
N
H
 
2,3-Dichloro-N-methylquinoxaline-6-carboxamide (25.7 mg, 0.10 mmol) and 3-
aminophenol (43.6 mg, 0.40 mmol) were reacted following method A. The crude material 
was purified by flash chromatography using an ethyl acetate gradient of 20 to 70 % in 
cyclohexane to give the named compound as a yellow powder (30.0 mg, 75 %). 
1H NMR (500 MHz, d6-DMSO) δ 9.42 (s, 1H, OH), 9.41 (s, 1H, OH), 9.04 (s, 1H, NH), 8.98 (s, 
1H, NH), 8.51 (d, J = 4.4 Hz, 1H, Ar-CONHCH3), 8.06 (s, 1H, ArCH), 7.80 (d, J = 8.4 Hz, 1H, 
ArCH), 7.55 (d, J = 8.4 Hz, 1H, ArCH), 7.50 (d, J = 12.0 Hz, 2H, 2 x ArCH), 7.28 (d, J = 8.0 Hz, 
2H, 2 x ArCH), 7.17 (t, J = 8.0 Hz, 2H, 2 x ArCH), 6.50 (d, J = 8.0 Hz, 2H, 2 x ArCH), 2.80 (d, J = 
4.4 Hz, 3H, Ar-CONHCH3). 
13C NMR (126 MHz, d6-DMSO) δ 166.5 (Ar-CONHCH3), 157.6 (ArC), 157.6 (ArC), 141.9 (ArC), 
141.6 (ArC), 141.0 (ArC), 140.9 (ArC), 137.9 (ArC), 135.3 (ArC), 130.8 (ArCH), 129.22 (ArCH), 
129.19 (ArCH), 124.9 (ArC), 124.3 (ArC), 123.7 (ArC), 111.7 (ArCH), 111.6 (ArCH), 110.2 
(ArCH), 110.0 (ArCH), 108.0 (ArCH), 107.9 (ArCH), 26.3 (Ar-CONHCH3). 
HRMS-EI (m/z): [M] calculated for C22H19N5O3, 401.1488; found, 401.1479. 
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4,4'-((6-aminoquinoxaline-2,3-diyl)bis(azanediyl))diphenol (75) 
N
N NH
NH
O2N
OH
OH
N
N NH
NH
H2N
OH
OH  
Tin (II) chloride dihydrate (112.5 mg, 0.5 mmol) was added to a solution of 4,4'-((6-
nitroquinoxaline-2,3-diyl)bis(azanediyl))diphenol (39 mg, 0.1 mmol) in ethanol (15 mL) and 
the resulting mixture was brought to boil. A solution of sodium borohydride (18.9 mg, 0.5 
mmol) in ethanol (5 mL) was added to the boiling mixture dropwise and refluxed for 1.5 
hrs. Upon cooling, water (10 mL) was added. Sodium hydroxide was added until 
neutralisation of the solution. The ethanol was evaporated from the mixture and an 
extraction with ethyl acetate (20 mL) was performed. The organics were washed with brine 
(3 x 10 mL) and dried over magnesium sulphate, filtered and the solvent evaporated under 
reduced pressure. The crude material was purified by flash column chromatography using a 
gradient of 50 to 80 % ethyl acetate in cyclohexane to give the named compound (22.0 mg, 
61 % ). 
1H NMR (500 MHz, d6-DMSO) δ: 9.13 (s, 1H, OH), 9.06 (s, 1H, OH), 8.47 (s, 1H, NH), 8.23 (s, 
1H, NH), 7.60 (d, J = 8.9 Hz, 2H, 2 x ArH), 7.53 (d, J = 8.9 Hz, 2H, 2 x ArH), 7.15 (d, J = 8.6 Hz, 
1H, ArH), 6.75 (dd, J = 10.8, 8.9 Hz, 4H, 4 x ArH), 6.64 (dd, J = 8.6, 2.4 Hz, 1H, ArH), 6.58 (d, J 
= 2.4 Hz, 1H, ArH), 5.06 (s, 2H, NH2). 
13C NMR (126 MHz, d6-DMSO) δ: 152.8 (ArC), 152.4 (ArC), 146.3 (ArC), 141.4 (ArC), 138.5 
(ArC), 137.6 (ArC), 132.5 (ArC), 132.0 (ArC), 128.4 (ArC), 125.4 (ArCH), 122.4 (ArCH), 121.8 
(ArCH), 115.0 (ArCH), 114.99 (ArCH), 114.8 (ArCH), 106.5 (ArCH). 
HRMS-CI (m/z): [M + H]+ calculated for C20H18N5O2, 360.1460; found, 360.1451. 
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N-(2-(3-chloro-7-nitroquinoxalin-2-ylamino)phenyl)acetamide or N-(2-(3-
chloro-6-nitroquinoxalin-2-ylamino)phenyl)acetamide (78) 
N
NO2N Cl
Cl
NH2
N
N
H
N
Cl
O2N
H
N
O
HN
O
 
A mixture containing the 2,3-dichloro-6-nitroquinoxaline (48.8 mg, 0.20 mmol), N-(2-
aminophenyl)acetamide (27 mg, 0.22 mmol), cesium carbonate (84.7 mg, 0.22 mmol), 4,5-
Bis(diphenylphosphino)-9,9-dimethylxanthene (11.6 mg, 0.02 mmol) and Pd2(dba)3 (18.3 
mg, 0.02 mmol) was made up in dioxane (6 mL) and allowed to react under microwave for 
5 min at 120 °C. The solvent was then evaporated under reduced pressure and the residue 
was taken up in ethyl acetate (30 mL) and washed with H2O (3 x 15 mL). The organic 
solution was dried over Na2SO4, filtered and the solvent removed under reduced pressure. 
The crude material was purified by flash column chromatography using a gradient of 20 to 
60% ethyl acetate in cyclohexane to give a yellow powder (29 mg, 40 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.86 (s, 1H, Ar-NHCOCH3), 9.45 (s, 1H, NH), 8.61 (d, J = 1.9 
Hz, 1H, ArH), 8.33 (dd, J = 9.1, 1.9 Hz, 1H, ArH), 7.80 – 7.73 (m, 1H, ArH), 7.65 (d, J = 9.1 Hz, 
1H, ArH), 7.56 – 7.49 (m, 1H, ArH), 7.31 – 7.24 (m, 2H, ArH), 2.04 (s, 3H, CH3). 
13C NMR (126 MHz, d6-DMSO) δ: 169.6 (NHCOCH3), 148.2 (ArC), 144.4 (ArC), 143.7 (ArC), 
134.7 (ArC), 132.4 (ArC), 130.2 (ArC), 126.9 (ArCH), 126.5 (ArCH), 126.2 (ArCH), 125.0 
(ArCH), 124.4 (ArCH), 124.1 (ArCH), 123.4 (ArCH), 23.3(NHCOCH3). 
HRMS-EI (m/z): [M] calculated for C16H12N5O3, 357.0629; found, 357.0632. 
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4,4'-((6-nitroquinoxaline-2,3-diyl)bis(azanediyl))bis(3-methylphenol) (79) 
N
NO2N Cl
Cl
NH2
N
N NH
NH
O2N
OH
OH
OH  
2,3-Dichloro-6-nitroquinoxaline (48.8 mg, 0.20 mmol) and 4-amino-3-methylphenol (98.4 
mg, 0.80 mmol) were reacted following method A. The crude material was purified by flash 
chromatography using an ethyl acetate gradient of 20 to 50 % in cyclohexane to give the 
name compound as a red powder (55.0 mg, 66 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.39 (s, 1H, OH), 9.36 (s, 1H, OH), 8.90 (s, 1H, NH), 8.66 (s, 
1H, NH), 8.00 (d, J = 2.5 Hz, 1H, ArH), 7.92 (dd, J = 8.9, 2.5 Hz, 1H, ArH), 7.37 (d, J = 8.9 Hz, 
1H, ArH), 7.20 (dd, J = 8.4, 2.2 Hz, 2H, 2x ArH), 6.73 (s, 2H, 2 x ArH), 6.67 (d, J = 8.4 Hz, 2H, 2 
x ArH), 2.13 (d, J = 3.6 Hz, 6H, 2 x CH3). 
13C NMR (126 MHz, d6-DMSO) δ: 155.73 (ArC), 155.56 (ArC), 144.67 (ArC), 142.90 (ArC), 
141.93 (ArC), 135.66 (ArC), 135.47 (ArC), 135.38 (ArC), 128.21 (ArCH), 128.09 (ArCH), 
127.76 (ArC), 125.28 (ArC), 119.91 (ArCH), 118.22 (ArC), 116.95 (ArCH), 113.11 (ArCH), 
113.07 (ArCH), 18.14(ArCH3). 
HRMS-EI (m/z): [M] calculated for C22H19N5O4, 417.14.316; found, 417.143144. 
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4-(3-chloro-7-nitroquinoxalin-2-yloxy)-2-methylaniline or 4-(3-chloro-6-
nitroquinoxalin-2-yloxy)-2-methylaniline (80) 
N
NO2N Cl
Cl
NH2
OH
N
N O
Cl NH2
O2N
 
A mixture containing the 2,3-dichloro-6-nitroquinoxaline (48.8 mg, 0.20 mmol), 4-amino-3-
methylphenol (27 mg, 0.22 mmol), cesium carbonate (84.7 mg, 0.22 mmol), 4,5-
Bis(diphenylphosphino)-9,9-dimethylxanthene (11.6 mg, 0.02 mmol) and Pd2(dba)3 (18.3 
mg, 0.02 mmol) was made up in dioxane (6 mL) and allowed to react under microwave for 
5 min at 120°C. The solvent was then evaporated under reduced pressure and the residue 
was taken up in ethyl acetate (30 mL) and washed with H2O (3 x 15 mL). The organic 
solution was dried over Na2SO4, filtered and the solvent removed under reduced pressure. 
The crude material was purified by flash column chromatography using a gradient of 20 to 
50 % ethyl acetate in cyclohexane to give a yellow powder (17 mg, 26 %). 
1H NMR (500 MHz, d6-DMSO) δ: 8.77 (d, J = 2.6 Hz, 1H, ArH), 8.41 (dd, J = 9.2, 2.6 Hz, 1H, 
ArH), 7.89 (d, J = 9.2 Hz, 1H, ArH), 6.92 (d, J = 2.6 Hz, 1H, ArH), 6.88 (dd, J = 8.5, 2.6 Hz, 1H, 
ArH), 6.67 (d, J = 8.5 Hz, 1H, ArH), 4.92 (s, 2H, NH2), 2.07 (s, 3H, CH3). 
13C NMR (126 MHz, d6-DMSO) δ: 155.3 (ArC), 145.9 (ArC), 144.9 (ArC), 142.7 (ArC), 142.3 
(ArC), 142.1 (ArC), 137.0 (ArC), 128.3 (ArCH), 124.1 (ArCH), 123.4 (ArCH), 122.4 (ArCH), 
122.2 (ArCH), 119.2 (ArCH), 114.2 (ArCH), 17.5 (CH3). 
HRMS-EI (m/z): [M] calculated for C15H11N4O3, 330.05142; found, 330.051748. 
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6-nitroquinoxaline-2,3-diol (81) 
Literature compound.150 
OHO
OHO
NH2
NH2
O2N
N
N OH
OH
O2N
 
4-Nitrobenzene-1,2-diamine (3.06 g, 20 mmol) was reacted with oxalic acid (1.980 g, 22 
mmol) using method C to give the named compound as a tan powder (1.870 g, 45 %). 
1H NMR (500 MHz, d6-DMSO) δ: 12.36 (s, 1H, OH), 12.16 (s, 1H, OH), 8.00 – 7.84 (peak 
overlapped, 2H, 2 x ArH), 7.24 (d, J = 8.6 Hz, 1H, ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 155.1 (ArC), 154.7 (ArC), 142.1 (ArC), 131.6 (ArC), 126.1 
(ArC), 118.6 (ArC), 115.5 (ArC), 110.3 (ArC). 
MS-EI (m/z): [M - H] calculated for C8H4N3O4, 206.1359; found 206.00. 
 
6,7-dinitroquinoxaline-2,3-diol (82) 
Literature compound.150 
N
N OH
OH
O2N
N
N OH
OH
O2N
O2N  
A solution of 6-nitroquinoxaline-2,3-diol 81 (1.0 g, 4.8 mmol) was made up in sulphuric acid 
(15 mL) at 0 °C and potassium nitrate (727 mg, 7.2 mmol) was added in several portions. 
The resulting solution was allowed to warm to room temperature and stirred for 48 hrs, 
until consumption of the starting material was observed by LC-MS. The mixture was 
carefully poured into 50 mL of ice/water and stirred for 30 min, filtered, washed with 
water, and dried to give the named compound (822 mg, 68 % recovery). 
1H NMR (500 MHz, d6-DMSO) δ: 12.47 (s, 2H, 2 x OH), 7.71 (s, 2H, 2 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 154.7 (ArC), 136.9 (ArC), 129.6 (ArC), 111.8 (ArCH). 
MS-EI (m/z): [M - H] calculated for C8H3N4O6, 251.1335; found 250.90. 
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2,3-dichloro-6,7-dinitroquinoxaline (83) 
Literature compound.150 
N
N OH
OH
O2N
O2N N
N Cl
Cl
O2N
O2N  
The reaction with 6,7-dinitroquinoxaline-2,3-diol (378 mg, 1.5 mmol) was carried out using 
method D to give the named compound as a red solid (400 mg, 92 %). 
1H NMR (500 MHz, d6-DMSO) δ 9.06 (s, 2H, 2 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ 150.3 (ArC), 142.2 (ArC), 140.8 (ArC), 126.5 (ArCH). 
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1-methyl-4-(4-nitrophenyl)piperazine (85) 
Literature compound.139 
NO2
N
N
H
NO2
N
N
 
1-(4-nitrophenyl)piperazine (1.0 g, 4.8 mmol) was reacted with formic acid (2 mL, 48 mmol) 
and 40 % formaldehyde (3.6 mL, 48 mmol) under microwave irradiation at 120 °C for 5 
minutes. Upon cooling, the mixture was added to ethyl acetate (100 mL) and 2M NaOH (70 
mL) and the layers were separated. The organic layer was washed with brine (50 mL) after 
which the brine layer was further extracted with ethyl acetate (50 mL). The organics were 
combined and dried over Mg2SO4, filtered and concentrated under vacuum to give the 
named compound (897 mg, 85% yield). Analysis of the compound showed no traces of 
starting material and it was used without further purification.  
1H NMR (500 MHz, CDCl3) δ: 8.14 – 8.08 (m, 2H, 2 x ArH), 6.84 – 6.78 (m, 1H, 2 x ArH), 3.45 
– 3.40 (m, 4H, 2 x CH2), 2.58 – 2.51 (m, 4H, 2 x CH2), 2.35 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ: 154.9 (ArC), 138.5 (ArC), 126.0 (ArCH), 112.8 (ArCH), 54.6 
(CH2), 47.1 (CH2), 46.1(CH3). 
MS-EI (m/z): [M + H]+ calculated for C11H16N3O2, 222.2648; found 222.00. 
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4-(4-methylpiperazin-1-yl)aniline (86) 
Literature compound.153 
NO2
N
N
NH2
N
N
 
Tin (II) chloride dihydrate (2.250 g, 10 mmol) was added to a solution of 85 (442 mg, 2 
mmol) in ethanol (250 mL) and the mixture was brought to boil. Sodium borohydride (378 
mg, 10 mmol) in ethanol (50 mL) was added to the boiling solution dropwise after which 
the resulting mixture was kept under reflux for 2.5 hrs until disappearance of starting 
material was observed by TLC. Upon cooling, sodium hydroxide was added until 
neutralisation of the solution was obtained. The ethanol was evaporated under reduced 
pressure and the compound extracted with ethyl acetate (3 x 100 mL). The organics were 
washed with brine and dried over Mg2SO4, filtered and concentrated under vacuum, to 
yield the name compound (216 mg, 57 % recovery).  
1H NMR (500 MHz, d6-DMSO) δ: 6.68 – 6.62 (m, 2H, 2 x ArH), 6.51 – 6.45 (m, 1H, 2 x ArH), 
4.57 (s, 2H, NH2), 2.90 – 2.85 (m, 4H, 2 x CH2), 2.43 – 2.38 (m, 2H, 2 x CH2), 2.19 (s, 3H, CH3). 
13C NMR (126 MHz, d6-DMSO) δ: 142.4 (ArC), 142.1 (ArC), 117.8 (ArCH), 114.7 (ArCH), 54.9 
(CH2), 50.2 (CH2), 45.9 (CH3). 
MS-EI (m/z): [M + H]+ calculated for C11H18N3, 192.2818; found 192.10. 
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4-((3-((4-(4-methylpiperazin-1-yl)phenyl)amino)-6,7-dinitroquinoxalin-2-
yl)amino)phenol (87) 
N
N Cl
Cl
NH2
N
N NH
NH
OH
N
O2N O2N
O2N O2N
NH2
N
N
OH
N
 
To a microwave vial containing a magnetic stirrer bar was added 2,3-dichloro-6,7-
dinitroquinoxaline (289 mg, 1 mmol), 4-(4-methylpiperazin-1-yl)aniline 86 (191 mg, 1 
mmol), 4-aminophenol (109 mg, 1 mmol) and NMP (5 mL). The mixture was reacted under 
microwave irradiation for 5 min at 160 °C in a closed vial. Upon cooling, the mixture was 
added to saturated sodium bicarbonate (50 mL) and extracted with ethyl acetate (3 x 50 
mL). The organics were washed with brine and the solvent evaporated under reduced 
pressure. Purification was carried on by reverse phase column chromatography, using a 
gradient of 0 to 100 % methanol in water containing 0.1 % formic acid, to obtain the name 
compound as a red powder (100 mg, 20 % yield). 
1H NMR (600 MHz, d6-DMSO) δ: 9.57 (s, 1H, OH), 8.24 (s, 2H, 2 x NH), 7.94 (s, 1H, ArH), 7.94 
(s, 1H, ArH), 7.69 (d, J = 8.7 Hz, 2H, 2 x ArH), 7.60 (d, J = 8.6 Hz, 2H, 2 x ArH), 6.99 (d, J = 9.0 
Hz, 2H, 2 x ArH), 6.82 (d, J = 8.8 Hz, 2H, 2 x ArH), 3.22 – 3.19 (m, 4H, 2 x CH2), 2.77 – 2.73 
(m, 4H, 2 x CH2), 2.41 (s, 3H, N-CH3). 
13C NMR (151 MHz, d6-DMSO) δ: 207.9 (ArC), 164.9 (ArCH), 154.3 (ArC), 147.4 (ArC), 137.9 
(ArC), 137.8 (ArC), 123.9 (ArCH), 123.0 (ArCH), 121.5 (ArCH), 115.8 (ArCH), 115.3 (ArCH), 
53.7 (CH2), 47.4 (CH2), 44.4 (CH3). 
HRMS-ES (m/z): [M + H] calculated for C25H25N8O5, 517.1948; found, 517.1948. 
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4-(3-(2-morpholinophenylamino)-6,7-dinitroquinoxalin-2-ylamino)phenol (89) 
N
NO2N
O2N Cl
Cl
NH2
OH
NH2
N
O
O2N
O2N
NH
NH
OH
N
O
 
To a microwave vial containing a magnetic stirrer bar was added 2,3-dichloro-6,7-
dinitroquinoxaline (289 mg, 1 mmol), 2-morpholinoaniline (178 mg, 1 mmol), 4-
aminophenol (109 mg, 1 mmol) and N-methyl-2-pyrrolidone (5 mL). The mixture was 
reacted under microwave irradiation for 5 min at 160 °C in a closed vial. Upon cooling, the 
mixture was added to saturated sodium bicarbonate (50 mL) and extracted with ethyl 
acetate (3 x 50 mL). The organics were washed with brine and the solvent evaporated 
under reduced pressure. Purification was carried on by reverse phase column 
chromatography, using a gradient of 0 to 100 % methanol in water containing 0.1 % formic 
acid, followed by preparative HPLC to give the named compound. 
HRMS-EI (m/z): [M+H]+ calculated for C24H21N7O6, 503.15533; found, 503.154112. 
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1,2-bis(3-hydroxyphenyl)ethane-1,2-dione (91) 
Literature compound.141  
O
O
O
O
O
O
OH
OH
 
1,2-Bis(3-methoxyphenyl)ethane-1,2-dione (500 mg, 1.85 mmol) was taken up in 48 % HBr 
in Acetic acid (20 mL) and refluxed for 36hrs. Upon cooling, the mixture was poured into 
water (20 mL) and extracted with ethyl acetate (20 mL). The organic layer was washed with 
water (20 mL), dried over Mg2SO4, filtered and the solvent removed under reduced 
pressure. The crude material was purified by flash column chromatography using a solvent 
gradient of 10 to 50 % ethyl acetate in cyclohexane to give the named compound in 60 % 
yield. 
1H NMR (500 MHz, d6-DMSO) δ 10.06 (s, 2H, 2 x Ar-OH), 7.44 – 7.38 (m, 2H, 2 x ArH), 7.30 – 
7.26 (m, 2H, 2 x ArH), 7.26 – 7.24 (m, 2H, 2 x ArH), 7.16 (ddd, J = 8.1, 2.5, 0.9 Hz, 2H, 2 x 
ArH). 
13C NMR (126 MHz, d6-DMSO) δ 195.1 (CO), 158.1 (ArC), 133.5 (ArC), 130.8 (ArCH), 122.8 
(ArCH), 120.6 (ArCH), 114.9 (ArCH). 
MS-EI (m/z): [M + Na]+ calculated for C14H10O4Na, 265.2179; found 265.00. 
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2,3-bis(3-methoxyphenyl)-6-(trifluoromethyl)quinoxaline (92) 
O
O
NH2
NH2
F3C
O
O
N
N
O
O
F3C
 
4-(Trifluoromethyl)benzene-1,2-diamine (35.2 mg, 0.20 mmol) and 1,2-bis(3-
methoxyphenyl)ethane-1,2-dione (54 mg, 0.20 mmol) were reacted using method B to give 
the name compound as a white powder (73 mg, 89 %). 
1H NMR (500 MHz, CDCl3) δ: 8.50 (s, 1H, ArH), 8.29 (d, J = 8.8 Hz, 1H, ArH), 7.94 (dd, J = 8.8, 
1.9 Hz, 1H, ArH), 7.26 (td, J = 7.8, 1.5 Hz, 2H, 2 x ArH), 7.13 – 7.07 (m, 4H, 4 x ArH), 6.97 – 
6.93 (m, 2H, 2 x ArH), 3.73 (s, 6H, 2 x CH3). 
13C NMR (126 MHz, CDCl3) δ: 159.60 (ArC-OCH3), 155.28 (ArC), 154.72 (ArC), 142.25 (ArC), 
140.21 (ArC), 139.75 (ArC), 139.71 (ArC), 131.82 (ArC-CF3 or CF3), 131.55 (ArC-CF3 or CF3), 
130.48 (ArCH), 129.53 (ArCH), 129.51 (ArCH), 127.34 (ArCH), 125.67 (ArCH), 122.39 (ArCH), 
122.36 (ArCH), 115.76 (ArCH), 115.73 (ArCH), 114.85 (ArCH), 114.79 (ArCH), 55.37 (OCH3). 
HRMS-CI (m/z): [M+H]+ calculated for C23H18F3N2O2, 411.13149; found, 411.130521. 
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2,3-bis(3-methoxyphenyl)quinoxaline-6-carbonitrile (93) 
O
O
NH2
NH2
O
O
N
N
N
N
O
O  
3,4-Diaminobenzonitrile (26.6 mg, 0.20 mmol) and 1,2-bis(3-methoxyphenyl)ethane-1,2-
dione (54 mg, 0.20 mmol) were reacted using method B to give the named compound as a 
white powder (73 mg, 99 %). 
1H NMR (500 MHz, CDCl3) δ: 8.54 (dd, J = 1.8, 0.5 Hz, 1H, ArH), 8.25 (dd, J = 8.6, 0.5 Hz, 1H, 
ArH), 7.91 (dd, J = 8.6, 1.8 Hz, 1H, ArH), 7.29 – 7.24 (m, 2H, 2 x ArH), 7.13 – 7.06 (m, 4H, 4 x 
ArH), 6.98 – 6.94 (m, 2H, 2 x ArH), 3.73 (s, 3H, CH3), 3.72 (s, 3H, CH3). 
13C NMR (126 MHz, CDCl3) δ: 159.6 (ArC-OCH3), 159.6(ArC-OCH3), 155.8(ArC), 155.2(ArC), 
142.6(ArC), 140.3(ArC), 139.5(ArC), 139.4(ArC), 135.2(ArC-CN), 130.8(ArCH), 130.8(ArCH), 
129.6(ArCH), 122.4(ArCH), 122.4(ArCH), 118.2(ArCH), 116.0(ArCH), 115.9(ArCH), 
114.9(ArCH), 114.8(ArCH), 113.4 (Ar-CN), 55.4 (OCH3). 
HRMS-CI (m/z): [M + H]+ calculated for C23H18F3N3O2, 368.1394; found, 368.1388. 
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6-chloro-2,3-bis(3-methoxyphenyl)quinoxaline (94) 
O
O
NH2
NH2
Cl
O
O
N
N
O
O
Cl
 
4-Chlorobenzene-1,2-diamine (28.4 mg, 0.20 mmol) and 1,2-bis(3-methoxyphenyl)ethane-
1,2-dione (54 mg, 0.20 mmol) were reacted using method B to give the named compound 
as a white powder (75 mg, 99 %). 
1H NMR (500 MHz, CDCl3) δ: 8.17 (d, J = 2.3 Hz, 1H, ArH), 8.10 (d, J = 8.9 Hz, 1H, ArH), 7.71 
(dd, J = 8.9, 2.3 Hz, 1H, ArH), 7.30 – 7.18 (m, 2H, 2 x ArH), 7.14 – 7.02 (m, 4H, 4 x ArH), 6.96 
– 6.86 (m, 2H, 2 x ArH), 3.71 (s, 6H, 2 x CH3). 
13C NMR (126 MHz, CDCl3) δ: 159.6(ArC-OCH3), 154.2(ArC), 153.5(ArC), 141.5(ArC), 
140.0(ArC), 139.9(ArC), 139.8(ArC), 135.8 (ArC-Cl), 131.1(ArCH), 130.5(ArCH), 129.5(ArCH), 
129.4(ArCH), 128.2(ArCH), 122.4(ArCH), 122.4(ArCH), 115.6(ArCH), 115.5(ArCH), 
114.8(ArCH), 114.8(ArCH), 55.4(OCH3). 
HRMS-CI (m/z): [M + H]+ calculated for C22H18ClN2O2, 377.1051; found, 377.1049. 
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6-fluoro-2,3-bis(3-methoxyphenyl)quinoxaline (95) 
O
O
NH2
NH2
F
O
O
N
N
O
O
F
 
4-Fluorobenzene-1,2-diamine (25.2 mg, 0.20 mmol) and 1,2-bis(3-methoxyphenyl)ethane-
1,2-dione (54 mg, 0.20 mmol) were reacted using method B to give the named compound 
as a white powder (64 mg, 89 %). 
1H NMR (500 MHz, d6-DMSO) δ: 8.23 (ddd, J = 10.4, 7.4, 3.1 Hz, 1H), 7.98 – 7.90 (m, 1H), 
7.81 (ddd, J = 10.4, 4.7, 2.3 Hz, 1H), 7.27 (td, J = 8.2, 2.0 Hz, 2H), 7.03 (s, 4H), 6.99 – 6.91 (m, 
2H), 3.65 (s, 6H). 
13C NMR (126 MHz, d6-DMSO) δ: 163.3 (ArC), 161.4 (ArC), 158.8 (ArC), 153.7 (ArC), 152.4 
(ArC), 141.1 (ArC), 139.9 (ArC), 139.8 (ArC), 137.8 (ArC), 131.4 (ArCH), 129.2 (ArCH), 122.0 
(ArCH), 121.9 (ArCH), 120.7 (ArCH), 120.5 (ArCH), 115.1 (ArCH), 114.8 (ArCH), 114.6 (ArCH), 
112.4 (ArCH), 112.2 (ArCH), 55.1 Ar-OCH3). 
HRMS-CI (m/z): [M + H]+ calculated for C22H18FN2O2, 361.1347; found, 361.1339. 
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3,3'-(6-(trifluoromethyl)quinoxaline-2,3-diyl)diphenol (96) 
O
O
NH2
NH2
F3C
OH
OH
N
N
OH
OH
F3C
 
4-(Trifluoromethyl)benzene-1,2-diamine (17.6 mg, 0.10 mmol) and 1,2-bis(3-
hydroxyphenyl)ethane-1,2-dione (24.2 mg, 0.10 mmol) were reacted using method B to 
give the named compound as a white powder (40 mg, 99 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.58 (s, 2H, 2 x OH), 8.50 (s, 1H, ArH), 8.33 (d, J = 8.7 Hz, 
1H, ArH), 8.11 (dd, J = 8.7, 2.0 Hz, 1H, ArH), 7.14 (t, J = 7.9 Hz, 2H, 2 x ArH), 7.02 – 6.98 (m, 
2H, 2 x ArH), 6.86 (d, J = 7.9 Hz, 2H, 2 x ArH), 6.82 – 6.78 (m, 2H, 2 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 157.1 (ArC-OH), 155.3 (ArC), 154.7(ArC), 141.6(ArC), 139.5 
(ArC), 139.5 (ArC), 139.3 (ArC), 130.7 (ArC-CF3 or CF3), 130.6 (ArC-CF3 or CF3), 129.1 (ArCH), 
126.7 (ArCH), 126.7 (ArCH), 125.5 (ArCH), 120.4 (ArCH), 116.4 (ArCH), 116.3 (ArCH), 116.2 
(ArCH). 
HRMS-EI (m/z): [M] calculated for C21H13F3N2O2, 382.0936; found, 382.0924. 
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2,3-bis(3-hydroxyphenyl)quinoxaline-6-carbonitrile(97) 
O
O
NH2
NH2
OH
OH
N
N
N
N
OH
OH  
3,4-diaminobenzonitrile (13.3 mg, 0.10 mmol) and 1,2-bis(3-hydroxyphenyl)ethane-1,2-
dione (24.2 mg, 0.10 mmol) were reacted using method B to give the named compound as 
a white powder (31 mg, 89 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.59 (s, 1H, OH), 9.58 (s, 1H, OH), 8.73 (d, J = 1.4 Hz, 1H, 
ArH), 8.27 (d, J = 8.6 Hz, 1H, ArH), 8.15 (dd, J = 8.6, 1.8 Hz, 1H, ArH), 7.17 – 7.11 (m, 2H, 2 x 
ArH), 7.01 – 6.98 (m, 2H, 2 x ArH), 6.89 – 6.82 (m, 2H, 2 x ArH), 6.82 – 6.76 (m, 2H, 2 x ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 157.1 (ArC), 155.5 (ArC), 154.8 (ArC), 141.9 (ArC), 139.5 
(ArC), 139.4 (ArC), 134.9 (ArCH), 131.1 (ArCH), 130.5 (ArCH), 129.1 (ArCH), 120.5 (ArCH), 
120.4 (ArCH), 118.2(ArC), 116.4 (ArCH), 116.4 (ArCH), 116.3 (ArCH), 112.4 (Ar-CN). 
HRMS-EI (m/z): [M] calculated for C21H13N3O2, 339.1008; found, 339.1002. 
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3,3'-(6-chloroquinoxaline-2,3-diyl)diphenol (98) 
O
O
NH2
NH2
Cl
OH
OH
N
N
OH
OH
Cl
 
4-Chlorobenzene-1,2-diamine (14.2 mg, 0.10 mmol) and 1,2-bis(3-hydroxyphenyl)ethane-
1,2-dione (24.2 mg, 0.10 mmol) were reacted using method B to give the named compound 
as a white powder (35 mg, 99 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.54 (d, J = 6.6 Hz, 2H, OH), 8.20 (d, J = 2.2 Hz, 1H), 8.14 (d, 
J = 9.0 Hz, 1H), 7.88 (dd, J = 9.0, 2.2 Hz, 1H), 7.13 (td, J = 7.9, 1.9 Hz, 2H), 6.98 – 6.95 (m, 
2H), 6.82 (ddd, J = 7.9, 4.9, 3.7 Hz, 2H), 6.80 – 6.76 (m, 2H). 
13C NMR (126 MHz, d6-DMSO) δ: 157.0 (ArC-OH), 154.0 (ArC), 153.4 (ArC), 140.7 (ArC), 
139.7 (ArC), 139.7 (ArC), 139.0 (ArC), 134.5 (ArC-Cl), 130.9 (ArCH), 130.6 (ArCH), 129.0 
(ArCH), 127.5 (ArCH), 120.5 (ArCH), 120.4 (ArCH), 116.37 (ArCH), 116.36 (ArCH), 116.1 
(ArCH), 116.0 (ArCH). 
HRMS-EI (m/z): [M] calculated for C20H13ClN2O2, 348.0666; found, 348.0666. 
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3,3'-(6-fluoroquinoxaline-2,3-diyl)diphenol (99) 
O
O
NH2
NH2
F
OH
OH
N
N
OH
OH
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4-Fluorobenzene-1,2-diamine (12.6 mg, 0.10 mmol) and 1,2-bis(3-hydroxyphenyl)ethane-
1,2-dione (24.2 mg, 0.10 mmol) were reacted using method B to give the named compound 
as a white powder (27 mg, 81 %). 
1H NMR (500 MHz, d6-DMSO) δ: 9.54 (s, 2H, 2 x OH), 8.20 (dd, J = 9.2, 5.9 Hz, 1H, ArH), 7.90 
(dd, J = 9.2, 2.8 Hz, 1H, ArH), 7.79 (td, J = 8.9, 2.8 Hz, 1H, ArH), 7.12 (td, J = 8.0, 1.2 Hz, 2H, 2 
x ArH), 7.00 – 6.93 (m, 2H, 2 x ArH), 6.87 – 6.81 (m, 2H, 2 x ArH), 6.81 – 6.74 (m, 2H, 2 ArH). 
13C NMR (126 MHz, d6-DMSO) δ: 157.0 (ArC), 153.8 (ArC), 152.5 (ArC), 141.1 (ArC), 139.9 
(ArC), 139.8 (ArC), 137.7 (ArC), 131.4 (ArCH), 131.3 (ArCH), 130.8 (ArC), 129.0 (ArCH), 120.4 
(ArCH), 120.4 (ArCH), 116.4 (ArCH), 116.3 (ArCH), 116.0 (ArCH), 115.9 (ArCH), 114.9 (ArCH), 
112.3 (ArCH), 112.1 (ArCH). 
HRMS-EI (m/z): [M] calculated for C20H13FN2O2, 332.09611; found, 332.097001. 
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Background
Endothelium-derived C-type natriuretic peptide (CNP)
possesses cytoprotective and anti-atherogenic functions
that regulate vascular tone and smooth-muscle relaxa-
tion and might be key in protecting against ischaemia-
reperfusion injury [1]. The finding that many of the
vasoprotective effects of CNP are mediated by the
natriuretic peptide receptor type-C (NPR-C) suggests
that this receptor might represent a novel therapeutic
target for the treatment of cardiovascular diseases. Thus,
we have designed and developed small molecule drug-
like mimetics of CNP agonists at NPRC.
Methods and results
We employ a multi-disciplinary approach that comprises
molecular modelling, chemical synthesis and biological
and functional assays. The crystal structure of NPR-C
was used as the starting point for the design of peptidic
and subsequently non-peptidic ligands to the receptor
[2]. We have determined which fragments of CNP are
crucial for binding to NPR-C and modified the NPR-C
antagonist AP-811 using pharmacophore searches to
replace the peptide component, which led to the design
of a library of compounds that were subsequently
synthesised, tested and optimised [3].
Conclusion
Novel and selective non-peptide NPR-C agonists have
been identified that relax rat isolated mesenteric arteries
in vitro. We foresee that such molecules will facilitate
the development of potential therapeutic agents for car-
diovascular diseases.
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